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Abstract 
 
IL-6 is a pleiotropic cytokine that has a significant role in inflammatory processes. In 
relation to ovarian cancer biology there is emerging evidence that it mediates 
processes relating to tumour growth, invasion, angiogenesis and chemo-resistance that 
lead to disease with poor prognosis. The aim of this thesis was to evaluate the efficacy 
and mechanism of action of an anti-human IL-6 antibody, CNTO328, in ovarian 
cancer. These aims were achieved with a clinical trial that was conducted in parallel 
with pre-clinical experiments.  
 
18 patients with advanced platinum-resistant ovarian cancer were treated with 
CNTO328 in a phase II clinical trial. One patient had a partial response and seven 
patients attained stable disease at the end of the initial 6-week study period with 
correlations seen between clinical benefit and baseline levels of CRP, β2-
microglobulin, TNF-α, IL-8 and VEGF. Four patients completed 6 months of 
treatment and had significantly decreased plasma CCL2 and increased sgp130 
concentrations. Furthermore, immunohistochemical analysis of diagnostic biopsies 
suggested that clinical benefit was related to a lower macrophage infiltrate and 
increased stromal expression of IL-6, IL-6 receptors and SOCS3.  
  
I have found two ovarian cancer cell lines that secreted IL-6 and expressed both 
components of the IL-6 receptor signalling complex. When these cells were grown on 
plastic, CNTO328 had no effect on cell proliferation or survival. This suggested that 
IL-6 was not a growth factor for ovarian cancer cells in vitro. However, CNTO328 
reduced constitutive secretion of IL-6, IL-1β, TNF-α, IL-8 and CCL2 by the ovarian 
cancer cells.  The in vivo studies with human ovarian cancer xenograft models in nude 
mice showed that anti-IL-6 treatment had biological activity by inhibiting cell 
proliferation, macrophage infiltration and angiogenesis. In conclusion, the xenograft 
models and cell line experiments together with the clinical trial show that IL-6 may be 
a therapeutic target in ovarian cancer and exhibits both autocrine and paracrine 
actions within the ovarian cancer microenvironment. 
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1 INTRODUCTION 
 
1.1  Ovarian cancer: Managing the silent killer 
 
Ovarian cancer is the most lethal gynaecological malignancy and the 4th commonest 
cause of cancer related death in women. In the UK, approximately 6,600 new cases 
are diagnosed annually and in 2007 there were over 4,300 deaths from this disease 
(Cancer Research UK data). Significant advances in the understanding of the natural 
history of the disease and thorough initial staging along with surgical and 
chemotherapeutic management have improved the short-term course of ovarian 
carcinoma. However despite such improvements, most patients relapse after primary 
treatment and succumb to disease progression. This chapter aims to outline historical 
and novel concepts relating to the pathophysiology of ovarian cancer with an 
emphasis on the role of inflammatory pathways in the tumour microenvironment and 
how targeting cytokines may offer a new approach to the treatment of patients who 
relapse with standard chemotherapy.  
 
1.2 The origins of ovarian cancer 
 
The pathophysiology of ovarian cancer has remained a controversial subject for many 
years and recent research has questioned the validity of established theories on this 
topic. This section aims to summarise the various ovarian cancer models that have 
evolved over the past few decades and how current hypotheses have impacted on our 
understanding of the biology of ovarian cancer. 
 
1.2.1 Ovarian surface epithelium and cortical inclusion cyst model 
Over 90% of ovarian tumours originate from epithelial cells with the remaining 
ovarian cell components i.e. sex-cord stroma and germ cells, comprising the less 
common histiotypes (figure 1.1).  
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Figure 1.1 Ovarian tumours: origins and cellular classification. 
The majority of ovarian cancers originate from the flat-cuboidal epithelial cells covering the 
exterior surface of the ovary. Each of the OSE subtypes can be further divided into benign, 
intermediate (borderline) and malignant. 
 
Historically, it was thought that all subtypes of epithelial ovarian cancer (EOC) were 
derived from a common surface epithelial cell (OSE). Through follicular rupture and 
oocyte release, ovulation induces OSE trauma that subsequently undergoes repair. 
This repetitive process is also associated with inflammatory cytokines and reactive 
oxygen species (ROS) that facilitate DNA damage and result in transformation of 
epithelial cells (Murdoch and Martinchick 2004; Karst and Drapkin 2010). In  
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addition, throughout the reproductive time course, invaginations develop on the 
ovarian epithelium into the cortical stroma. These can develop as separate entities 
known as cortical inclusion cysts (CICs) that under the influence of hormones within 
the stroma and homeobox (HOX) genes have the capacity to proliferate and 
differentiate into epithelium similar to those found in Mullerian derived organs 
(Drapkin, Crum et al. 2004; Cheng, Liu et al. 2005; Karst and Drapkin 2010). 
Furthermore, if CICs have pre-existing DNA damage, gonadotrophins and oestrogens 
can also facilitate their malignant transformation that ultimately leads to ovarian 
cancer.  Hence, this model appears to address the phenotypic features that are evident 
in some ovarian cancers e.g. cystic malignant tumours and ovarian cancers with 
Mullerian characteristics (Karst and Drapkin 2010).  
 
1.2.2 Two pathway model 
 
The OSE-derived tumours are classified into varying subtypes that can either be 
benign, borderline or malignant.  However, amongst these subtypes a large degree of 
heterogeneity exists in relation to their genetic origins and biological behaviour.  For 
example, distinct differences exist between serous borderline tumours (SBTs) and 
serous carcinomas (table 1.1). SBTs represent a spectrum of tumours that originate 
from benign cystadenomas that can slowly transform in a step-wise fashion into 
atypical proliferative serous tumours to non-invasive micropapillary serous 
carcinomas (non-invasive MPSC) to low-grade invasive serous carcinomas (Shih Ie 
and Kurman 2004). The low-grade tumours generally follow an indolent course, 
which contrasts with the high-grade counterparts, which behave very aggressively 
with early metastatic spread and poor clinical outcome. These tumours can also be 
characterised by particular genotypes, with p53 mutations associated with high-grade 
serous carcinomas but not SBTs. The features described led to the two pathway model 
proposed by Shih and Kurman (Shih Ie and Kurman 2004) that describes a novel 
method of classifying ovarian tumours as either Type I or Type II (figure 1.2). 
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 Frequency Histological 
features 
Precursor 
lesions 
Clinical 
behaviour 
 
Type I 
(Low-grade) 
 
~25% serous 
carcinomas 
 
Micropapillary 
architecture; 
low-grade 
nuclei; low-
grade mitotic 
index 
 
Serous 
cystadenoma 
Serous atypical 
proliferative 
(borderline) 
tumour 
 
Indolent; slow 
progression 
5-year survival 
~55% 
     
 
Type II 
    
(High-grade) ~75% serous 
carcinomas 
Solid nests and 
masses; high-
grade nuclei; 
high mitotic 
index 
Not known, 
possibly from 
OSE or CICs (de 
novo) 
Aggressive; 
rapid 
progression 
5-year survival 
~30% 
     
 
Table 1.1 Summary of clinicopathological features of the phenotypic Type I and 
Type II tumours: Low-grade and high-grade serous carcinomas. 
Adapted from Shih and Kurman (2004). Ovarian tumourogenesis: A Proposed Model Based 
on Morphological and Molecular Genetic Analysis. 
 
 
a) Type I tumours 
Type I tumours encompass all the EOC sub-types that are phenotypically low-grade, 
slow growing and derived from a precursor lesion (table 1.2). KRAS and BRAF 
mutations that activate mitogen activated protein kinase (MAPK) signalling are 
commonly associated with these tumours. In addition, PTEN mutations are found in 
approximately 20% of Type I endometrial tumours. Furthermore, both WNT and 
transforming growth factor-β (TGF-β) signalling pathways that are involved in 
epithelial-mesenchymal transition have also been linked to the development of Type I 
tumours.   
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Table 1.2  Precursors and molecular genetic alterations of Type I Tumours of the 
ovary. 
Adapted from Shih and Kurman (2004). Ovarian tumourogenesis: A Proposed Model Based 
on Morphological and Molecular Genetic Analysis. 
 
 
 
 
 
 
Type I tumours Precursors Known molecular 
genetic alterations 
 
Low-grade serous 
carcinoma (invasive 
MPSC) 
 
Serous 
cystadenoma/adenofibroma 
Atypical proliferative serous 
tumour (APST) 
Non-invasive MPSC 
 
 
BRAF and KRAS mutations 
(~67%) 
 
Mucinous carcinoma 
Mucinous cystadenoma 
Atypical proliferative 
mucinous tumour 
Intraepithelial carcinoma 
 
KRAS mutations (>60%) 
 
 
 
Endometrioid carcinoma 
 
Endometriosis 
Endometrioid adenofibroma 
Atypical proliferative 
endometrioid tumour 
Intraepithelial carcinoma 
 
LOH or mutations in PTEN 
(20%) 
β-catenin gene mutations 
(16-54%) 
KRAS mutations (4-5%) 
Microsatellite instability (13-
50%) 
 
 
 
Clear cell carcinoma 
 
Endometriosis 
Clear cell adenofibroma 
Atypical proliferative clear 
cell tumour 
Intraepithelial carcinoma 
 
 
KRAS mutations (5-16%) 
Microsatellite instability 
(~13%) 
TGF-β RII mutation (66%) 
 
Transitional cell tumour 
 
Brenner tumour 
Atypical proliferative 
Brenner tumour 
 
 
 
To be identified 
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b) Type II tumours 
These tumours mainly consist of high-grade serous carcinomas and less frequently 
undifferentiated carcinomas and malignant mixed mesodermal tumours. Unlike Type 
I tumours they are typified by p53 mutations, generally progress rapidly and are not 
commonly associated with a precursor lesion (table 1.3). They can also be associated 
with AKT2 oncogenes and HER2/neu overexpression. 
 
 
Table 1.3 Precursors and molecular genetic alterations of Type II tumours of the 
ovary.  
Adapted from Shih and Kurman (2004). Ovarian tumourogenesis: A Proposed Model Based 
on Morphological and Molecular Genetic Analysis. 
 
 
 
 
 
 
Type II tumours Precursors Known molecular 
genetic alterations 
 
High-grade serous  
carcinoma 
 
To be identified 
 
p53 mutations (50-97%)  
Amplification and 
overexpression of 
HER2/neu gene (10-20%) 
and AKT2 gene (12%-
18%) 
Inactivation of p16 gene 
(10%-17%) 
 
   
Undifferentiated 
carcinoma 
To be identified To be identified 
   
Malignant mixed 
mesodermal tumour  
(carcinosarcomas) 
 
To be identified 
 
p53 mutations (>90%) 
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Figure 1.2 Two pathway model. 
This illustration depicts the development of serous ovarian carcinomas. Low-grade serous 
carcinoma (invasive MPSC) is the prototype of Type I tumours and develops in a stepwise 
fashion from atypical proliferative tumours (APST) through to the non-invasive stage of 
MPSC before manifesting as invasive tumours. The Type I pathway is frequently associated 
with BRAF and KRAS mutations. High-grade serous carcinomas are the prototype of Type II 
tumours and develop from OSE or CICs without any identifiable precursors. In this pathway 
p53 mutations are more commonly found. (CIN=chromosomal instability). Adapted from Shih 
and Kurman (2004). Ovarian tumourogenesis: A Proposed Model Based on Morphological 
and Molecular Genetic Analysis. 
 
 
 
1.2.3 Tubal origins of ovarian cancer 
The study of genetic mutations in ovarian cancer has revealed some interesting 
observations relating to the potential origins of ovarian cancer. Mutations in DNA 
repair genes, in particular the breast cancer susceptibility genes, BRCA1 and BRCA2 
account for 10% of all EOC cases and are associated with a 15-60% lifetime risk of 
developing ovarian cancer (Easton, Ford et al. 1995). Surgical management of these 
patients usually involves the removal of both ovaries and fallopian tubes prior to the 
onset of disease.  In certain cases, tubal cancers have co-existed with type II serous 
ovarian subtypes and genetic analysis has shown identical mutations in p53 (Crum, 
Drapkin et al. 2007).  
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Furthermore, the fimbrial region of the fallopian tube has been implicated as a 
specific site of origin for serous ovarian cancer. Crum et al proposed a model that also 
has two pathways to support this theory (Crum, Drapkin et al. 2007). Firstly, CICs 
could develop from the invagination of fimbrial tissue or tubal epithelium that 
becomes adherent to the ovarian cortex (i.e. endosalpingiosis) and malignant 
transformation occurs as a result of p53 mutations. Secondly, tubal intraepithelial 
carcinomas (TIC) developing within the fimbrae may metastasise locally to adjacent 
ovarian surface epithelium or to the peritoneal cavity, giving rise to primary 
peritoneal carcinoma in the apparent absence of a primary tumour within the ovary 
(figure 1.3).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Fimbrial origins of ovarian cancer. 
The pathway on the right originates from CICs that give rise to most Type I tumours by step-
wise mutations (signified by the colour transitions from green to red) and includes 
endometriosis, benign and borderline cystadenomas. The pathway on the left could arise from 
either fimbrial mucosa that invaginates the ovarian cortex (endosalpingiosis) or TIC that 
develop in the fimbrae and have the potential to invade other peritoneal surfaces. This 
pathway consists of an initial p53 mutation following genotoxic injury that leads to the 
development of Type II tumours. Adapted from Crum et al 2007. Lessons from BRCA: The 
Tubal Fimbrae Emerges as an Origin for Pelvic Serous Cancer. 
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1.3 Ovarian cancer: Epidemiology and risk factors  
 
The risk of ovarian cancer increases with age. The majority of patients are 
postmenopausal with 80% of cases diagnosed over 50 years and a peak incidence of 
61.8 per 100, 000 women is observed in the 60-64 age group (Cancer Research UK 
data). Germ-cell and sex cord-stromal tumours are more common in younger cohorts. 
Racial and geographical variations are also evident for this disease.  For example, 
lower incidences are seen in African-American and Afro-Caribbean women compared 
to their Caucasian counterparts (Grulich, Swerdlow et al. 1992; Whittemore, Harris et 
al. 1992). In addition the rate of EOC is significantly higher in Europe and the United 
States in comparison with Sub-Saharan Africa and Japan respectively (Parkin and 
Muir 1992; Daly and Obrams 1998). The association of social class with EOC risk 
remains uncertain with studies showing both increased and reduced risk with more 
favourable socio-economic groups (Tavani, Negri et al. 1993; Purdie, Green et al. 
1995). 
 
Several studies have confirmed the significant effects of reproductive and hormonal 
factors on EOC risk.  Both nulliparity and unexplained infertility confer increased risk 
of EOC development (Whittemore, Harris et al. 1992; Venn, Watson et al. 1995). 
However there is no current evidence to confirm that fertility treatment serves as an 
independent risk factor (Venn, Watson et al. 1995; Mosgaard, Lidegaard et al. 1997; 
Venn, Watson et al. 1999). Similarly, although there has been a general consensus 
linking early menarche (<12 years) and late menopause (>50 years) to EOC risk, most 
large-scale studies fail to show any significant association (Whittemore, Harris et al. 
1992; Hankinson, Colditz et al. 1995). 
 
Extensive research has confirmed a protective effect of the oral contraceptive pill 
(OCP) on ovarian cancer risk. A recent re-analysis of data from 45 worldwide 
epidemiological studies confirmed that any OCP use is associated with significantly 
reduced EOC risk (RR 0.73, 95% CI 0.70-0.76) compared with subjects who never  
took OCP (Beral, Doll et al. 2008). This reduction was more pronounced with a 
longer duration of OCP use and the protective effect continued for up to 30 years after  
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discontinuation (Beral, Doll et al. 2008). Significant beneficial effects are also evident 
with tubal ligation and, to a lesser degree, hysterectomy (Hankinson, Hunter et al. 
1993; Daly and Obrams 1998).  In view of the model proposed by Crum et al, the 
protective effect seen with tubal ligation may be due to the removal of precursor 
lesions forming within the fimbrae. The proposed theory is that these surgical 
procedures can prevent mutagens accessing the peritoneal cavity through the vagina 
and fallopian tubes (Whittemore, Harris et al. 1992). In BRCA1 carriers, Narod et al 
reported that tubal ligation decreased EOC risk (OR 0.39) after adjusting for factors 
including parity and OCP (Narod, Sun et al. 2001). Meta-analysis of smaller studies 
has also shown modest protection against EOC gained from breastfeeding 
(Whittemore, Harris et al. 1992). 
 
 Increased 
risk 
  Decreased 
risk 
 
  
2-3 relatives with ovarian cancer Previous oral contraceptive use 
 
 1st or 2nd degree relative with ovarian cancer 
 
Past pregnancy 
 
Infertility 
 
Past breast feeding 
Nulliparity 
 
                                HRT 
 
Tubal ligation  
 
Hysterectomy 
Polycystic ovary syndrome 
 
Endometriosis 
 
Asbestos/talc exposure 
 
Obesity 
 
  
  
 
Table 1.4  Factors associated with ovarian cancer risk. 
 
In contrast, the increased use of hormone replacement therapy to combat the 
deleterious effects of menopause has been linked to increased EOC risk.  A 
prospective study by Rodriguez et al observed increased ovarian cancer-related  
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mortality in women taking HRT for >10 years  (OR 1.23, 95% CI 1.06-1.43) 
(Rodriguez, Patel et al. 2001). These results have recently been confirmed in the  
Million Women Study whereby current HRT users were more likely to develop and 
die from ovarian cancer compared to never users (Beral, Bull et al. 2007).  There is 
also evidence of increased EOC risk attributed to polycystic ovary syndrome (PCOS) 
(Schildkraut, Schwingl et al. 1996), a disease characterised by high circulating 
androgen levels. Furthermore, this risk increases in women who have never used OCP 
(Schildkraut, Schwingl et al. 1996). The increased risk of EOC associated with 
inflammatory agents (talc/asbestos) and diseases causing ovarian inflammation 
(endometriosis) are discussed later in this chapter. 
 
1.4 Clinical presentation and initial assessment 
 
As symptoms relating to early stage disease are generally non-specific, tumours are 
seldom diagnosed at this point. However, as the disease progresses patients can 
present with a number of signs and symptoms ranging from moderate abdominal 
bloating to a palpable adnexal mass (figure 1.4). At this juncture the disease is 
commonly at an advanced stage and is frequently incurable. In such cases metastases 
may be detected in the pleural spaces (most common), liver, lung and brain. 
 
Alongside initial physical examination, the serum tumour marker cancer antigen-125 
(CA-125) is analysed. CA-125 is a 220kD glycoprotein that is expressed by over 80% 
of non-mucinous epithelial ovarian carcinomas and most commonly in serous 
endometrioid ovarian carcinomas (Bast, Klug et al. 1983). It was initially detected 
using a murine monoclonal antibody (OC125) that reacted with both ovarian cancer 
cell lines and cryo-preserved tumour biopsies from ovarian cancer patients (Bast, 
Feeney et al. 1981). However, CA-125 is not specific for ovarian cancer and is also 
expressed in other malignancies (e.g. lung, breast, endometrial, pancreatic cancers) 
and benign conditions including endometriosis and uterine leiomyoma. Levels in  
excess of 65U/ml can discriminate between malignant and benign conditions in over 
80% of cases (Cannistra 2004). Nevertheless, normal values (<35U/ml) should not 
preclude further investigation in patients with suspicious signs and symptoms. The  
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average half-life of CA-125 is 4.5 days (Hunter, Daly et al. 1990) and, as a diagnostic 
tool, CA-125 appears to be more reliable in post-menopausal women where the 
incidence of EOC is significantly higher than in pre-menopausal subjects. In such 
cases (i.e. CA-125 > 65U/ml) the positive predictive value for malignancy is over 
95% (Brooks 1994; ACOG 2002). Recent research has also indicated that increased 
pre-surgical CA-125 levels are associated with advanced stage, high-grade and poor 
prognosis (Cooper, Sood et al. 2002; Markman, Liu et al. 2006; Zorn, Tian et al. 
2009). 
 
 
Figure 1.4 Clinical signs and symptoms in ovarian cancer. 
 
After physical examination and CA-125 evaluation, loco-regional disease is initially 
staged by ultrasonography (US) or magnetic resonance imaging (MRI). In addition, 
computer tomography (CT) or positron emission tomography (PET) scanning is used 
to detect any metastatic spread outside of the pelvis.   
 
 
 
 
 34 
 
1.5 Surgical management and staging 
 
Surgical management is essential to EOC diagnosis, staging and treatment. First and 
foremost, the ultimate aim is to resect all macroscopic tumour inside the pelvis and 
perform careful surveillance of the abdomen to detect any subtle sites of metastatic 
disease. This process is termed optimal debulking and should always remain the focus 
during the initial surgical procedure as it profoundly influences prognosis in EOC. 
The surgical procedures usually consist of a total abdominal hysterectomy (TAH) and 
bilateral salpingo-ophorectomy (BSO) together with omentectomy, peritoneal 
washings, pelvic and para-aortic lymph node sampling. 
 
Over the past few decades, numerous trials have confirmed that patients who have 
≤3cm of residual disease have a significantly superior median overall survival (26-96 
months) compared to patients who are sub-optimally debulked (>3cm residual 
disease; 16-29 months) (Hoskins, McGuire et al. 1994; Allen, Heintz et al. 1995; 
Eisenkop, Friedman et al. 1998; Bristow, Tomacruz et al. 2002). Currently, the 
Gynaecological Oncology Group (GOG) has defined optimal debulking as residual 
disease of ≤1cm.  However, there is recent evidence documenting further 
improvements in survival for debulking with either <1mm or no residual disease 
(Winter, Maxwell et al. 2008). Attaining optimal cytoreduction can be impeded by 
particular presentations e.g. large tumour bulk. In such situations, a course of 
chemotherapy prior to undergoing surgery (i.e. neoadjuvant chemotherapy) may be 
considered. The issues relating to the survival advantages with interval debulking 
surgery remain unanswered with a recent Cochrane review confirming neither a 
decrease or benefit in survival for patients treated in this manner (Tangjitgamol, 
Manusirivithaya et al. 2009). On the completion of surgery, EOC can be fully staged 
according to the International Federation of Gynaecology and Obstetrics (FIGO) and 
American Joint Committee on Cancer (AJCC) staging system (table 1.5). The extent 
of disease dissemination has significant effects on overall survival and also dictates 
the subsequent treatment strategies adopted. 
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STAGE 
 
 
DEFINITION 
 
5-YEAR SURVIVAL (%) 
 
Stage I 
(23-33%) 
 
Growth limited to the ovaries. 
 
 
 
 
Ia 
Growth limited to one ovary; no ascites 
containing malignant cells. 
No tumour on external surface; capsule intact. 
 
 
89.6 
 
Ib 
Growth limited to both ovaries; no ascites 
containing malignant cells. 
No tumour on external surface; capsule intact. 
 
 
86.1 
 
Ic 
Tumour stage Ia or Ib with tumour on surface of 
one or more both ovaries; or with capsule(s) 
rupture; or with ascites containing malignant 
cells or with positive peritoneal washings. 
 
65% 
   
Stage II 
(9-13%) 
Growth involving one or both ovaries with 
pelvic extension. 
 
 
 
IIa Extension and/or metastases to the uterus and/or 
tubes. 
 
70.7 
IIb Extension to other pelvic tissues. 65.5 
 
 
IIc 
Tumour stage IIa or IIb with tumour on surface 
of one or both ovaries; or with capsule(s) 
rupture; or with ascites containing malignant 
cells or with positive peritoneal washings. 
 
71.4 
   
Stage III 
(46-47%) 
Tumour involving one or both ovaries with 
peritoneal implants outside the pelvis and/or 
positive retroperitoneal or inguinal nodes.  
 
 
 
 
 
IIIa 
Tumour limited to true pelvis with negative 
nodes but with confirmed microscopic 
peritoneal metastasis beyond pelvis. 
 
 
46.7 
 
IIIb 
Tumour of one or both ovaries with microscopic 
peritoneal deposits outside the pelvis ≤ 2cm in 
diameter. Nodes negative. 
 
 
41.5 
IIIc Abdominal implants >2cm in diameter and/or 
positive retroperitoneal or inguinal nodes. 
 
32.5 
   
Stage IV 
(12-16%) 
Distant metastasis (excluding peritoneal 
metastasis). 
18.6 
 
 
   
Table 1.5: FIGO & AJCC staging system for primary ovarian cancer. 
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1.6 Histopathology evaluation 
 
Prior to the initiation of treatment, it is essential that tissue specimens removed at the 
time of surgery are formally reviewed for histopathological classification. This is 
imperative as the treatment and prognosis for non-epithelial ovarian cancer subtypes 
differ distinctly from EOC. Along with the significant differences seen in the 
biological behaviour of Type I and II ovarian tumours, there is also a large degree of 
heterogeneity with certain patterns in stage distribution. High FIGO stages are more 
prevalent in the Type II serous subtypes whereas most early stage cancers are found 
amongst the Type I clear cell, mucinous (Pignata, Ferrandina et al. 2008) and 
endometrioid carcinomas (Storey, Rush et al. 2008). Furthermore, there appear to be 
notable differences in clinical behaviour and prognosis between histiotypes and this is 
particularly exemplified by clear cell carcinoma.  In comparison with other Type I 
tumours, this sub-type presents more often at a higher stage and grade, is associated 
with inferior responses to platinum/taxane based chemotherapy and higher rates of 
recurrence (Goff, Sainz de la Cuesta et al. 1996; Sugiyama, Kamura et al. 2000; Tian, 
Markman et al. 2009).  Mucinous tumours can also show poor response to platinum- 
based chemotherapy (Tian, Markman et al. 2009; Pignata, Ferrandina et al. 2008) and 
endometrioid cancers appear to have better survival outcome compared to serous 
subtypes (Storey, Rush et al. 2008).  
 
Unlike staging, there is not a standardised grading system used for EOC tumours and 
the interpretation varies amongst pathologists. However, most UK institutions grade 
according to tumour differentiation as follows: 
 
 Grade 1: Well differentiated 
 Grade 2: Moderately differentiated (N.B. no longer used for serous sub-types) 
 Grade 3: Poorly differentiated 
 
High-grade tumours are associated with poorer prognosis and may also predict the 
development of metastasis (Young, Decker et al. 1983; Ahmed, Wiltshaw et al. 1996). 
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Despite these inherent differences between the EOC histological subtypes, this is not 
reflected in the chemotherapeutic management of this disease.  
  
1.7 First-line chemotherapy in EOC 
 
With the exception of good prognosis early stage disease (i.e. stage Ia and Ib grade1 
type I tumours), where standard care involves cytoreductive surgery followed by 
observation (Herrin and Thigpen 1999; Sonoda 2004), chemotherapy remains the 
principal form of adjuvant treatment for EOC. Over the past 40 years a myriad of 
trials have been conducted in order to establish a ‘gold standard’ of therapy and 
validate the optimal timing and mode of cytotoxic delivery.   
 
In the 1960s, alkylating agents such as chlorambucil and melphalan were commonly 
used in first-line treatment with reported response rates (RR) of 40-50%. The 1970s 
witnessed advances in drug development that would shape the future of EOC 
chemotherapy. Seminal research by Gottlieb and Drewinko observed clinical activity 
of single agent cisplatin in ovarian carcinomas (Gottlieb and Drewinko 1975), which 
led to FDA approval for this disease in 1978. Since then, cisplatin and other platinum 
derivatives such as carboplatin have been at the forefront of first-line treatment for 
EOC and several studies have confirmed superior response rates, progression free- 
and overall survival compared to non-platinum containing regimens (Omura, Blessing 
et al. 1986; AOCTG 1991; Aabo, Adams et al. 1998). During the 1980s and 1990s, 
the focus switched to studying the benefits of combining cisplatin with other 
cytotoxic agents. As there appeared to be some marginal advantage over single agent 
platinum therapy, the use of cisplatin with cyclophosphamide +/- doxorubicin had 
become standard therapy worldwide (AOCTG 1991; Fanning, Bennett et al. 1992; 
West and Zweig 1997). However at this time, cisplatin and carboplatin containing 
regimes appeared to have equivalent efficacy (AOCTG 1991). 
 
The next major advance in EOC treatment was the introduction of paclitaxel; a 
microtubular toxin with cytotoxic activity derived from Yew tree bark.  Interest in the 
use of paclitaxel in first-line treatment of EOC gained momentum after a few trials  
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highlighted its efficacy in patients who had relapsed after platinum-based therapy 
(Einzig, Wiernik et al. 1992; Kohn, Sarosy et al. 1994). Several trials were 
subsequently designed to compare platinum-taxane combinations with platinum 
control groups and the clear survival benefit shown in two phase III trials; GOG 111 
(McGuire, Hoskins et al. 1996) and OV10 (Piccart, Bertelsen et al. 2000), initially 
established the combination of cisplatin and paclitaxel as the standard for first-line 
chemotherapy in EOC. This has now been complicated by two follow-up studies, 
GOG 132 (Muggia, Braly et al. 2000) and ICON-3 (ICON 2002), that show no 
significant survival differences between single agent platinum and platinum/taxane 
regimes. Furthermore, due to the more favourable toxicity profile and equivalence in 
progression-free survival (PFS), carboplatin-containing regimes (table 1.6) are now 
emerging as a suitable alternative to those with cisplatin (Neijt, Engelholm et al. 
2000; du Bois, Luck et al. 2003; Ozols, Bundy et al. 2003).  
 
Research into the use of another taxane derivative; docetaxel, has confirmed 
equivalence with paclitaxel in terms of progression free and 18-month survival 
(Vasey, Jayson et al. 2004). However docetaxel induces more myelosuppression but 
less myalgia and neurotoxicity compared with paclitaxel. In view of these findings, 
most institutions consider six courses of carboplatin and paclitaxel given 
intravenously every three weeks as the gold standard first-line treatment in EOC. The 
possibility of extending survival by adding other cytotoxic drugs to platinum-taxane 
combinations has recently been addressed in the ICON-5/GOG-182 trial.  However 
there was no advantage in terms of progression free survival with the addition of a 
third agent (Bookman, Brady et al. 2009). 
 
As EOC has a predilection for peritoneal dissemination, there has been increasing 
interest in the role of intraperitoneal (i.p.) chemotherapy.  One of the advantages of 
this approach relates to the higher concentrations of cisplatin and paclitaxel that can 
be achieved in the peritoneal cavity compared with plasma (Howell, Pfeifle et al. 
1982; Markman, Rowinsky et al. 1992). Until recently, the results from two phase III 
GOG trials (in patients with residual stage III disease) have been conflicting, with the 
GOG-104 study showing a median survival advantage for i.p. cisplatin (p=0.02)  
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(Markman, Rowinsky et al. 1992) and the GOG-114 confirming no significant benefit 
with this mode of treatment (p=0.05) (Markman, Bundy et al. 2001). As a follow-up 
to the promising results seen in the GOG-104 trial, a further GOG study (GOG 172) 
(Armstrong, Bundy et al. 2006) has aimed to resolve these issues. 417 patients with 
optimally debulked (<1cm) stage III disease were randomised to receive 6 courses 
every three weeks of either standard i.v. cisplatin-paclitaxel or i.v. paclitaxel with i.p. 
cisplatin (day 1) followed by i.p. paclitaxel (day 2). Despite less than half of the i.p. 
group completing all six cycles, this cohort had superior median progression free 
survival (23.8 mo vs. 18.3 mo, p=0.05) and overall survival (65.6 mo vs. 49.7 mo, 
p=0.03) (Armstrong, Bundy et al. 2006). However, i.p. therapy had a less favourable 
toxicity profile with significant myelosuppression, neuropathy, abdominal pain, poor 
quality of life and catheter complications (Armstrong, Bundy et al. 2006). The general 
oncological opinion is that this form of treatment should be reserved for patients who 
have small-volume residual disease. 
 
1.8 Management of relapsed EOC 
 
After the completion of first-line treatment, patients are followed up with periodic 
physical examinations, CT scanning and CA-125 evaluation. With respect to serial 
CA-125 monitoring during this period, there is no evidence to support the initiation of 
chemotherapy based on rising CA-125 in the absence of clinical symptoms or 
radiological evidence of disease progression (Rustin and van der Burg 2009). The 
duration of time from completion of platinum-based chemotherapy to relapse has a 
major influence on response to second or even third-line treatment. Patients with EOC 
recurrence are defined according to the platinum-free interval that has elapsed from 
first-line therapy; platinum sensitive (> 6 months), platinum resistant (< 6 months) 
and platinum refractory (relapse during 1st line treatment).  In addition, Markman et al 
confirmed that the response rate to platinum-based therapy positively correlates with 
the duration of the treatment free interval (Markman, Rothman et al. 1991). 
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Trial Regime Evaluable 
patients 
FIGO Stage Result 
 
 
GOG-111  
(McGuire, 
Hoskins et al. 
1996) 
 
Cis/Tax vs. 
Cis/Cyclo 
 
386 
 
III (suboptimal) 
& IV 
 
PFS: 18 mo vs. 
13mo (p<0.001) 
OS: 38 mo vs. 24 
mo (p<0.001) 
 
OV10 
(Piccart, 
Bertelsen et al. 
2000) 
Cis/Tax vs. 
Cis/Cyclo 
680 IIb-c, III & IV 
with optimal or 
suboptimal 
residual disease 
PFS: 16 mo vs. 
12 mo (p<0.001) 
OS: 35 mo vs. 25 
mo (p<0.001) 
 
GOG-132 
(Muggia, Braly 
et al. 2000) 
Cis/Tax vs. Cis 424 III (suboptimal) 
& IV 
PFS: 14.1 mo vs. 
16.4 mo (n.s) 
OS: 26 mo vs. 
30.2 mo (n.s) 
 
ICON-3 
(ICON 2002) 
Carbo/Tax vs. 
Carbo/CAP 
2,074 I-IV (any 
residual disease) 
PFS: 17.3 mo vs. 
16.1 mo (n.s) 
OS: 36.1 mo vs. 
35.4 mo (n.s) 
 
AGO study  
(Neijt, 
Engelholm et 
al. 2000) 
Cis/Tax vs. 
Carbo/Tax 
208 IIb-IV PFS:16 mo vs. 16 
mo (n.s) 
OS: 31 mo vs. 31 
mo (n.s) 
 
GOG 158 
(Ozols, Bundy 
et al. 2003) 
Cis/Tax vs. 
Carbo/Tax 
792 III (optimal) PFS: 19.4 mo vs. 
20.7 mo (n.s) 
OS: 48.7 mo vs. 
57.4 mo (n.s) 
 
SCOTROC 
(Vasey, 2002) 
Carbo/Tax vs. 
Carbo/Doc 
1,077 Ic-IV PFS: 15.4 mo vs. 
15.1 mo (n.s) 
 
 
 
Table 1.6 Platinum and taxane combination trials.  
n.s. not significant; PFS, progression free survival. Cis/Tax, Cisplatin and Paclitaxel; 
Cis/Cyclo, Cisplatin and Cyclophosphamide; Carbo/Tax, Carboplatin and Paclitaxel;  
Carbo-CAP, (Cyclophosphamide/(Adriamycin) Doxorubicin/Cisplatin-choice of Carboplatin 
or CAP); Carbo/Doc, Carboplatin and Docetaxel. 
 
It follows that at relapse, platinum-sensitive patients should be re-challenged with 
platinum-containing regimes.  Patients who are either platinum resistant or refractory 
can be treated with a number of agents that show only modest activity at this stage of 
disease progression (table 1.7) with average response rates of up to 20%. In this  
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subset of patients we appear to have reached a therapeutic ceiling and there is 
currently a desperate need to identify novel approaches that incorporate targeting of 
mechanisms which underpin processes related to EOC proliferation, survival, 
metastasis and platinum resistance.  There is growing evidence that inflammatory 
pathways are integral to such processes. Their role and the effects of targeting 
mediators of inflammation in EOC are outlined later in this chapter. 
 
1.9 Biological therapies in EOC 
 
The development of new chemotherapeutic agents (e.g. epothilone, taxoprexin, 
capecitabine) along with trials investigating different drug combinations has only led 
to modest increments in EOC survival rates.  Consequently, attention has now turned 
towards alternative approaches that focus upon targeting biological pathways related  
to disease progression.  To date, the agents studied comprehensively in EOC are those 
targeting vascular endothelial growth factor (VEGF) and epidermal growth factor 
receptor (EGFR), both of which have prominent roles within the tumour 
microenvironment. Along with a number of other factors, VEGF facilitates tumour 
neovascularisation and is expressed in high concentrations in ascites and pleural 
effusions (Kraft, Weindel et al. 1999). In EOC, VEGF levels also correlate with 
advanced stage, increased microvessel density and poor overall survival (Paley, 
Staskus et al. 1997; Kraft, Weindel et al. 1999; Kassim, El-Salahy et al. 2004). In vivo 
models have demonstrated the beneficial effects of VEGF inhibition in ovarian 
cancer. Using human EOC xenografts in immunodeficient mice, anti-VEGF 
monoclonal antibody therapy (mAb) has been shown to decrease tumour growth,  
tumour vascular density and ascites (Kim, Li et al. 1993; Hu, Hofmann et al. 2002). 
Furthermore, this therapy has a synergistic effect on apoptosis when combined with 
paclitaxel chemotherapy (Hu, Hofmann et al. 2002). Subsequent clinical studies have 
shown therapeutic activity with the humanised anti-VEGF mAb, bevacizumab 
(Avastin) in EOC. Decreased ascitic recurrence and response rates of up to 20% 
have been reported with monotherapy regimes in patients with multiple relapsed 
disease (Burger, Sill et al. 2007).  Although generally well tolerated, side-effects such  
 
 42 
 
 
Agent Single-agent 
response rate (%) 
Evaluable 
patients 
Reference 
 
Paclitaxel 
 
25 
 
16 
 
 
100 
 
140 
 
 
(Seewaldt, Greer et al. 
1994) 
(Gore, Levy et al. 1995) 
    
Liposomal 
doxorubicin 
(Caelyx) 
9 
 
17 
 
44 
 
89 
 
(Markman, Kennedy et al. 
2000) 
(Gordon, Granai et al. 
2000) 
    
Topetecan 14 
 
16 
 
130 
 
92 
 
(Creemers, Bolis et al. 
1996) 
(Bookman, Malmstrom et 
al. 1998) 
    
Gemcitabine 19 
 
22 
42 
 
40 
 
(Lund, Hansen et al. 1994) 
 
(von Minckwitz, Bauknecht 
et al. 1999) 
 
    
Docetaxel 30 
 
24 
315 
 
76 
(Piccart, Gore et al. 1995) 
 
(Kaye, Piccart et al. 1997) 
    
Etoposide 26-34 
 
24 
82 
 
41 
(Seymour, Mansi et al. 
1994) 
(Rose, Blessing et al. 1998) 
    
29 
 
15 
38 
 
33 
(Bajetta, Di Leo et al. 
1996) 
(Burger, DiSaia et al. 1999) 
Vinorelbine 
   
16 
 
26 
42 
 
42 
(Piccart, Green et al. 2000) 
 
(Dieras, Bougnoux et al. 
2002) 
Oxaliplatin 
   
Epirubicin 20 
 
32 
85 
 
19 
(Vermorken, ten Bokkel 
Huinink et al. 1999) 
(Vermorken, Kobierska et 
al. 2000) 
    
 
Table 1.7 Single agent activity in relapsed EOC. 
Although a variety of cytotoxic agents show activity in relapsed ovarian cancer, the response 
rates are generally quite modest. 
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as proteinuria, hypertension, thromboembolism and intestinal perforation can prove to 
be life threatening (Kumaran, Jayson et al. 2009). 
 
As bevacizumab enhances the anti-angiogenic effects of chemotherapy by 
normalising tumour vasculature (Frederick, Straughn et al. 2009), further clinical 
benefit can be achieved with combined therapy, with reported response rates of up to 
80% and 40% for first-line treatment and recurrent disease respectively (Wright, 
Viviano et al. 2006; Chura, Van Iseghem et al. 2007; Micha, Goldstein et al. 2007). 
The benefits of this regime over first-line gold standard therapy are currently being 
addressed by two large phase III trials (GOG-218 and ICON-7) which directly 
compare carboplatin and paclitaxel with or without bevacizumab (Kumaran, Jayson et 
al. 2009). Furthermore, promising results are emerging with trials using tyrosine 
kinase inhibitors targeting VEGF receptors (VEGFR-1, -2,-3) and VEGF trap; a 
soluble decoy receptor (Kumaran, Jayson et al. 2009). 
 
The epidermal growth factor receptor (EGFR) family consists of a number of tyrosine 
kinase receptors that can promote cell proliferation, angiogenesis and chemoresistance 
in EOC. Following the success of HER-2 targeting with trastuzumab (Herceptin) in 
breast cancer, survival advantages have been documented in combination with 
chemotherapy in EOC xenograft models (Delord, Allal et al. 2005). However, this 
observation does not translate to a clinical setting. Amongst 837 patients with  
recurrent or persistent EOC, Bookman et al reported a low frequency of HER-2 
overexpression (2+/3+) in EOC patients (11.4% compared with 20% in breast cancer) 
and found no relationship between HER-2 expression, clinical response to Herceptin 
and survival (Bookman, Darcy et al. 2003). Furthermore, the 7% response rate seen in 
this study was far inferior to analogous studies with single agent Herceptin in breast 
cancer. Similar results observed with other agents targeting EGFRs e.g. Cetuximab 
(anti EGFR-1) (Secord, Blessing et al. 2008) have limited any further investigation of 
these drugs in Phase III trials in ovarian cancer. Despite the recent advances in anti-
angiogenic therapy in EOC, the development of drugs targeting other key processes 
integral to tumour progression remains a necessity. 
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1.10  Inflammation and Cancer  
 
1.10.1 Inflammation: a synopsis   
Inflammation represents the primary defence mechanism in response to the invasion 
of pathogens and is paramount to cell survival. It is an integral part of innate 
immunity and involves an acute phase characterised by the stimulation of chemical 
mediators that induce a rapid influx of leucocytes to the affected region. This results 
in destruction of microorganisms, subsequent tissue repair and initiation of further 
processes that consolidate defence against injury and infection. However, when the 
acute phase is dysregulated, chronic inflammation ensues and the cellular response 
changes.  In order to further understand the link between inflammation and cancer, it 
is essential to first focus on how inflammation contributes to immunity. Initially, 
tissue injury or microbial infection sensed by Toll like receptors (TLR) leads to the  
release of a myriad of chemical mediators by mast cells and macrophages that are 
responsible for recruiting neutrophils to the affected site. This migration involves four 
pivotal steps: vascular endothelial attachment via activation of adhesion molecules (L-
, P- and E-selectin), activation and up-regulation of integrins by cytokines (such as 
tumour necrosis-α (TNF-α), interleukin-1β (IL-1β), IL-6) and leucocyte-activating 
molecules; immobilisation of neutrophils on vascular endothelium (through binding to 
adhesion molecules); and migration through endothelium to sites of injury with the 
aid of proteases, e.g. matrix metalloproteases (MMPs) (Coussens and Werb 2002).  
Furthermore, neutrophil transmigration is significantly influenced by chemotactic 
cytokines called chemokines. These are small proteins that are designated into four 
groups C, CC, CXC and CX3C, according to the position of the first cysteine residues 
in the amino-terminal part of the protein (Mantovani, Savino et al. 2010).  Currently, 
50 human chemokines have been described along with 20 seven-transmembrane-
domain chemokine receptors. These molecules are stimulated by lipopolysaccharide 
(LPS) and cytokines such as IL-6, IL-1, TNF-α and interferon-γ (IFN-γ). The CXC 
subfamily plays a significant role in neutrophil chemoattraction, with CXCL8 (IL-8) 
and CXCL5 possessing particularly potent chemoattractive functions. Furthermore 
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CCL2 that is released from endothelial cells and fibroblasts in response to IL-6, IL-1 
and TNF-α stimulation is very effective in recruiting blood monocytes to areas of  
tissue insult (Baggiolini 1998). Microbial destruction is then aided by the action of 
antibodies, complement and acute phase proteins that facilitate phagocytosis by 
macrophages and granulocytes. Normal acute inflammation is self-limiting and 
influenced by a number of regulatory mechanisms. This involves a switch from anti-
microbial tissue damage to tissue repair that utilises pro-inflammatory and anti-
inflammatory agents (Maiuri, Tajana et al. 2004; Lu, Ouyang et al. 2006). This 
change requires rapid scavenging of the inflammatory agent by macrophages and 
dendritic cells that induce apoptotic pathways and phagocytosis (Savill and Fadok 
2000; Savill, Dransfield et al. 2002; Lu, Ouyang et al. 2006). Prostaglandin E2 (PGE2) 
(Levy, Clish et al. 2001), TGF-β (Hodge-Dufour, Marino et al. 1998), 
glucocorticoids, reactive oxygen and nitrogen intermediates all act as powerful 
regulators (Nathan 2002). In addition to mediating inflammatory response, PGE2 
inhibits lymphocyte proliferation and cytokine synthesis by T-cells and macrophages 
(Levy, Clish et al. 2001). TGF-β exhibits multiple regulatory functions including 
downregulation of major histocompatability complex (MHC) II expression, inhibition 
of reactive oxygen intermediates and amelioration of macrophage and IFNγ activity 
(Hodge-Dufour, Marino et al. 1998). Glucocorticoids are potent suppressors of 
adhesion molecule and cytokine gene expression. All of these processes are essential 
to resolving inflammation and tissue remodelling.  
 
In situations where these regulatory mechanisms are subverted or the insult persists, 
inflammation becomes chronic and the cellular milieu is characterised by an 
abundance of macrophages and lymphocytes (Philip, Rowley et al. 2004). Pro-
inflammatory mediators such as reactive oxygen intermediates can induce DNA 
damage. Consequently damaged cells which usually undergo apoptosis are allowed to 
flourish and their proliferation is assisted by inflammatory cells and growth factors, a 
process which ultimately enhances tumourogenic potential (Mantovani, Allavena et 
al. 2008).  
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1.10.2 Inflammation and the tumour microenvironment 
Although inflammation initially serves as a protective process, there is growing 
evidence that inflammation can enhance tumourogenesis by facilitating proliferation,  
invasion, migration and ultimately survival of malignant cells (Balkwill and 
Mantovani 2001). This is substantiated by the increased risk attributed to particular 
inflammatory triggers in several malignancies (table 1.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.8 Inflammatory agents and conditions associated with malignancy. 
 
Tumour type Inflammatory stimulant 
 
  
Bladder cancer Schistosomiasis 
 
Bronchial Cancer Asbestos 
Silica 
 
Colorectal cancer Inflammatory bowel disease 
  
Gastric cancer Helicobacter pylori 
  
Hepatocellular carcinoma Hepatitis B & C 
 
Kaposi’s sarcoma Human Herpes Virus (HHV) 8 
 
MALT lymphoma Helicobacter pylori 
  
Mesothelioma Asbestos 
 
  
Oesophageal cancer Barrett’s metaplasia 
  
 
Ovarian cancer 
Asbestos 
Talc 
Endometriosis 
Ovulation 
 
Prostate cancer Prostatitis 
  
Thyroid cancer Thyroiditis 
  
 47 
 
The “double-edged sword” concept is now commonly attributed to the role of 
inflammation (Coussens and Werb 2002) and it now appears to be very fitting that 
Celsus assigned ‘tumour’ (i.e. swelling) as one of the cardinal signs of inflammation. 
More specifically, Virchow in 1863 was the first to suggest that neoplasms can 
originate at inflammatory sites (Balkwill and Mantovani 2001). Indeed, the features of 
cancer-related inflammation share all the principal elements that signify chronic 
inflammation, i.e. infiltration of inflammatory cells, release of cytokines and  
chemokines, induction of an angiogenic switch and tissue remodelling (Grivennikov, 
Greten et al. 2010).  
 
The inflammatory origins of cancer (figure 1.5) are believed to be governed by two 
pathways: the extrinsic pathway (i.e. inflammatory stimulants that increase cancer 
risk, table 1.8), and the intrinsic pathway (i.e. induction of cancer-related 
inflammation by oncogenes) (Mantovani, Allavena et al. 2008). Oncogenic mutations 
are known to have a significant effect on inflammatory signalling pathways within 
most solid malignancies.  This is typified by the role of mutations in the protein 
tyrosine kinase, RET, in the early stages of papillary thyroid cancer. In this disease, 
RET activation results in an inflammatory cascade involving cytokine and chemokine 
induction, leucocytic recruitment, angiogenesis and subsequent tumour cell invasion 
and metastasis (Mantovani, Allavena et al. 2008). This phenomenon is also evident 
with RAS and MYC mutations in pancreatic cancer, although it is believed that 
extrinsic factors such as chronic pancreatitis are also required to facilitate this 
malignant process (Guerra, Schuhmacher et al. 2007; Mantovani, Allavena et al. 
2008). The pivotal role of the intrinsic pathway in cancer-related inflammation is 
exemplified by mutations in tumour suppressor genes such as von Hippel-Lindau 
(VHL) in renal cancer, which stimulates angiogenesis via HIF-1α.  VHL also induces 
TNF-α and the chemokine receptor CXCR4 in malignant cells by interacting with the 
transcription factor NF-κB (Schioppa, Uranchimeg et al. 2003; Balkwill 2004). 
 
In addition to being a principal transcription factor in inflammatory processes, NF-κB 
is a key player in the initiation and progression of inflammation related cancers (e.g. 
hepatocellular carcinoma and colitis-associated cancer) by inducing inflammatory  
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mediators, angiogenic factors and anti-apoptotic genes (Greten, Eckmann et al. 2004; 
Pikarsky, Porat et al. 2004). Another transcription factor, signal transducer and 
activation of transcription 3 (STAT3) also has a pivotal role in inflammatory and 
tumorogenic processes by encoding for pro-survival genes (e.g. bcl-xl, cyclin-D1) 
(Bromberg, Wrzeszczynska et al. 1999), promoting evasion of tumour immunity by 
 
   
Figure 1.5 Intrinsic and extrinsic pathways in inflammation.  
(Adapted from Mantovani et al. Cancer and Inflammation, Nature 2008. 
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aiding myeloid derived suppressor cell (MDSC) expansion (Yu, Pardoll et al. 2009) 
and impeding the maturity of dendritic cells (Wang, Niu et al. 2004). NF-κB and 
STAT3 can be constitutively activated in the same tumour cells and both serve as the 
predominant signalling pathway for inflammatory mediators such as TNF-α, IL-6, 
COX-2 and IL-17 (Yu, Pardoll et al. 2009). Furthermore both can interact on multiple 
levels to enhance tumour progression whereby STAT3 can maintain or increase  
NF-κB activity in cancers (Yu, Kortylewski et al. 2007; Lee, Herrmann et al. 2009). 
 
One of the most significant components of the cancer microenvironment are tumour 
associated macrophages (TAM) which are polarised M2 cells that have poor antigen 
presenting capacity and suppress T-cell activation (Mantovani, Sozzani et al. 2002). 
This polarisation is thought to be directed by immunosuppressive cytokines such as 
IL-10 and TGF-β alongside regulatory T cells (Treg). Cytokines such as TNF-α, M-
CSF, IL-6 and leukaemia inhibitory factor (LIF) also skew monocytic cell 
differentiation towards M2 cells (Duluc, Delneste et al. 2007). Together with TGF-β, 
IL-10, CCL2 and VEGF, these cytokines also promote TAM infiltration into tumour 
cells (Duluc, Delneste et al. 2007). TAM can contribute to tumour progression 
through enhancing angiogenesis, extracellular matrix remodelling and metastatic 
development (Condeelis and Pollard 2006). Furthermore, in conjunction with 
MDSCs, TAMs significantly influence suppression of anti-tumour immunity in 
tumour cells via STAT3 signalling (Yu, Pardoll et al. 2009). 
 
Other inflammatory cells have been implicated in tumour progression. Mast cells can 
induce angiogenesis by releasing a variety of mediators (e.g.VEGF, heparin, 
heparanase, histamine, basic fibroblast growth factor (bFGF), CXCL8, TNF-
α, serine- and metalloproteinases) (Coussens and Werb 2001) and correlate with poor 
clinical outcome in diseases such non small cell lung cancer (NSCLC) and melanoma 
(Imada, Shijubo et al. 2000; Ribatti, Vacca et al. 2003). Neutrophils promote 
angiogenesis by releasing CXCL8 and VEGF and elevated levels serve as a 
prognostic factor for adverse outcome in renal cell carcinoma treatment with VEGF 
targeted agents (Heng, Xie et al. 2009).  Furthermore, neutrophils produce reactive 
oxygen species (ROS) and metalloproteinases that both promote tumour cell  
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migration and invasion (Wu, Wang et al. 2001; Wu 2006). In addition, cancer 
associated fibroblasts (CAF) are frequently found in stromal compartments of tumour 
cells and can enhance neoangiogenesis and tumour cell invasion (Shimoda, Mellody 
et al. 2009). 
 
Further evidence of cancer-related inflammation is seen with the relationship between 
tumour cell dissemination, chemokines and chemokine receptors. In parallel with the 
role of directing cell migration to inflammatory foci, chemokines also facilitate 
tumour cell migration down chemokine gradients to distant sites which then manifest 
as metastasis (Balkwill 2004; Bonecchi, Galliera et al. 2009).  Chemokine receptors 
and their respective ligands are expressed on malignant cells in numerous tumour 
types and it is now widely accepted that chemokines can modulate the migration of 
tumour cells that cause metastatic disease. Muller et al demonstrated that both 
CXCR4 and CCR7 were highly expressed in breast cancer cells (Muller, Homey et al. 
2001). This group have also shown in a breast cancer xenograft model that treatment 
with a CXCR4 antibody inhibits metastasis to lung and lymph nodes (Muller, Homey 
et al. 2001).  Interestingly, CXCR4 expression appears to be omnipresent in the 
majority of malignancies studied so far and its corresponding ligand, CXCL12 
(alternatively known as stromal cell-derived factor 1 (SDF-1)) is highly expressed in 
organs which serve as common sites for metastases, i.e. liver, lung, bone marrow and 
lymph nodes. Furthermore, during organogenesis both CXCR4 and CXCL12 both 
play important physiological roles, with CXCR4 in particular being intimately 
involved with cell proliferation, differentiation and angiogenesis (Burger and Kipps 
2006; Zlotnik 2006), all processes vital to the development of metastases.  Conditions 
that facilitate metastasis also influence CXCR4 activation. In vivo, under normoxic 
conditions, CXCR4 is usually inhibited by pVHL by neutralising hypoxia inducible 
factor (HIF) (Staller, Sulitkova et al. 2003). During hypoxia, this process is itself 
suppressed and CXCR4 is up-regulated in renal cancer cells (Schioppa, Uranchimeg 
et al. 2003). Similarly, in breast cancer, HER2 is believed to induce CXCR4 and 
inhibit ligand induced CXCR4 degradation (Li, Pan et al. 2004).  
 
However, the effect of chemokines in tumour progression and metastases is not only 
restricted to facilitating tumour cell migration. CXCL1 and CXCL8 which both bind  
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to CXCR2 are associated with autocrine cell growth in melanomas (Singh, Gutman et 
al. 1994). Furthermore, both of these ligands have been linked oncogenic cellular  
transformation and angiogenesis (Yang, Chen et al. 2000; Tanaka, Bai et al. 2005). 
Chemokines also facilitate recruitment of TAM that are instrumental in promoting 
cancer progression.  CCL5 (regulation on activation, normal T cell expressed and 
secreted [RANTES]) and CCL2 (MCP-1) are commonly expressed in a variety of 
tumours. In breast cancer, high CCL5 correlates with increased TAM infiltration and 
lymph node metastases (Luboshits, Shina et al. 1999; Tanaka, Bai et al. 2005). 
Similarly, in oesophageal cancer, CCL2 expression also correlates with TAM 
infiltration, invasion and tumour angiogenesis (Ohta, Kitadai et al. 2002; Tanaka, Bai 
et al. 2005).  
 
1.11  Ovarian cancer related inflammation 
 
1.11.1 Inflammation and the aetiology of EOC 
 
The relationship between incessant ovulation and ovarian cancer is based upon the 
hypothesis that recurrent damage inflicted upon the ovarian epithelium encourages 
defective DNA repair, tumour suppressor gene inactivation and ultimately malignant 
transformation (Ness and Cottreau 1999). Furthermore, ovulation is characterised by 
local release of inflammatory mediators including the cytokines IL-1β, IL-6, TNF-α, 
GM-CSF (Makinoda, Hirosaki et al. 2008) platelet-activating factor, prostaglandins, 
histamine and bradykinin (Espey 1994). These substances may influence the 
epithelium in ovulatory tissue by enhancing cell replication and create oxidative stress 
that can potentially facilitate the development of malignant cells (Espey 1994).  
 
There is also increasing evidence that elevated C-Reactive protein (CRP), a marker of 
inflammation, may predict the risk of developing EOC. A case-control study 
conducted by McSorley et al measured serum CRP levels in 167 patients with ovarian 
cancer and found that increased ovarian cancer risk correlated with increased CRP 
(OR 1.72; 95% CI 1.06-2.77) (McSorley, Alberg et al. 2007). These observations  
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have recently been supported by prospective cohort studies. Lundin et al analysed the 
association between ovarian cancer risk and pre-diagnostic CRP in 237 cases and 427 
matched controls in three cohorts from Sweden, USA and Italy and found a 
substantial increase in ovarian cancer risk with CRP concentrations > 10mg/l (OR 4.4; 
95% CI 1.8-10.9) (Lundin, Dossus et al. 2009).  The relationship between CRP and 
EOC also extends to predicting prognosis. Using an inflammation-based prognostic 
score, Sharma et al found that chronic elevation of CRP (>10mg/l) was an 
independent poor prognostic indicator in patients with stage III/IV disease (Sharma, 
Hook et al. 2008). 
 
A number of aetiological factors have been consistently linked to the development of 
chronic ovarian inflammation and subsequent manifestation of EOC.  Although there 
is convincing evidence relating to the role of talc/asbestos exposure or endometriosis 
in EOC pathogenesis (Gertig, Hunter et al. 2000; Van Gorp, Amant et al. 2004), the 
contribution of pelvic inflammatory disease is now less certain (Merritt, Green et al. 
2008).  Endometriosis, implantation of endometrial tissue outside of the uterus, is 
believed to occur in the ovary secondary to either retrograde menstruation or 
lymphatic spread. The presence of ectopic tissue sets up an inflammatory reaction 
reflected in the release of pro-inflammatory cytokines and macrophage activation. 
Moreover, there is evidence to support the relationship between endometriosis and 
different histological subtypes of EOC.  A recent literature review focusing on the 
development of a series of EOC subtypes has confirmed that endometriosis was 
evident in 4.5% serous, 1.4% mucinous, 35.9% clear cell and 19% endometrioid 
ovarian cancers (Van Gorp, Amant et al. 2004). In addition, it appears that 
endometriosis confers a relative risk of ovarian cancer of 2.5 and this risk increases to 
4.0 if the ovary is involved in the endometriosis (Brinton, Gridley et al. 1997). 
 
The association between asbestos exposure and ovarian cancer originated from 
research in the 1960s (Graham and Graham 1967) and retrospective analyses of 
female asbestos workers identified an increased risk of developing EOC  
(Newhouse, Berry et al. 1972; Acheson, Gardner et al. 1982; Newhouse, Oakes et al. 
1985). This observation was further substantiated by in vivo studies showing the  
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development of EOC in animals who had received intraperitoneal injections of 
asbestos (Neugut, Eisenberg et al. 1978; Acheson, Gardner et al. 1982). Similarly, 
dusting of the perineum with talc, which prior to the 1970s contained asbestos, also 
increases the risk of EOC. Cramer et al found a significant association between 
genital talc exposure and EOC risk in a population based case control study with 563 
EOC cases (OR 1.60; 95% CI 1.18-2.15) (Cramer, Liberman et al. 1999).  Merritt 
found similar observations amongst 1,573 women with invasive or low malignant 
potential (LMP) ovarian tumours (adjusted OR 1.17; 95% CI 1.01-1.36) (Merritt, 
Green et al. 2008). As with a number of other studies, this link was particularly 
significant with serous tumours (Cook, Kamb et al. 1997; Cramer, Liberman et al. 
1999; Gertig, Hunter et al. 2000; Merritt, Green et al. 2008). Talc exposure, in 
combination with endometriosis, can result in a three fold increased risk of ovarian 
cancer, which was more than the risk incurred by either of these factors alone (Wu, 
Pearce et al. 2009). Although these studies establish the fact that talc particles can 
seed into the genital tract to induce ovarian malignancy, the inflammatory mechanism 
underlying this process requires further investigation.  
 
With respect to pelvic inflammatory disease (PID), there is a paucity of data to 
support its role in EOC pathogenesis. Rich and Howe conducted a case-control study 
with 450 EOC cases and concluded that there was an increased risk of EOC in 
patients with a history of recurrent PID (OR 1.60; 95% CI 1.09-2.35; p = 0.016) 
(Risch and Howe 1995). However, the Merritt study did not find this association 
(Merritt, Green et al. 2008). 
 
1.11.2 Inflammatory cells in the EOC microenvironment 
 
Inflammatory cells have diverse functions in cancer related inflammation and this is 
certainly evident within in the EOC tumour microenvironment (table 1.9). The 
interaction between macrophages and tumour cells has been shown to enhance EOC 
progression.  Through NF-κB and TNF-α, macrophages promote ovarian cancer cell  
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Cell types Function/Prognostic associations 
Macrophages (TAM), dendritic cells Immunosuppression (Curiel, Wei et al. 2003; 
Kryczek, Wei et al. 2007) 
 
Inhibition of T cell proliferation via IL-10 & 
TGF-β (Loercher, Nash et al. 1999) 
 
Induction of angiogenesis and tumour cell 
invasion (Turner, Scotton et al. 1999; 
Hagemann, Wilson et al. 2005) 
 
Neutrophils Facilitate ECM remodelling & tumour cell 
invasion (Klink, Jastrzembska et al. 2008) 
 
B cells, NK cells Tumour infiltrates linked with poor survival 
(Dong, Elstrand et al. 2006) 
 
Mast cells High tumour density associated with 
improved overall survival (Chan, Magistris et 
al. 2005) 
 
Fibroblasts Facilitate ECM remodelling & tumour cell 
invasion (Boyd and Balkwill 1999) 
 
CD4+ Th17 cells Promotes tumour growth (Charles, Kulbe et 
al. 2009) 
 
High counts from ascites associated with 
improved overall survival (Kryczek, Banerjee 
et al. 2009) 
 
CD4+  Treg cells Suppress IL-2 and IFN-γ anti-tumour 
function, increased density associated with 
poor prognosis (Curiel, Coukos et al. 2004) 
 
CD8+ T cells Increased density associated with improved 
outcome (Zhang, Conejo-Garcia et al. 2003; 
Sato, Olson et al. 2005; Stumpf, Hasenburg 
et al. 2009) 
 
Table 1.9 Roles and prognostic associations of immune and inflammatory cells in 
the EOC microenvironment. 
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invasion in vitro (Hagemann, Wilson et al. 2005) and when co-cultured in vitro, these 
cancer cells can polarise macrophages to the TAM phenotype (Hagemann, Wilson et 
al. 2006).  TAM can also inhibit T cell proliferation by producing IL-10 and TGF-
β (Loercher, Nash et al. 1999). In addition, macrophages can accumulate in areas of  
hypoxia within ovarian cancer cells and can induce angiogenesis and invasion 
resulting in tumour progression (Turner, Scotton et al. 1999). In comparison to normal 
subjects, macrophages isolated from EOC patients have been shown to have defective 
cytotoxic functions (Gordon and Freedman 2006). TAM infiltration can correlate with 
overall survival in EOC. Wan et al analysed CD68 expression in 67 ovarian cancer 
specimens and reported a 5-year survival of 41.2% and 73.3% for high TAM density 
and low TAM density group respectively (p=0.01) (Wan, Liu et al. 2009). They also 
observed high-density TAM in serous and poorly differentiated carcinomas; both of 
which are independent poor prognostic factors (Wan, Liu et al. 2009).  
 
Tumour infiltrating lymphocytes (TILs) appear to have contrasting roles in the realms 
of tumour immunity within the EOC microenvironment.  Dense populations of CD3+ 
and CD8+ T cells in tumour epithelium are associated with increased progression free 
and overall survival (Zhang, Conejo-Garcia et al. 2003; Sato, Olson et al. 2005; 
Stumpf, Hasenburg et al. 2009). Certain T-cell populations can paradoxically enhance 
tumour development.  Forkhead-box P3 (FoxP3+) CD25+ regulatory T (Treg) cells 
function by subverting anti-tumour immunity and can be found in high percentages 
amongst TIL populations in EOC patients. Woo et al documented that Treg cells can 
contribute to immunosuppression by secreting TGF-β (Woo, Chu et al. 2001) and 
may also impair the functioning of neighbouring cytotoxic CD8+ T cells. Further 
studies have confirmed the association of CD4+CD25+ T cells with poor prognosis in 
EOC. Curiel et al observed that the proportion of these cells in ascites increased along 
with advanced stage and they were preferentially concentrated in areas of tumour 
mass as opposed to tumour draining lymph nodes (Curiel, Coukos et al. 2004). This 
group also noted that CD4+CD25+ T cells suppressed in vitro production of IFN-γ and 
IL-2; cytokines that both promote anti-tumour immunity (Curiel, Coukos et al. 2004).   
 
Several other cell types are known to have immunosuppressive functions within the 
EOC tumour microenvironment. Poor prognosis can be associated with increased B  
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and natural killer (NK) cell infiltrates found in ascites from EOC patients (Dong, 
Elstrand et al. 2006). T-cell mediated immunity can be inhibited by B7-H1 (a ligand 
for inhibitory receptor PD-1 on T cells) found on the surface myeloid dendritic cells  
(MDCs) (Curiel, Wei et al. 2003). Furthermore, macrophages can recruit Tregs into 
tumour cells through CCL22 (Kryczek, Wei et al. 2007).  
 
The role of a new subset of CD4+ Th cells, Th17 cells, in ovarian cancer has yet to be 
established as conflicting opinions remain as to whether they promote or inhibit 
tumour promotion.  These IL-17 secreting cells, which also release IL-2, TNF-α and 
IFN-γ (Kryczek, Banerjee et al. 2009) have been linked to both protective immunity 
in pulmonary infections and pathological immunity in autoimmune diseases (Yu, 
Pardoll et al. 2009). The opposing functions of Th17 in ovarian cancer have been 
highlighted in two recent publications. Kryczek et al analysed CD4 + populations in 
201 ovarian cancer samples and found positive correlations between high Th17 counts 
and improved overall survival in ovarian cancer patients (Kryczek, Banerjee et al. 
2009). However, Charles et al have shown that under the influence of TNF-α, Th-17 
cells can exhibit tumour promoting activity in a syngeneic model of ovarian cancer 
(Charles, Kulbe et al. 2009). In addition, Th17 differentiation and expansion is 
enhanced by other inflammatory cytokines that are implicated in EOC progression, 
e.g. IL-6, IL-1β and IL-23 (Miyahara, Odunsi et al. 2008).  Further research is 
required to confirm the prognostic significance of these cells within the EOC tumour 
microenvironment.  
 
There is evidence to suggest that neutrophils have a role in EOC progression.  Klink 
et al have shown that by direct contact with EOC cells, neutrophils have increased 
ROS production through extracellular signal-regulated kinase (ERK) 1/2 signalling  
and upregulated CD11b/CD18 adhesion molecule expression; both of which are 
central to ECM remodelling and tumour cell migration (Klink, Jastrzembska et al. 
2008).  
 
The invasive capacity of EOC cells can be dictated by tumour associated fibroblasts 
and their relationship with matrix metalloproteases. A number of studies have shown 
that fibroblasts at the edge of invasive ovarian tumours have increased mRNA for  
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MMP2 and its negative regulator, TIMP-2 (Campo, Merino et al. 1992; Autio-
Harmainen, Karttunen et al. 1993; Naylor, Stamp et al. 1994). Balkwill et al have 
postulated that ovarian cancer cell interaction with fibroblasts can increase proMMP2  
and TIMP-2 production by these fibroblasts (Boyd and Balkwill 1999). Furthermore, 
proMMP2 can be activated by the presence of collagen I in the tumour 
microenvironment which consequently leads to extracellular remodelling and tumour 
invasion (Boyd and Balkwill 1999). 
 
Although recent evidence suggests that increased tumour mast cell infiltrates in EOC 
are associated with improved overall survival (Chan, Magistris et al. 2005), the study 
of lymphocyte and/or monocyte ratios in EOC specimens is emerging as a novel 
method of predicting prognosis. Through IHC analysis, Sato et al correlated high 
CD8+: Treg ratios in intraepithelial cells with improved overall survival in a cohort of 
patients who predominantly had advanced stage disease (Sato, Olson et al. 2005). In 
addition, further studies have shown that increased monocyte or neutrophil to 
lymphocyte ratios in pre-treatment blood samples from EOC patients are linked to 
poor outcome (Bishara, Griffin et al. 2008; Cho, Hur et al. 2009). 
 
1.12 Inflammatory mediators in ovarian cancer 
 
Pro-inflammatory cytokines and chemokines mediate interactions between the 
malignant and stromal cells in the ovarian cancer microenvironment.  Research has 
identified a number of pro-inflammatory molecules and growth factors that have 
important roles in EOC progression (table 1.10).  
 
1.12.1 TNF-α  
Since TNF-α was discovered in the mid-1970s, it has become established as a 
principal regulator of inflammation and plays essential roles in the cytokine network. 
Historically, the understanding of the relationship between TNF-α and cancer has 
proved to be quite intriguing. Initial reports revolving around the beneficial effects of 
a tumour necrosing factor have been documented from the early 20th century with the  
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Cytokine Function 
        IL-1β  Enhances tumour cell proliferation, invasion, motility & 
metastasis (Auersperg, Wong et al. 2001) 
Increase memory Th17 expansion (Miyahara, Odunsi et al. 2008) 
  
IL-6 Enhances tumour cell proliferation (Watson, Berek et al. 1993; 
Burke, Jin et al. 2001), motility & invasion (Silver, Naora et al. 
2004) 
 Up-regulates anti-apoptotic genes (Huang, Page et al. 2000; 
Duan, Foster et al. 2006) 
 Stimulates angiogenesis by VEGF induction (Nilsson, Langley et 
al. 2005) 
 Promote chemoresistance by MDR1 up-regulation (Duan, Foster 
et al. 2006) 
 Th17 expansion in conjunction with TGF-β (Miyahara, Odunsi et 
al. 2008)   
  
IL-8 Enhances tumour cell proliferation, invasion and metastasis 
(Toutirais, Chartier et al. 2003; Wang, Ngalame et al. 2005) 
 Promotes angiogenesis (Merritt, Lin et al. 2008) 
 Subverts tumour immunity (Toutirais, Chartier et al. 2003) 
  
TNF-α  Tumour initiation (Kwong, Chan et al. 2009), proliferation and 
metastasis (Kulbe, Thompson et al. 2007) 
 Promotes neo-vascularisation (Kulbe, Thompson et al. 2007) 
 Induction of pro-inflammatory cytokines and chemokines (Kulbe, 
Thompson et al. 2007) 
 Increase memory Th17 expansion (Charles, Kulbe et al. 2009) 
  
  
TGF-β  Promotes Th17 differentiation with IL-6 (Miyahara, Odunsi et al. 
2008) 
 Subverts tumour immunity (Toutirais, Chartier et al. 2003) 
  
IL-17 Promotes tumour growth (Charles, Kulbe et al. 2009) 
 Myeloid cell recruitment in tumour microenvironment (Charles, 
Kulbe et al. 2009) 
 Promotes angiogenesis (Kato, Furumoto et al. 2001) 
  
CCL2 Facilitates leucocytic infiltration into tumour (Negus, Stamp et al. 
1997) 
  
CXCR4/CXCL12 Promotes tumour proliferation, invasion and metastasis (Milliken, 
Scotton et al. 2002; Tanaka, Bai et al. 2005) 
  
MIF          Enhances tumour cell proliferation (Hagemann, Robinson et al. 
2007) and invasion (Hagemann, Wilson et al. 2005) 
          Promotes angiogenesis (Hagemann, Robinson et al. 2007) 
  
M-CSF          Promotes tumour invasion and metastasis (Toy, Azodi et al. 2009) 
  
 
Table 1.10 Important cytokines & chemokines in the EOC microenvironment. 
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use of Coley’s mixed toxins; where the injection of bacterial isolates into cancer 
patients resulted in sustained remissions (Balkwill 2009). 
 
Furthermore, these observations were subsequently recapitulated by using bacterial 
extracts in animal cancer models (Balkwill 2009). However, the true origin of TNF-α 
can be pinpointed to the discovery by Carswell et al that a factor that they named TNF 
was produced by host cells in response to endotoxin, and was responsible for tumour 
destruction rather than the bacterial endotoxin itself (Carswell, Old et al. 1975). 
Although there have been a few more recent examples of effective recombinant TNF 
treatment for specific cancers (Lienard, Ewalenko et al. 1992; Grunhagen, de Wilt et 
al. 2006) over the last decade, there has been a paradigm shift in the way the role of 
TNF-α in cancer is viewed. 
 
Ligand binding to TNFR1 induces a myriad of inflammatory mediators and growth 
factors through activation of transcription factor activator protein-1 (AP-1) or 
Iκβ kinases that can activate NF-κB. Consequently, NF-κB suppresses apoptosis 
through cFLIPL and Bcl-2 (Balkwill 2009) and acts as a key regulator of 
proangiogenic factors such as Vascular Endothelial Growth Factor (VEGF) and 
CXCL8 (Yamamoto and Gaynor 2001; Karin, Cao et al. 2002; Dobrovolskaia and 
Kozlov 2005; Lin, Kunnumakkara et al. 2007).  In situations where NF-κB activation 
is inadequate, TNFR1 signalling can drive apoptosis through caspase 8 and c jun N-
terminal kinase (JNK) (Balkwill 2009).  The functions exhibited by TNFR1 may be 
modulated by TNFR2 on immune and endothelial cells. Moreover, in addition to 
mediating inflammatory processes through TNFR1 signalling, TNF-α production in 
tumour cells is increased by mutations in tumour suppressor genes (Galban, Fan et al. 
2003) and possibly through Toll-like receptor signalling (Tsan 2006).  There is 
emerging evidence to suggest that TNF-α may contribute to either the initiation or the 
early stages of the malignant transformation of ovarian cells. Using an  
in vitro organoid model of normal human ovarian surface epithelial (HOSE) cells 
treated periodically with recombinant human TNF-α, Kwong et al demonstrated that 
these cells developed phenotypic features resembling precancerous lesions of EOC 
(Kwong, Chan et al. 2009).   
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Figure 1.6 Tumourogenic actions of TNF-α  in the tumour microenvironment.   
TNF-α, made by malignant cells and myeloid cells in the tumour microenvironment functions 
predominantly through TNF receptor 1 (TNFR1) in an autocrine and paracrine manner. 
TNF-α also induces further expression of TNF-α and other cytokines, chemokines and the 
chemokine receptor CXCR4 by the malignant cells. Cytokines and chemokines combine to act 
on, and are produced by, myeloid cells within the tumour microenvironment. This can 
promote the development of tumour-associated (M2) macrophages that play significant roles 
in extracellular matrix remodelling and angiogenesis. Ultimately, these processes facilitate 
tumour growth, tumour survival, leucocytic infiltration, angiogenesis, chemoresistance and 
metastatic spread.  
 
TNF-α has evolved as the principal mediator between other cytokines/chemokines 
and processes resulting in the progression of EOC (Kulbe, Thompson et al. 2007) and 
many other cancers (figure 1.6). Kulbe et al have shown that constitutive production  
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of TNF-α by malignant cells is associated with increased production of IL-6, 
macrophage migration inhibitory factor (MIF),VEGF, CCL2 and CXCL12 (Kulbe, 
Thompson et al. 2007), promotion of metastasis and neo-vascularisation of tumours in 
EOC xenograft models (Kulbe, Thompson et al. 2007). This study also confirmed that 
when stable TNF-α knockdown was achieved, both tumour growth and dissemination 
were significantly reduced. Furthermore, the tumours derived from these knockdown 
cell lines were phenotypically less aggressive with reduced vascularisation, smaller 
deposits and increased levels of apoptosis (Kulbe, Thompson et al. 2007). 
 
In tissue culture studies TNF-α was only secreted by malignant ovarian cells and 
these malignant cells expressed up to 1000 times more TNF-α mRNA than normal 
ovarian surface epithelial cells (Szlosarek, Grimshaw et al. 2006). These levels 
decreased after treatment with infliximab, a neutralizing antibody to TNF-α. The links 
between TNF-α and cancer are also supported by the elevated concentrations found in 
the serum/plasma taken from patients with a range of tumour types in comparison to 
normal healthy subjects who have almost undetectable levels (Balkwill 2006). 
Moreover, these levels in cancer patients also correlate with advanced stage along 
with poor prognosis (Ferrajoli, Keating et al. 2002; Pfitzenmaier, Vessella et al. 2003; 
Szlosarek and Balkwill 2003; Michalaki, Syrigos et al. 2004). 
 
Recent studies have found that the tumour promoting activity induced by TNF-α in 
EOC can occur through novel inflammatory pathways. Using an ID8 syngeneic model 
of ovarian cancer, Charles et al have observed that CD4 TNFR1 signalling results in 
increased IL-17 in tumour bearing mice. Subsequently, this led to myeloid cell 
recruitment in the tumour microenvironment and enhanced tumour growth. 
Interestingly, through a bioinformatic approach, they identified that genes associated 
with the Th17 pathway mapped closely with those ascribed to the TNF-α signalling 
pathway (Charles, Kulbe et al. 2009). 
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1.12.2 IL-1β  
Alongside TNF-α, IL-1β is also responsible for IL-6 induction during inflammation. 
As with IL-6, IL-1β is believed to play a critical role in the expansion of memory 
Th17 cells in the ovarian tumour microenvironment (Miyahara, Odunsi et al. 2008).  
 
Serum IL-1β concentrations are significantly elevated in EOC and this can correlate 
with serum IL-6 levels. Maccio et al investigated the role of inflammatory processes 
in the development of anaemia in 91 patients with advanced EOC compared with 95 
healthy matched controls. In this study, the lowest haemoglobin levels were 
associated with high concentrations of IL-1β, IL-6 and TNF-α. Furthermore, IL-6 
levels correlated significantly with IL-1β (single regression analysis p=0.020) 
(Maccio, Madeddu et al. 2005). There is also evidence to suggest that IL-1β behaves 
as a growth factor in EOC. Marth et al demonstrated that OSE cell proliferation is 
stimulated by IL-1β and this effect can be partially inhibited with TNF-α blockade 
(Marth, Zeimet et al. 1996). In addition, IL-1β can enhance tumour cell invasion, 
motility and metastasis (Auersperg, Wong et al. 2001; Denkert, Koch et al. 2003).  
Despite this, the relationship between IL-1β and prognosis in EOC remains unclear. 
Although certain studies show some correlations between FIGO stage and elevated 
serum and ascitic IL-1β (Maccio, Madeddu et al. 2005; Mustea, Pirvulescu et al. 
2008), there are also data that confirm no relationship between high serum IL-1β 
concentration and prognosis in EOC (Zeisler, Tempfer et al. 1998). 
 
1.12.3 Chemokines and chemokine receptors 
As previously described in this chapter, chemokines regulate directed leucocyte 
trafficking during inflammation and are induced by a number of inflammatory 
cytokines and growth factors. They also display homeostatic functions by controlling 
migration of dendritic cells, lymphocytes and haematopoietic stem cells (Balkwill 
2004). Furthermore, chemokines and their receptors can control movement of cells in 
and out of tumours and chemokine signalling results in transcription of genes vital to 
processes such as cell invasion, motility and survival. Cells that possess the relevant  
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chemokine receptors migrate along a gradient (i.e. the chemokine gradient) towards 
areas with high concentrations of chemokines (Balkwill 2004; Bonecchi, Galliera et 
al. 2009).   
 
There is substantial evidence to support the concept that chemokine networks within 
the EOC microenvironment play an important role in metastatic development and  
tumour survival. Tumour cells and macrophages in ascites from patients with EOC 
and in ovarian cancer cell lines in vitro express the chemokine CCL2 (MCP-1) 
(Negus, Stamp et al. 1995). In addition, within ovarian tumour epithelial regions there 
are significant correlations between leucocytic infiltrates with chemokines (CCL2, 
CCL3 (MIP-1α), CCL4 (MIP-1β) and CCL5) (Negus, Stamp et al. 1997), chemokine 
receptors (CCR1, CCR2) (Scotton, Milliken et al. 2001, Milliken, Scotton et al. 
2002).  Chemokines may also influence the phenotyping of macrophages in EOC. 
Hagemann et al have reported that macrophages co-cultured with ovarian cancer cells 
exhibited a phenotypic switch to TAM and up to 500-fold increase in CCL2 mRNA 
expression when compared to control cultured macrophages (Hagemann, Wilson et al. 
2006). 
 
Scotton et al performed further exhaustive analysis of chemokine receptors in EOC 
biopsies and out of 14 chemokine receptors analysed only CXCR4 was expressed 
(Scotton, Wilson et al. 2001). They subsequently observed that the interaction 
between CXCL12 and CXCR4 also promotes extracellular matrix invasion, TNF-α 
synthesis and tumour proliferation. Moreover, these processes can be abrogated via 
inhibitors to both TNF-α and MMPs (Scotton, Wilson et al. 2002).  As CXCR4 is 
associated with poor prognosis in EOC (Kajiyama, Shibata et al. 2008), it has 
emerged as an attractive therapeutic target. Kajiyama et al have observed reduced 
peritoneal dissemination in vivo with the CXCR4 antagonist, AMD3100 (Kajiyama, 
Shibata et al. 2008). Furthermore, Kwong et al (Kwong, Kulbe et al. 2009) have also 
shown that CXCR4 inhibition using CTCE-9908 not only inhibits cell migration in 
EOC, but also causes cytotoxicity via mitotic catastrophe. Furthermore, this effect 
appears to be synergistic when CTCE-9908 is combined with paclitaxel. There is also 
emerging evidence to support the notion that CXCR4 may also influence EOC 
proliferation through interactions with the EGFR pathway i.e. ERK1/2 and Akt  
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kinases (Porcile, Bajetto et al. 2005). In addition, CXCR4 may act synergistically with 
EGFR in promoting EGFR mediated metastases in EOC (Guo, Cai et al. 2007). Hence 
combined inhibition of CXCR4 and EGFR may prove to be a promising future 
approach for targeted therapy in EOC (Guo, Cai et al. 2007). 
 
In a number of malignancies, CXCL8, also known as IL-8 exhibits a multitude of 
functions including stimulation of cell proliferation, induction of neutrophil 
attraction/activation and angiogenesis (Peveri, Walz et al. 1988; Koch, Polverini et al. 
1992; Miyamoto, Shimizu et al. 1998). In relation to tumour microenvironments, IL-8 
may also influence tumour growth and the invasive potential of malignant cells by 
regulating MMP-2 activity (Luca, Huang et al. 1997).  There is also evidence linking 
the constitutive production of IL-8 to EOC progression (Plante, Rubin et al. 1994; 
Ivarsson, Runesson et al. 1998; Penson, Kronish et al. 2000). Significantly, in vitro, 
both IL-6 and IL-8 in conjunction with TGF-β promote tumour growth, spread and 
evasion from immune responses in EOC cell lines (Toutirais, Chartier et al. 2003).  
Furthermore, they can amplify EOC proliferation through androgen receptor 
activation (Wang, Yang et al. 2005). 
 
Both NF−κB and AP-1 transcription factors are central to IL-8 expression. 
Additionally, in EOC, hypoxia can induce IL-8 gene transcription through signalling 
via Akt and p38 MAPK pathways, which are integral to regulating NF−κB and AP-1 
respectively (Kallunki, Deng et al. 1996; Sizemore, Leung et al. 1999). Xu et al 
observed that IL-8 expression could be reduced by targeting these pathways with 
specific PI3K and MAPK inhibitors (Xu, Pathak et al. 2004). Targeting NF−κB in 
vivo has also been shown to diminish the expression of both IL-8 and VEGF and has 
subsequently resulted in decreased tumour vascularisation and ultimately prolonged 
survival (Huang, Robinson et al. 2000).  More specifically, silencing IL-8 expression 
in EOC has potent anti-angiogenic effects. Research by Merritt et al not only 
correlated high IL-8 expression with poor prognosis in EOC patients, but they also 
demonstrated in HeyA8 and SKOV3ip1 xenograft models that liposome encapsulated 
IL-8siRNA could significantly reduce tumour vascular density both alone and in 
combination with taxane chemotherapy (Merritt, Lin et al. 2008).  
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1.12.4 Cyclooxygenases and EOC 
One of the strongest links between inflammation and EOC originates from the 
function of cyclooxygenases (COXs) in the ovarian tumour microenvironment. The 
principal role of COXs is to catalyse the conversion of arachidonic acid to 
prostaglandin H2, a process that serves as a key regulatory step in inflammation. 
These enzymes exist as two isoforms; COX-1 which is constitutively expressed by a 
variety of cells and mediates the housekeeping functions of prostaglandins, and COX-
2 which is induced by inflammatory cytokines (O'Banion, Winn et al. 1992). In 
normal ovarian tissue COX-2 has an important physiological role, as COX-2(-/-) 
female mice exhibit infertility and defective ovulation (Dinchuk, Car et al. 1995; Lim, 
Paria et al. 1997). Furthermore, COX-2 has been implicated in the pathogenesis of 
EOC and a number of other malignancies including colorectal, gastric, pancreatic and 
lung adenocarcinomas and squamous head and neck carcinomas (Wolff, Saukkonen et 
al. 1998; Chan, Boyle et al. 1999; Koga, Sakisaka et al. 1999; Tucker, Dannenberg et 
al. 1999). Shigemasa et al studied COX-2 mRNA expression using semi-quantitative 
PCR in 36 ovarian adenocarcinomas and observed a significant positive correlation 
between COX-2 expression and p53 accumulation (p=0.003) (Shigemasa, Tian et al. 
2003). Moreover, dysfunctional p53 may result in COX-2 overexpression in EOC 
(Shigemasa, Tian et al. 2003). Furthermore, Denkert et al have shown that COX-2 
expression is not only more common in EOC and borderline malignant tumours 
compared to benign cystadenomas, but it is also associated with significantly reduced 
overall survival in invasive tumours and hence serves as a poor prognostic factor in 
EOC (Denkert, Kobel et al. 2002). This observation has been substantiated by another 
study that correlates increased COX-2 expression with chemoresistance and 
ultimately poor clinical outcome (Ferrandina, Lauriola et al. 2002).  
 
It has been proposed that the mechanisms underlying NSAID-induced cytotoxicity in 
EOC is related to suppression of NF-κB activity which results in decreased 
transcription of a number of cytokines and chemokines which are central to  
angiogenesis, inhibition of apoptosis and promotion of invasion in EOC progression 
(Altinoz and Korkmaz 2004). Rodriguez-Burford et al analysed the effects of 
NSAIDs in EOC cell lines by treating OVCAR-3, SKOV-3 and CAOV-3 cells with  
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aspirin, paracetamol and a COX-2 inhibitor (NS-398) (Rodriguez-Burford, Barnes et 
al. 2002). All NSAID agents showed cytotoxicity in these cell lines and there were 
significant decreases in Ki-67 expression in both OVCAR-3 and SKOV-3 cells 
treated with NS-398. Additionally NS-398 decreased mitotic activity and increased 
apoptosis in all three cell lines (Rodriguez-Burford, Barnes et al. 2002). In vivo 
studies have also confirmed the efficacy of specific COX-2 inhibition in EOC. Using 
OVCAR-3 and DISS xenografts, Xin et al showed that blocking COX-2 activity with 
meloxicam suppressed tumour growth more effectively than non-selective COX 
inhibition with aspirin (Xin, Yokoyama et al. 2007). Furthermore, this group have 
shown that these anti-tumour effects are due to decreased VEGF expression together 
with diminished microvascular density and induction of apoptosis (Xin, Yokoyama et 
al. 2007).  
 
These studies have generated a lot of interest in the use of NSAIDs as preventative 
agents in EOC along with a number of other malignancies.  Various epidemiological 
studies have confirmed clear correlations between decreased risk and increased 
NSAID intake in colorectal, lung, prostate and lung tumours. These links were also 
observed in ovarian cancer whereby regular NSAID intake resulted in a 47% risk 
reduction (Harris, Beebe-Donk et al. 2005). In addition, case-control studies of long-
term aspirin use (i.e. >20yrs) amongst the general population have confirmed a 
relative risk of 0.82 (95%CI 0.69-0.99) for ovarian cancer (Cuzick, Otto et al. 2009).   
 
This section has outlined key inflammatory mediators that have well documented 
roles in the ovarian cancer microenvironment. However, another inflammatory 
cytokine, IL-6, is emerging as a significant mediator of a number of processes linked 
to disease progression and poor prognosis. 
 
1.13 Interleukin-6 (IL-6) 
 
IL-6 is a cytokine with a broad spectrum of biological activity relating to regulation of 
inflammation, cell differentiation, cell proliferation, immunomodulation,  
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haematopoiesis and oncogenesis. Human IL-6 consists of 184 amino acids and is 
produced by multiple host and tumour cells in the tumour microenvironment (figure 
1.7).  It was initially cloned in 1986 and identified as an antigen-nonspecific B-cell 
differentiation factor that induced B-cell production of immunoglobulins (Muraguchi, 
Kishimoto et al. 1981; Yoshizaki, Nakagawa et al. 1982; Naka, Nishimoto et al. 
2002). For this reason IL-6 was initially known as B-cell stimulatory factor 2 (BSF-
2). However around this time came the serendipitous discovery of other proteins, such 
as IL-1 inducible 26-kDa protein (Zilberstein, Ruggieri et al. 1986; Sehgal, Walther et 
al. 1987), that had identical biological functions. Since then IL-6 has been ascribed a 
variety of synonyms that relate to its specific functions e.g. hepatocyte-stimulating 
factor, monocyte-granulocyte inducer type-2, T-cell activating factor and cytotoxic T-
cell differentiation factor (Kishimoto, Taga et al. 1989). 
 
The human IL-6 gene has been mapped to chromosome 7p21-24 and is approximately 
5Kb with four introns and five exons (Yasukawa, Hirano et al. 1987). There is a 
significant degree of similarity to murine IL-6, with homology of 65% at the DNA 
level and 42% at the amino acid level (Kishimoto 1989). Furthermore, it contains a 
highly conserved domain that consists of four cysteine residues that are identical to its 
murine counterpart and this region is believed to play a critical role in IL-6 activity 
(Tanabe, Akira et al. 1988; Kishimoto 1989).  The human IL-6 gene is flanked by an 
upstream promoter which contains three TATA-like transcription initiation sites 
which are integral to IL-6 gene activation (Tanabe, Akira et al. 1988). Gene activation 
is mediated through a number of responsive elements, namely NF-κB, transcription  
factor AP-1, CCAAT enhancer binding protein β (CEBPβ; formerly known as nuclear 
factor IL-6 (NF-IL6)) and the multiple response element (MRE) (Keller, Wanagat et 
al. 1996). Together, CEBPβ and MRE constitute the serum response element (SRE). 
When SRE was first discovered in c-fos, it was found to activate gene transcription 
when serum starved cells were exposed to serum (Fisch, Prywes et al. 1987; Gilman 
1988). Various stimuli are responsible for inducing the IL-6 promoter through MRE; 
e.g. TNF-α, IL-1α, lipopolysaccharide (LPS), serum, cAMP, phorbol ester and 
forskolin (Walther, May et al. 1988; Ray, Sassone-Corsi et al. 1989; Ray, Tatter et al. 
1989). 
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Figure 1.7 IL-6 producing cells and biological functions. 
Adapted from Naka et al. (2006) The paradigm of IL-6: from basic science to medicine. 
 
Although cooperation between these individual elements may modulate IL-6 gene 
expression (Libermann and Baltimore 1990), there is evidence to show that NF-κB is 
critical to IL-6 promoter activation. Liberman et al reported that IL-6 induction by 
these stimulants in U-937 monocytic cells and HeLa cells was significantly 
diminished when the NF-κB binding site was abolished (Libermann and Baltimore 
1990). 
 
1.13.1 IL-6 signalling 
IL-6 acts through the formation of a high-affinity complex with its receptor. The IL-6 
receptor consists of an 80-kDa IL-6 binding glycoprotein gp80 (α-chain, IL-6Rα) and 
the 130-kDa signal transducer gp130 (β-chain). Both gp80 and gp130 exist in  
transmembrane and soluble forms (sgp80 and sgp130). The transmembrane domain of 
gp80 consists of a short intracytoplasmic region which associates with gp130 as a  
consequence of IL-6 binding. This leads to gp130 homodimerisation and signal 
transduction (i.e. classic signalling, figure 1.8 A).  
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Figure 1.8 Classic and trans-signalling of IL-6.  
A. The classic mode of IL-6 signalling involves IL-6 complexing with membrane bound IL-
6Rα. Trans-signalling is mediated via IL-6-sIL-6Rα complexes. Both modes involve 
association with membrane bound gp130 induce downstream signalling. B. sgp130 has no 
effect on classic signalling, however it inhibits trans-signalling by preferentially binding to 
IL-6-sIL-6Rα  complexes (Adapted from Scheller et al (2006) Interleukin-6 Trans-signalling 
in Chronic Inflammation and Cancer). 
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Both sgp80 and sgp130 are formed either by cleavage from the cell membrane by 
transmembrane metalloproteinases or translated from alternate mRNA splicing 
(Mullberg, Schooltink et al. 1993; Horiuchi, Koyanagi et al. 1994; Montero-Julian, 
Brailly et al. 1997; Jones, Horiuchi et al. 2001). IL-6 can still exert influences on cells 
lacking transmembrane gp80 by forming a complex with sgp80 and membrane bound 
gp130 to initiate downstream events. This is known as trans-signalling and is 
critically involved in inflammatory diseases (e.g. rheumatoid arthritis, peritonitis, 
asthma and inflammatory bowel disease) and malignancies such as colorectal cancer 
and AIDS-associated Kaposi’s sarcoma (Murakami-Mori, Taga et al. 1996; Scheller, 
Ohnesorge et al. 2006). Trans-signalling can be regulated by sgp130 which is able to 
selectively neutralise IL-6-sgp80 complexes. Furthermore, sgp80 can enhance the 
antagonistic activity of sgp130 (Muller-Newen, Kuster et al. 1998). Of note, the 
inhibitory effects of sgp130 are specific to trans-signalling as it has no effect on 
classic IL-6 signalling through transmembrane gp130 (Narazaki, Yasukawa et al. 
1993; Heinrich, Behrmann et al. 1998; Scheller, Ohnesorge et al. 2006) (figure 1.8 B).  
 
Whilst gp80 expression is limited to certain cell types (hepatocytes, monocytes, T 
cells, B cells, neutrophils and malignant cells (Jones, Horiuchi et al. 2001), gp130 
expression is ubiquitous. Furthermore gp130 acts as a common signal transducer for 
other cytokines in addition to IL-6, namely IL-11, ciliary neurotrophic factor (CNTF), 
cardiotropin-1 (CT-1), oncostatin M (OSM), neurotrophin-1 and leukaemia inhibitory 
factor (LIF). This group of cytokines are collectively known as the IL-6 cytokine 
superfamily (Autissier, De Vos et al. 1998) and their interaction with their respective 
binding receptors leads to heterodimerisation of gp130 (figure 1.9). Intracellular 
signalling is then initiated through activation of gp130 associated cytoplasmic 
tyrosine kinases, namely the Janus-activated kinases 1 and 2 (JAK1, JAK2) which 
phosphorylate STAT1 and STAT3 (Murakami, Hibi et al. 1993; Gerhartz, Heesel et 
al. 1996). IL-6 also activates Ras-Raf signalling, which regulates the phosphorylation 
of MAPK/JNK (Ogata, Chauhan et al. 1997). 
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Figure 1.9 IL-6 superfamily receptors. 
(Adapted from Bauer et al. Nature Reviews Neuroscience 8, 221–232 (March 2007). 
 
The association between IL-6 and cancer appears to revolve around gp130 activation 
of IL-6 signalling pathways that ultimately lead to evasion of apoptosis. This appears 
to be principally mediated through the aforementioned JAK/STAT transduction 
pathway. Within normal eukaryotic cells, STATs, particularly STAT3, are involved in 
the transduction of signals from the cell surface to its nucleus and activation of gene 
transcription. This results in the inhibition of apoptosis during inflammation and cell 
survival in suboptimal conditions. However, dysregulation of such processes may also 
promote the development of a number of malignancies including ovarian cancer 
(Hodge, Hurt et al. 2005). The heterodimer complex formed as the result of IL-6 
ligand binding associates with the JAK2 which is integral to phosphorylation in 
MAPK, PI-3K as well as STAT signalling. JAK2 mediated phosphorylation of 
STAT3 occurs at a single tyrosine residue (Yang, Chatterjee-Kishore et al. 2005) 
which is situated in a domain that facilitates the formation of dimeric structures 
(figure 1.10). Subsequently, STAT dimers form stable complexes that contain an 
exposed nuclear translocation signal. The complex is then able to translocate to the 
nucleus where enhancer elements in the promoter and enhancer regions of target 
genes are recognised which leads to the initiation of transcription (Sasse, Hemmann et 
al. 1997). Induced genes include acute phase proteins (C-reactive protein, fibrinogen) 
and anti-apoptotic mediators, namely Bcl-xL, cyclin D1 and Mcl-1. STAT3 signalling 
can also impair functioning of mature dendritic cells and mediate immunosuppression  
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(Wang, Niu et al. 2004). Furthermore, inhibition of STAT3 signalling may serve to 
restore anti-tumour immunity (Kortylewski, Kujawski et al. 2005). Through STAT3, 
IL-6 also has the ability to induce genes which themselves regulate further STAT3 
signalling.  Suppressor of cytokine signalling 3 (SOCS3) is induced by IL-6 and 
inhibits STAT3 signalling through a negative feedback loop (Nishimoto and 
Kishimoto 2006) (figure 1.10). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 STAT3 signalling.  
From Nishimoto N and Kishimoto T (2006) Interleukin 6: from bench to bedside Nat Clin 
Pract Rheumatol 2: 619–626. 
 
 
Recent research has emphasised the importance of the IL-6-gp130-STAT3 axis in 
tumour promotion. In colitis associated cancer (CAC) in vivo models, IL-6 can 
enhance proliferation of tumour initiating cells, increase tumour burden at late stages 
of disease and protect both normal and malignant intestinal epithelial cells (IEC) from 
apoptosis in a STAT3 dependent fashion (Grivennikov, Karin et al. 2009). 
Hyperactive STAT3 activity induced by mutant gp130 can also promote tumour 
growth in both colorectal and gastric carcinomas in vivo (Ernst, Najdovska et al. 
2008; Bollrath, Phesse et al. 2009). In contrast, within the CAC model, STAT3 
deletion in IEC resulted in a reduced number of tumours and shared phenotypic 
features seen with IL-6-/- models (Grivennikov, Karin et al. 2009).  
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Autocrine and paracrine IL-6 loops are evident in other tumour types. In vitro studies 
have confirmed that IL-6 behaves as an autocrine growth factor in both prostate 
(Cavarretta, Neuwirt et al. 2007) and renal cancers (Miki, Iwano et al. 1989). EGFR 
mutations in lung adenocarcinoma have been shown to induce IL-6 mediated STAT3 
activation (Gao, Mark et al. 2007) and, in neuroblastoma, stromal derived IL-6 can 
create a bone marrow microenvironment that potentiates metastatic development 
(Ara, Song et al. 2009).  
 
Alongside the aforementioned tumour types, both IL-6 and STAT3 signalling appear 
to be central to a number of key processes related to ovarian cancer progression. 
Constitutive activation of STAT3 is present in ovarian cancer lines but not in normal 
ovarian surface epithelial cells (Huang, Page et al. 2000). By utilising phospho-
specific STAT3 (Tyr-705) antibody, Huang et al showed that certain EOC cell lines 
(MDAH 2774, OV-1063, CAOV-3 and O.C 22819) expressed high levels of 
phosphorylated STAT3. Significantly, these cells also expressed high levels of anti-
apoptotic Bcl-xL and cyclin  D1 (Huang, Page et al. 2000). This was in contrast to 
normal ovarian surface epithelium and one other EOC cell line (A2780) which 
showed minimal STAT phosphorylation and low levels of Bcl-xL and cyclin D1.  
Research by Silver et al supports these findings as they found that activated STATs 
were not detected in surface epithelium of normal ovarian cells and phosphorylated 
STAT3 (pSTAT3) levels were more evident in high-grade carcinomas compared with 
indolent lower grade ovarian tumours (Silver, Naora et al. 2004). Furthermore, it has 
been hypothesised that methylation of SOCS proteins could contribute to aberrant IL-
6 signalling in ovarian cancer (Hong, Angelo et al. 2007). 
 
IL-6 has also been shown to influence tumour promotion through alternate signalling 
pathways such as Notch3.  Notch is a membrane protein that is integral to a variety of 
processes in normal tissues such angiogenesis, T cell maturation and neuronal 
development. In tumour cells, Notch signalling pathways are constitutively activated 
and may be continually upregulated as a result of genetic mutations (Park, Shih Ie et 
al. 2008). Recently, Sansone et al noted that IL-6 can stimulate Notch3 dependent 
upregulation of the Notch ligand Jagged1 and this promoted growth of breast cancer 
cells and maintained their aggressive phenotype (Sansone, Storci et al. 2007). 
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In ovarian cancer, the Notch3 gene is over-expressed and the interaction with Jagged1 
encourages cell proliferation and metastatic spread (Park, Li et al. 2006; Nakayama, 
Nakayama et al. 2007; Choi, Park et al. 2008). Furthermore, Kulbe et al have noted 
that exogenous IL-6 can induce Notch mRNA in ovarian cancer cell lines in vitro and 
this effect diminishes with STAT3 inhibition (Kulbe et al, manuscript submitted 
2010). 
 
1.13.2 IL-6 as an autocrine growth factor in ovarian cancer 
A number of in vitro studies have reported increased IL-6 expression in ovarian 
cancer. Elevated levels of IL-6 have been identified in ovarian tumour cell cultures 
with cells displaying intracellular IL-6 by immunoperoxidase staining (Watson, 
Sensintaffar et al. 1990). Additionally, most EOC cell lines display detectable levels 
of IL-6 mRNA expression (Berek, Martinez-Maza et al. 1993). Watson et al have 
demonstrated constitutive production of IL-6 in EOC cell lines such as CAOV-3, 
OVCAR-3 and SKOV-3 and its activity appears to be up-regulated by IL-1β, TNF-α 
and IFN-γ (Watson, Sensintaffar et al. 1990).  
 
Significantly, this group also discovered that inhibition of IL-6 gene expression using 
IL-6 anti-sense oligonucleotides could result in up to 85% inhibition of cellular 
proliferation (Watson, Berek et al. 1993). However this effect was not reversed with 
the addition of exogenous IL-6. Hence the role of IL-6 as an autocrine growth factor 
in ovarian cancer does not seem clear. The influence of IL-6 on cell growth appears to 
be related more to its downstream signalling pathways. Using a JAK-selective 
inhibitor, AG490, Burke et al illustrated significant reduction in cellular proliferation 
in EOC cell lines with constitutively activated STAT3 production (Burke, Jin et al. 
2001). These treated cells also exhibited decreased pSTAT3, STAT3 DNA binding 
activity and expression of Bcl-xL. More recently, Huang et al have shown that STAT3 
knockdown with shRNA in CAOV-3 cells can inhibit anchorage independent growth, 
induce apoptosis in vitro and decrease tumour growth in vivo (Huang, Tong et al. 
2008). 
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The constitutive activation of STAT3 in ovarian cancer cell lines has been further 
established through experiments focusing on the influence of reproductive hormones  
in EOC. Syed et al demonstrated that sex steroid hormones and gonadotrophins could 
stimulate growth in both human ovarian surface epithelium (HOSE) and EOC cell  
lines via IL-6 and STAT3 signalling.  Increased IL-6 mRNA and protein levels were 
evident in all cells treated with FSH, LH, oestrone and 17β-oestradiol. For both 
HOSE and EOC cell lines, IL-6 also stimulated cell proliferation in a dose dependent, 
STAT3 mediated fashion and this effect diminished with treatment with an IL-6 
antibody. In addition, some EOC cell lines exhibited higher levels of STAT3 
transcription factors and IL-6Rα than HOSE cells (Syed, Ulinski et al. 2002).   
 
1.13.3 Serum and ascitic IL-6  
Numerous studies have also focused on analysing IL-6 levels in blood and ascites 
from patients with ovarian cancer. In healthy human subjects, IL-6 concentrations 
found in blood greater than 10pg/ml are considered to be abnormally elevated (Song 
and Kellum 2005; Heikkila, Ebrahim et al. 2008). It is secreted in a biphasic circadian 
pattern with peaks at approximately 19:00 hrs and 05:00 hrs (Vgontzas, Bixler et al. 
2005). Higher concentrations of IL-6 have been found in cystic fluid of patients with 
malignant compared with benign ovarian tumours (van der Zee, de Cuyper et al. 
1995).  Patients with ovarian cancer also have higher serum IL-6 concentrations than 
normal healthy controls (Moradi, Carson et al. 1993). Additionally, there is evidence 
to suggest a relationship between elevated serum IL-6, tumour burden, disease stage 
and prognosis. Berek et al published data illustrating that high IL-6 levels correlated 
with bulky disease, elevated CA-125, disease progression and ultimately poorer 
prognosis (Berek, Chung et al. 1991).  
 
In parallel with the Berek study, Tempfer et al reported serum IL-6 levels in 73 
patients with FIGO stage I to IV EOC and higher IL-6 concentrations were observed 
in EOC patients compared with healthy controls. These IL-6 concentrations correlated 
with increasing tumour burden and subsequently decreased after surgery. The 
concentration observed prior to surgery had a statistically significant correlation to 
FIGO stage, but not to tumour grade or lymph node involvement. Furthermore,  
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elevated pre-surgical IL-6 concentration significantly correlated with both poorer 
disease-free survival (p=0.003) and overall survival (p=0.01) (Tempfer, Zeisler et al. 
1997). 
 
The prognostic significance of plasma IL-6 in ovarian cancer has since been 
substantiated in further studies. Scambia et al observed 114 patients who underwent 
surgery followed by adjuvant chemotherapy and 50% of these had high IL-6 levels  
(Scambia, Testa et al. 1995).  Again these levels correlated with poor prognosis as 
patients with low IL-6 levels had a better survival compared to those with elevated IL-
6  (51mo vs. 21 mo, p= 0.0009). This trend was also evident in patients who had 
either complete or partial response to chemotherapy. Univariate analysis of this study 
concluded that high pre-treatment IL-6 levels, together with stage IV disease and 
post-operative residual tumour diameter >2cm, correlated significantly with short 
survival. However, multivariate analysis showed that only FIGO stage and high IL-6 
significantly correlated with poor survival. Despite the prognostic information 
rendered from measuring IL-6 concentrations in EOC, its use as a tumour marker has 
yet to be validated. Earlier studies by Scambia et al on large population samples in 
ovarian cancer have shown that IL-6 is indeed less sensitive than CA-125. 
Additionally, the combination of IL-6 and CA-125 only marginally increased the 
overall sensitivity as compared to CA-125 alone (Scambia, Testa et al. 1994).  
 
Ascitic IL-6 concentrations appear to be generally higher than serum or plasma levels. 
Plante et al (Plante, Rubin et al. 1994) focused on the relationship between serum and 
ascitic IL-6 concentration in 70 patients with untreated, newly diagnosed EOC. All 
subjects subsequently received platinum-based chemotherapy following surgery. They 
found significantly higher ascitic IL-6 concentration (median: 49 612 pg/ml) 
compared with serum (median: 10 pg/ml). Ascitic IL-6 significantly correlated with 
volume of ascites (p<0.0001) and tumour size found at surgery (p = 0.05). However, 
there was no correlation between serum and ascitic IL-6 levels, survival time or 
tumour parameters such as grade and stage. 
 
The higher concentration of IL-6 in ascites compared with serum may relate to a surge 
in IL-6 production by EOC cells followed by rapid clearance into the vasculature  
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where IL-6 becomes either protein bound or degraded (May, Viguet et al. 1992; 
Plante, Rubin et al. 1994). As such, it has been postulated that biological activity and  
immunoreactivity of high serum IL-6 can be masked by such processes 
(May, Viguet et al. 1992). Other reasons contributing to the ascitic IL-6 profile relate 
to the presence of TAM. Punnonen et al observed that peritoneal fluid derived from 
EOC patients consisted of mesothelial cells, macrophages, neutrophils and 
lymphocytes (Punnonen, Teisala et al. 1998). Peritoneal mesothelial cells are a rich 
source of IL-6 production which is regulated by other cytokines such as IL-1β, TNF-
α and IFN-γ (Offner, Obrist et al. 1995). In addition, IL-6 is constitutively released by 
TAM in response to the presence of EOC cells and this is independent of TNF-α 
(Erroi, Sironi et al. 1989; Scambia, Testa et al. 1995). There is also evidence to 
suggest that a hierarchy of increased cytokine production is associated with different 
EOC histiotypes. Kutteh et al performed cytokine analysis for TNF-α, IL-1β and IL-6 
in ascitic/cystic fluid from 35 EOC patients (Kutteh and Kutteh 1992). Although all 
were identified in large concentrations, IL-6 was significantly higher than TNF-α and 
IL-1β in all histological groups studied. Papillary serous cases had a tendency to 
produce more IL-6 than non-papillary serous subtypes. In a similar study Kryczek et 
al demonstrated higher IL-6 activity in serous/mucinous than in endometrioid and 
undifferentiated EOC (Kryczek, Grybos et al. 2000). 
 
1.13.4 IL-6 gene promoter, p53 and ovarian cancer 
The tumour suppressor gene p53 appears to have variable effects on the IL-6 
promoter. Santhanam et al demonstrated that p53 was able to repress IL-6 
transcription in HeLa cells (Santhanam, Ray et al. 1991). However, in contrast to this 
study, Margulies et al demonstrated IL-6 up-regulation in cells with p53 mutants Val-
135 and Phe-132, both of which enhanced C/EBPβ mediated gene activation 
(Margulies and Sehgal 1993). Asschert et al also evaluated the role of IL-6 promoter 
regulation by p53 by using various stable mutant p53 transfectants of the human 
ovarian wt-p53 cell line A2780. This study concluded that the DNA binding activity 
of the AP-1 transcription factor differed in the various p53 clones, i.e. binding was 
either reduced or enhanced. Alterations were also evident in the AP-1 structure, 
particularly with respect to Fos and Fra proteins (Asschert, De Vries et al. 1999). 
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Interestingly, IL-6 promoter polymorphisms can affect the biological phenotype of 
ovarian tumours. In 121 patients with ovarian cancer, Hefler et al investigated a 
common G/C polymorphism at position-174 of the IL-6 promoter. The presence  
of at least one mutant allele was associated with early stage disease, improved disease 
free- and overall survival (Hefler, Grimm et al. 2003). However, these results would 
have to be reproduced in larger cohorts of patients prior to any correlations being 
established between these polymorphisms and prognosis in ovarian cancer. 
 
1.13.5 IL-6 induction of cell migration and invasion in ovarian 
cancer 
The influence of IL-6 on ovarian cancer cell motility is also mediated through STAT3 
signalling. As previously mentioned, Silver et al correlated constitutive pSTAT3 
production in ovarian cancer cell lines with phenotypically aggressive tumours 
(Silver, Naora et al. 2004). By using confocal micrographs of SKOV3 and OVCAR3 
cells plated on fibronectin, this group detected localisation of pSTAT3 in focal 
adhesions, structures that enhance cell migration by transducing extracellular signals 
into changes in the cytoskeleton and hence potentially facilitate invasion of malignant 
cells. Furthermore this localisation occurred when these cells were stimulated with IL-
6 in vitro (Silver, Naora et al. 2004). More recently, Colombiere et al have shown 
with wound healing assays that IL-6 can induce OVCA 433 cell migration and this 
can be reversed with a neutralising anti-IL-6R antibody (Colomiere, Ward et al. 
2009). 
 
1.13.6  IL-6 and angiogenesis in ovarian cancer  
As with VEGF, IL-6 is inducible in hypoxic conditions and indirectly promotes 
angiogenesis through the induction of VEGF expression in epithelial cells (Cohen, 
Nahari et al. 1996). Within normal ovarian tissue, IL-6 is involved in the formation of 
new blood vessels that accompany ovarian folliculogenesis (Motro, Itin et al. 1990). 
However, in relation to ovarian cancer and angiogenesis there are few studies that 
specifically focus on the role of IL-6 in this process.  Using immunohistochemistry 
analysis, Nilsson et al showed that IL-6R is expressed on endothelial cells in human  
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ovarian cancer specimens. Furthermore, with western blot analysis they demonstrated 
that IL-6 induced pSTAT3 in ovarian and mesentery endothelial cells. Furthermore, 
through STAT3 activation, IL-6 also promoted endothelial cell migration in vitro 
(Nilsson, Langley et al. 2005). This study also reported potent angiogenic effects 
associated with IL-6 in vivo. Gel foam sponges previously incubated with IL-6, bFGF 
or PBS, were implanted into the peritoneum of BALB/c mice for two weeks and then 
immunostained with CD31 and VEGFR-1 antibodies to estimate microvascular  
density. The vessel density with IL-6 treated sections was equivalent to bFGF, but 
significantly greater than PBS (p<0.0001) (Nilsson, Langley et al. 2005). 
 
1.13.7 IL-6 mediated chemoresistance in ovarian cancer 
Failure of response to platinum- and taxane-based chemotherapy in ovarian cancer is  
due to the development of chemoresistance. It is interesting to note that  
IL-6 behaves as a prominent mediator in molecular processes relating to failure of 
cytotoxic treatments in a variety of malignancies. In myeloid leukaemia, IL-6 inhibits 
apoptosis induced by p53, TGFβ1 and chemotherapy which reduces the efficacy of 
agents such as vinca alkaloids and anthracyclines (Yonish-Rouach, Resnitzky et al. 
1991; Lotem and Sachs 1992). IL-6 can also act as a resistance factor for platinum-
mediated cytotoxicity in hormone-refractory drug-resistant prostate cancer and these 
effects can be reversed by inhibition of signalling through the gp130 receptor 
(Borsellino, Belldegrun et al. 1995; Borsellino, Bonavida et al. 1999).  In ovarian 
cancer IL-6 is preferentially overexpressed in certain paclitaxel-resistant EOC cell 
lines compared with chemo-naïve counterparts (Duan, Foster et al. 2006). 
Furthermore, upregulation of IL-6 signalling pathways contributes to chemoresistance 
in ovarian cancer. Using paired resistant and sensitive human ovarian cancer cell 
lines, Duan et al demonstrated that STAT3 was overexpressed in some paclitaxel 
resistant lines and correlated high levels of IL-6 with increased STAT3 expression in 
the chemoresistant cell lines (Duan, Foster et al. 2006).  They concluded that 
chemoresistance could be reversed by STAT3 knockdown using siRNA, and found 
that apoptosis was enhanced when resistant lines were treated with a STAT3 inhibitor 
(AG490), paclitaxel or a combination of both drugs (Duan, Foster et al. 2006). Figure 
1.11 summarises the data implicating IL-6 in the pathophysiology of EOC. 
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Figure 1.11 IL-6 function and the EOC tumour microenvironment.   
IL-6 can exhibit pleiotropy within the EOC microenvironment primarily through pSTAT3 
signalling and interaction with other cytokine and chemokines. IL-6 contributes to ovarian 
tumours with aggressive phenotypes by promoting tumour cell proliferation, angiogenesis 
and platinum resistance alongside subverting tumour immunity. 
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1.14 Clinical trials targeting IL-6 in cancer  
 
With the evidence supporting the significant influence of IL-6 in numerous cancers, 
this cytokine is emerging as an attractive therapeutic target in the clinical setting. 
Several clinical trials using anti-IL-6/IL-6R therapy have been conducted in a range a 
tumour types with diverse results. These are summarised in table 1.11.  These studies 
have primarily been conducted in patients with poor prognosis disease and clinical 
benefit (stable disease or better) can be achieved by targeting IL-6 or IL-6R in this 
setting. The encouraging outcome from these trials has provided a sound rationale for 
developing further studies with anti-IL-6 therapy in ovarian cancer. 
 
1.15   Rationale for clinical trials targeting IL-6 in EOC 
 
This chapter has highlighted the involvement of inflammatory mediators in a number 
of biological processes that promote EOC progression and survival. Although there is 
an abundance of in vivo and in vitro experiments that clearly illustrate the beneficial 
effects of manipulating the EOC tumour microenvironment, translating these findings 
into the clinical setting remains a necessity. The closing section of this chapter aims to 
outline a rationale for anti-IL-6 trials in EOC by summarising key clinical studies 
targeting TNF-α, a principal inducer of IL-6.  
 
Targeting TNF/TNFR and downstream signalling 
Research using animal models over the past decade has implicated TNF-α in both 
tumour initiation and promotion. Moore et al have previously shown that deletion of 
TNF-α or its receptor TNFR1 induced resistance to skin carcinogenesis in mice 
(Moore, Owens et al. 1999).  Similarly, TNFR1 knockout mice appear to be resistant 
to chemical carcinogenesis of the liver (Arnott, Scott et al. 2004). Other studies 
relating to hepatic malignancies have highlighted the tumourocidal effects caused by 
selective deletion of NF-κB in hepatocytes or inhibition of TNF-α in parenchymal 
cells (Pikarsky, Porat et al. 2004). This decreased incidence in tumour development 
secondary to targeting TNF-α and its downstream pathways has also been confirmed 
in other cancer types such as colorectal cancer (Greten, Eckmann et al. 2004).  
 82 
 
 
Table 1.11 Clinical trials targeting IL-6/IL-6R in cancer. 
 
 
Tumour 
type 
Antibody Study 
design 
Clinical 
outcome 
Reference 
 
Multiple 
Myeloma 
 
Anti-IL-6 
 
10 patients with 
extramedullary 
disease; i.v. 
BE-8 (n=9) and 
intrapleural 
(n=1) Rx 
 
4 patients with 
previous PD, 
i.v. CNTO328 
12mg/kg every 
3weeks 
 
No objective 
remission; 
significant 
↓myeloma cell 
proliferation, 
CRP & IL-6 
 
2 patients with M 
protein bone 
marrow plasma cell 
% stabilisation 
 
 
 
Bataille, 
Barlogie et al. 
1995 
 
 
 
 
Kurzrock, 
Voorhees et al. 
2006 
 
 
Castleman’s 
disease 
 
Anti-IL-6R 
 
 
 
 
 
 
Anti-IL-6 
 
28 patients 
multicentric 
disease, 8 x i.v. 
MRA 8mg/kg 
biweekly 
 
 
9 patients, i.v. 
CNTO328 3-
12mg/kg every 
1-3 weeks 
 
 
↓lymph node 
size, fatigue, 
anaemia, CRP, 
ESR, fibrinogen 
 
 
 
7 patients 
obtained clinical 
benefit 
 
Nishimoto, 
Kanakura et al. 
2005 
 
 
 
 
van Rhee, 
Fayad et al. 
2006 
     Lymphoma        Anti-IL-6 11 patients 
HIV+ with 
polymorphic 
large cell 
lymphoma, i.v. 
BE-8 daily for 
21 days 
1 PR, 5 SD, 5 
PD; 8-24 wk 
disease 
stabilisation, 
↓fever & 
cachexia 
 
Emilie et al; 
1994 
 
Prostate 
 
Anti-IL-6 
 
8 patients 
HRPC, 
CNTO328 i.v. 
6mg/kg q2wks 
+ docetaxel 
75mg/m2 q3wks 
 
6 patients with ≥ 
50% PSA 
reduction, 
undetectable 
CRP after 7 
days and 
throughout 
treatment 
 
 
 
Hudes, Nanus 
et al. 2007 
 
Renal 
 
Anti-IL-6 
 
18 patients 
metastatic 
disease, 
CNTO328 i.v. 
6mg/kg q2wks 
 
 
11 SD, 7 PD, 
sustained ↑Hb 
levels 
 
Schipperus, 
Cornfeld et al. 
2009  
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There is also evidence implicating the efficacy of NF−κB inhibition in EOC. Lin et al 
observed the effects of Curcumin, an anti-inflammatory agent that is a constituent of 
turmeric, with and without docetaxel on SKOV3ip1, HeyA8 and HeyA8-MDR cell 
lines in athymic mice (Lin, Kunnumakkara et al. 2007). In vitro, Curcumin suppresses 
NF−κB and STAT3 activation and cell proliferation. Furthermore, this group also 
presented data suggesting that this agent reduced in vivo tumour growth both alone 
(SKOVip1 49%, p=0.08 & HeyA8 55%, p=0.01) and synergistically in combination 
with docetaxel (SKOVip1 96%, p<0.001 & HeyA8 77%). Interestingly, both 
treatment conditions resulted in significant reductions in cell proliferation (p<0.001), 
microvessel density (p<0.001) and increased apoptosis in malignant cells (p<0.05) 
(Lin, Kunnumakkara et al. 2007).  
 
In a clinical setting, our group have been involved in a phase II study with the TNF-α 
antagonist, etanercept (Madhusudan, Muthuramalingam et al. 2005). In this trial, 6 of  
30 patients with advanced ovarian cancer showed prolonged disease stabilisation and 
whole blood cytokine assay showed a significant decrease in IL-6 levels (11 of 17 
patients) (Madhusudan, Muthuramalingam et al. 2005).  In a recent phase I clinical 
trial in patients with advanced cancer (Brown, Charles et al. 2008), we investigated 
the clinical efficacy and biological activity of infliximab (anti-TNF antibody). In this 
study, 41 patients with advanced cancer (8 of whom had EOC) received infliximab at 
5mg/kg (n=21) or 10mg/kg (n=20) i.v. at 0 and 2 weeks and then every 4 weeks. Prior 
to intravenous infusion of 5 or 10 mg/kg infliximab, IL-6 levels were measured in 
plasma with levels ranging from undetectable to 35 pg/ml (median 20pg/ml). During 
the antibody infusion, we also obtained serial samples of plasma over a 24-96 hour 
time period. Plasma IL-6 levels decreased significantly in all patients at 24 and 48 
hours after the first treatment with both doses. However, at the end of the study, IL-6 
levels had started to rise, although not significantly (Brown, Charles et al. 2008). 
Furthermore, one of the eight patients with EOC attained stable disease. 
 
Our group have also observed the effects of infliximab on plasma and ascitic cytokine 
levels specifically in advanced EOC (manuscript in preparation). 17 patients were 
treated with infliximab at 5mg/kg (n=6) and 10mg/kg (n=11) i.v. at 0, 2 and 6 weeks. 
Plasma and ascites from these patients was serially collected during treatment and  
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changes in cytokines were observed. Median ascitic IL-6 levels were three logs higher 
than plasma concentrations at 12ng/ml.  We could detect microgram quantities of 
infliximab in ascitic fluid that would be sufficient for biological activity in laboratory 
assays. Although there was a decrease in ascitic TNF-α levels 24 and 48 hours and 
IL-17 levels 24 hours after the start of the infusion, only marginal ascitic IL-6 
inhibition was seen. Interestingly, despite IL-6 production by peripheral blood cells 
being decreased by infliximab, IL-6 mRNA in cells isolated from ascites was not 
altered significantly with this treatment (Charles, Kulbe et al. 2009).  
 
Furthermore, the use of infliximab has been investigated in patients with 
immunotherapy-resistant or refractory renal cell cancer (RCC) (Harrison, 
Obermueller et al. 2007). This research involved two sequential studies. Study 1 
involved infliximab dosing at 5mg/kg (n=19) at weeks 0, 2 and 6 and then every 8 
weeks. Study 2 used infliximab 10mg/kg (n=18) at weeks 0, 2 and 6, and then every 6 
weeks. In both studies there was evidence of stable disease and partial response, with 
one patient in study 1 showing a long term response in excess of 40 months. Although 
higher levels of TNF-α, CCL2 and IL-6 were associated with poor prognosis, 
infliximab did not reduce plasma IL-6 levels in these patients. This suggests that IL-6 
regulation could be independent of TNF-α (Harrison, Obermueller et al. 2007). 
 
Hence, the interim conclusion from all clinical studies on TNF-α antagonists is that 
these agents have biological activity, with some possibility of therapeutic activity, but 
they only have variable effects on the production of IL-6 in the tumour 
microenvironment. Based on this and the aforementioned observations from research 
in EOC and other malignancies, this thesis is based upon the in vitro and in vivo 
experiments conducted alongside a phase II clinical trial investigating the effects of 
targeting IL-6 using a monoclonal antibody, CNTO328, as a single agent in patients 
with recurrent platinum-resistant ovarian cancer. 
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1.16 Aims and hypothesis of thesis  
 
Research into the biology of ovarian cancer and the role of inflammatory cytokines in 
cancer progression, suggests that antagonists to certain cytokines may complement 
standard chemotherapy and prolong disease-free survival in an adjuvant setting. The 
hypothesis underlying the research outlined in this thesis is that neutralisation of key 
cytokines may suppress or reverse the pro-inflammatory tumour-promoting 
microenvironment of epithelial ovarian cancer and therefore inhibit tumour growth 
and proliferation.  Both the clinical trial and pre-clinical experiments documented in 
this thesis aim to investigate this hypothesis in relation to the inflammatory and anti-
apoptotic cytokine IL-6. 
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2 Materials and Methods  
2.1   CO328X05 study: sample processing 
 
All specimens described in this section were collected and handled by designated 
individuals who had completed GCLP training and were deemed as competent in 
sample processing after receiving supervised training by the principal investigators in 
the CO328X05 study. All samples were processed according to standard operating 
procedures and logged accordingly in a file stored in a locked cupboard. In addition 
freezer temperatures were monitored and logged on a daily basis where possible. In 
November 2008, the conduct of this study was subject to a MHRA inspection with no 
critical findings. 
2.1.1 Plasma processing 
At the designated time-points outlined in the study protocol, 10 ml of blood was 
withdrawn from each patient and transferred into a 15 ml sterile, pyrogen free falcon 
tube (BD Falcon) containing 300 units of heparin (CP Pharmaceuticals). The tubes 
were inverted gently several times to ensure thorough mixing, kept on wet ice and 
processed within 1 hour of collection by centrifugation at 3100 rpm or 2000 x g for 10 
min at 4°C.  The plasma was then aspirated using sterile pastettes and 100 µl 
aliquoted into 10 x 1.5 ml cryovial tubes. Subsequently, all samples were snap frozen 
on dry ice prior to storage within labelled cryostorage boxes in a monitored -80°C 
freezer. The remaining blood pellet was stored under the same conditions after the 
addition of Phosphate Buffered Saline (PBS) and 10% Dimethyl Sulphoxide (DMSO, 
Sigma; D2650) in a total volume of 10 ml. 
2.1.2 Ascites processing 
Ascites was collected in 2 l Duran bottles and kept on wet ice during transfer to the 
Centre for Cancer and Inflammation. If collection occurred just prior to CNTO328 
treatment, the ascitic drain was clamped for 2 hr after completion of the infusion. The 
ascites was then centrifuged in 250 ml aliquots at 1500 rpm for 10 min at 4°C. The 
ascitic fluid supernatant was aspirated using sterile pastettes/pipettes and aliquoted 
into 5 x 1.8 ml cryovial tubes and 4 x 40 ml in 50 ml falcon tubes. The fluid was then  
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snap frozen by placing the tubes on dry ice. The remaining cell pellet was washed in 
10 ml sterile RPMI 1640 medium and transferred into a 50 ml centrifuge tube. Any 
visible red cell contamination was treated with 10 ml 1x Pharmlyse solution (BD 
Pharmingen, 555899) and 40 ml sterile PBS (without Ca2+ or Mg2+, endotoxin-free) 
and incubated at room temperature for 10 min prior to centrifugation at 1400 rpm for 
10 min at 4°C. This process was repeated until there were no red blood cells 
remaining in the cell pellet. The cells were suspended in 10 ml of sterile RPMI 1640 
media and an aliquot was counted using a ViCell cell counter (Beckman Coulter). The 
cells were then processed as follows; 
 
a) Ascitic cell cytospin  
100 000 cells were loaded in a volume of 100 µl into a cassette containing a glass 
slide. This was centrifuged at 450 rpm for 5 min allowing the cells to adhere to the 
glass slide. These were fixed in formal saline for 5 min, rinsed briefly in dH2O, air 
dried and stored at room temperature (RT). 
 
b) Ascitic cell storage 
5 ml (3 x 106 cells/ml) of ascitic cells were centrifuged at 1400 rpm for 4 min at 4°C. 
The remaining cells were then resuspended in 5 ml foetal bovine serum (FBS), low 
endotoxin (Autogen Bioclear) with 10% DMSO (Sigma) and stored as 1 ml aliquots 
in a monitored -80°C freezer. 
2.1.3 Measurement of ascites protein concentration 
Protein concentration in ascitic fluid was determined using a BCA (Bicinchoninic 
acid) assay. The BCA reagent was prepared by combining 50 parts of Bicinchoninic 
acid solution (Sigma, B9643-L) with 1 part Copper (II) Sulphate solution (Sigma, 
C2284). 200 µl of BCA reagent was added to 10 µl of control or ascitic fluid samples 
(diluted 1:20 in dH20) in a 96-well plate. Control protein standards were generated by 
serial (1:2) dilutions of a known amount of bovine serum albumin (BSA, Sigma) in 
the appropriate volume of dH20. Samples were incubated for 20 min at 37°C. The 
absorbance at 570 nm was measured with an Opsys MR plate reader (Dynex  
Technologies), and the protein concentration determined by reference to the standard 
curve. 
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2.2  Electrochemiluminescence detection  
 
a) Principle of the method 
 
Cytokine concentrations were estimated using electrochemiluminescence (ECL) 
detection with Meso Scale Discovery (MSD) assays (figure 2.1). The technology 
uses a 96 well microplate with electrodes integrated into the bottom of the plate. The 
floor of each well has either single-spots or multi-spots (multi-plex) that are coated 
with capture antibodies. The electrodes are made from carbon and the antibodies can 
be attached to the carbon by passive adsorption and retain a high level of biological  
activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Cytokine detection with electrochemiluminescence.  
This illustration demonstrates the mechanisms involved in ECL detection of cytokines within 
the well of a single spot plate. Ru(bpy)32+=MSD-Tag™, TPA=Tripropylamine. Adapted from 
MSD® catalogue. 
 
The assay uses detection antibodies with stable non-radioactive ECL labels (MSD 
SULFO-TAG). The ECL labels emit light when electronically stimulated and the 
detection process is initiated at the electrodes located in the bottom of the microplate.  
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Only labels near the electrode are excited and detected. In order to quantify the signal, 
MSD Read buffer is applied to the wells. This contains tripropylamine (TPA), a co-
reactant that enhances the ECL signals and is also stimulated when in close proximity 
to the microplate electrodes. The ECL labels emit light at 620 nm and multiple 
excitation cycles of each label amplify the signal to enhance light levels and improve 
sensitivity. 
 
b) ECL analysis of plasma and ascitic fluid 
 
Prior to this analysis, a series of experiments were conducted in order to validate the 
MSDassays. Over a period of six months, the standard concentrations for these 
assays (ranging from 2500 pg/ml to 0.6 pg/ml with 1 in 4 dilutions) and cytokines in 
plasma samples from normal healthy female controls were measured in duplicate 
wells (in the microplates outlined in table 2.1) on five separate occasions. This 
enabled validation of precision, standard curve linearity and the effect of freeze-
thawing on these aforementioned observations. The coefficient of variation (CV) for 
each standard concentration and plasma sample per cytokine for precision was within 
acceptable limits (i.e. < 10%). Furthermore, all standard curves were linear with an 
average r2 value of > 0.95 and freeze-thawing did not have a significant effect on the 
analysis of these samples. 
 
Plasma and ascites cytokine analysis using MSDassays were performed according to 
the manufacturer’s protocol.  After defrosting at 4°C, the samples were centrifuged 
briefly at 3100 rpm or 2000 x g for 1-2 min at 4oC. The calibrator standards, patient 
and normal healthy control samples were incubated in duplicate wells on the 
MSDmicroplates outlined in table 2.1. Plates were washed and read using SECTOR 
Imager 2400 software (MSD). For plasma sgp130 and VEGF analysis, uncoated 
single-spot microplates were developed according to manufacturer’s instructions with 
calibrator standards, capture and detection antibodies obtained from alternate sources 
(R&D Systems; human sgp130 DuoSet; DY228 and human VEGF DuoSet; 
DY293B).  
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Human cytokine assay Microplate Cat. No. 
IL-6 Single-spot K151AKB-2 
sgp80 Single-spot K151ALC-2 
sgp130 Single-spot K15A01-1 
IL-1β , TNF-α , IL-8, 
IFNγ  
Multi-plex (Custom made) N05CA-1 
VEGF Single-spot K15A01-1 
CCL2 Single-spot K151AYC-2 
 
Table 2.1 Summary of human cytokine MSD®  assays. 
 
MSD Streptavidin SULFO-TAG (R32AD-1) was used for the secondary detection 
antibody with these plates. These were performed as sgp130 MSDassays were not 
available at the time of analysis and poor results were previously obtained when the 
VEGF assay was performed with multiplex microplates.  
 
c) CNTO328 detection antibody development 
 
CNTO328 was labelled for ECL analysis according to a protocol supplied by MSD. 
The SULFO-TAG NHS-ester label is an amine-reactive, N-hydroxysuccinimide ester 
that readily couples to primary amine groups of proteins under mildly basic  
conditions to form a stable amide bond. This was incubated with CNTO328 for 2 hr 
and the solution was placed into a spin column to quickly isolate the labelled 
antibody. The antibody concentration was estimated using a BCA protein assay 
(outlined in section 2.1.3). The final concentration was made up to 1µg/ml by 
resuspending in an appropriate volume of MSD human antibody diluent (R151BA-
4). 
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2.3 Plasma CXCL12 analysis 
 
To determine the concentration of human CXCL12 in plasma samples, a Quantikine®  
enzyme linked immunosorbant assay (ELISA) kit (R&D Systems, DSA00) was used 
and analysis was performed according to the manufacturer’s instructions. For this 
ELISA the absorbance at 450 nm was measured and corrected at 570 nm in an Opsys 
MR plate reader (Dynex Technologies). 
 
2.4 Blood analysis 
 
Blood samples taken from all patients enrolled into the CO328X05 study were 
analysed for haematological and biochemical indices, CRP, β2-microglobulin and 
CA-125 in the relevant departments at Barts and the London NHS Trust, London, 
UK. 
 
2.5 CNTO328 serum concentration assay 
 
At the designated times in the study protocol, 5 ml of blood was withdrawn 
from each patient and transferred into a 15ml sterile, pyrogen free, non-heparinised 
falcon tube (BD Falcon). The tubes were kept on wet ice for up to 1 hour prior to 
centrifugation at 2500 rpm or 1300 x g for 10 min at 4oC. The serum was then 
aspirated using sterile pastettes and 1ml aliquoted into 2 x 1.5 ml cryovial tubes. 
Subsequently, all samples were snap frozen on dry ice prior to storage within labelled 
cryostorage boxes in a monitored -80°C freezer.  
CNTO328 serum concentrations were determined using an 
electrochemiluminescent-based immunoassay (MSD) method with a lower limit of 
quantification (LLOQ) of 0.045 µg/mL in serum at a required dilution of 1:4. 
Validated assays were used to determine the concentration of CNTO328 in the serum 
of all evaluable patients in the CO328X05 study. According to standard operating 
procedures, bioanalysis was conducted under the auspices of Uma Prabhakar, 
Associate Director of Clinical Pharmacology, Centocor Inc, Malvern, PA, USA.  
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2.6 Cell culture 
 
All glassware used for cell culture was baked at 220°C for 12 hours to remove 
contaminating endotoxin.  All medium and culture reagents were prepared at Cancer 
Research UK Clare Hall, South Mimms, UK. 
 
The human ovarian carcinoma cell lines (all from American Type Culture Collection, 
Rockville, MD, table 2.2) were grown in a humidified atmosphere at 37°C and 5% 
CO2 in either endotoxin-free RPMI medium (IGROV-1, TOV11D and TOV21G) or 
endotoxin free DMEM medium (SKOV-3 cell line) supplemented with 10% FBS 
(Autogen Bioclear, Calne, Wiltshire, UK). Cell lines were passaged twice weekly 
once 75% confluency was reached. This was performed as follows: detachment from  
the flask surface by briefly rinsing with PBS (without Ca2+ or Mg2+, endotoxin-free) 
followed by a 5 min incubation at 37°C in trypsin-EDTA (Invitrogen) and then  
resuspension in 10% FBS/medium prior to centrifugation at 1100 rpm for 4 min at 
4°C. Fresh medium was used to re-plate cells into 175 cm2 flasks (BD Falcon, UK).  
Cell lines were regularly tested for mycoplasma infection (Cancer Research UK Clare 
Hall, Hertfordshire, UK).  
 
2.7   CNTO328 treatment of cells 
 
CNTO328 (a kind gift from Centocor Ortho-Biotech Oncology R&D) was added at 
concentrations of 10, 25, 50 and 100 µg/ml (each in triplicate) to 12-well plates (BD 
Falcon) containing cells that had been cultured for 24 hr in 500 µl 10% FBS/medium. 
Equivalent concentrations of IgG antibody (a kind gift from Centocor Ortho-Biotech 
Oncology) were used as a control.  Cells were detached from the well surface by 
briefly rinsing with PBS (without Ca2+ or Mg2+, endotoxin-free) followed by a 5 min 
incubation at 37°C in 200 µl trypsin-EDTA (Invitrogen). The cells were then 
resuspended in 300 µl RPMI and counted using a Vi-cell cell counter (Beckman 
Coulter) at days 4, 7 and 11.  On day 4 and 7, the wells were refreshed with the 
appropriate antibody and medium. 
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 IGROV-1 TOV21G TOV112D SKOV-3 
Species Human Human Human Human 
Histological 
subtype 
Adenocarcinoma 
 
 
Clear cell 
carcinoma 
 
Endometrioid 
carcinoma 
Adenocarcinoma 
 
Source Ascites Primary tumour 
Primary 
tumour Ascites 
 
Table 2.2 Human ovarian cancer cell lines.  
All four cell lines were cultured for the in vitro and in vivo experiments described in this 
thesis. 
 
Supernatants were collected on day 4 for cytokine analysis using the same ECL 
assays outlined in table 2.1. CXCL12 analysis was also analysed in these samples 
using a Quantikine® ELISA kit (R&D Systems, DSA00). These experiments were 
also repeated with IGROV-1 and TOV21G cells cultured in suboptimal conditions 
with 1% FBS/RPMI. 
 
2.8  Fluorescent assisted cell sorting (FACS) analysis 
 
Phycoerythrin (PE)-conjugated mouse monoclonal antibodies against the trans-
membrane IL-6 receptors gp80 (BD Pharmingen; 551850), gp130 (Santa Cruz 
Biotechnology, sc-9994 PE) and isotype-matched control (Santa Cruz Biotechnology, 
sc-2866) were used. Cells were resuspended in DMEM supplemented with 2% heat 
inactivated FBS and 0.01% NaN3. Antibodies diluted in this buffer were used 
between 40-200 µg/ml and incubated for 40 min on ice.  Cells were washed and 
analysed by flow cytometry on a FACScan flow cytometer using Cellquest software 
(BD Pharmingen). 
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2.9 Growth of tumours in mice 
2.9.1 Mice and housing 
Female BALB/c nu/nu mice from the Special Pathogen Free (SPF) Unit, Clare Hall 
Laboratories, South Mimms, UK, 6-8 weeks of age, were used in all experiments. The 
mice were housed in sterile individually ventilated cages (IVC) at 20°C. All IVC 
supplies were sterilised and autoclaved before entering the cage. All the following 
experiments were conducted in collaboration with Dr Hagen Kulbe (Postdoctorate 
research assistant) and Richard Thompson (Laboratory technician). 
2.9.2 Lentiviral vector and infection of cells with luciferase 
reporter construct 
Lentiviral vector containing a luciferase reporter construct was cloned (a kind gift 
from David Gold, Senior Lecturer, William Harvey Institute, London, UK). IGROV-
1, TOV21G or TOV112D cells were plated 1 to 200 000 per well in six-well plates. 
Medium was replaced with 0.5 ml DMEM (10% FCS, penicillin/streptomycin, and 
glutamine) containing polbrene (6 µg/ml). Concentrated lentivirus (5 µl) was then 
added and incubated for 6 hours, at which point 2.0 ml DMEM (10% FCS, 
penicillin/streptomycin, and glutamine) was added, and incubation was continued  
overnight. Medium was replaced the next day, and cells were expanded the following 
day. In vitro luciferase activity was assayed in 0.5 x 106 IGROV-1, TOV212G or 
TOV112D cells in triplicates according to the manufacturer’s instructions (Promega). 
2.9.3 Injection of ovarian cancer cell lines and CNTO328 treatment 
Mice (each weighing approximately 20g) were injected intraperitoneally (i.p.) with 
either 0.5 x 106 IGROV-1-luc, TOV21G-luc or TOV112D-luc cells in 300 µl of 
sterile, endotoxin free, PBS. After 24 hr, 3 groups each consisting of 5-6 mice were 
treated for 4 wks as follows. 
 
Group A: 100 µl PBS i.p 2 times weekly  
Group B: 100 µl IgG control antibody (400 µg/mouse) in PBS i.p twice weekly  
Group C: 100 µl CNTO328 (400 µg/mouse) in PBS i.p 2 twice weekly 
All PBS used for injection was sterile and endotoxin free. 
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2.10 Bioluminescence imaging 
 
At 1 hour, 1, 2 and 4 wks after tumour cell injection, tumour growth and spread were 
monitored by a bioluminescent assay.  At these time-points mice were anaesthetised 
with isoflourane and injected i.p with 150 µg/g body weight D-luciferin in 100 µl 
PBS. Bioluminescence imaging with a charged-coupled device camera (IVIS, 
Xenogen) was initiated 10 min after injection. Bioluminescence images were obtained 
with a 15-cm field of view, binning (resolution) factor of 8, l/f stop, and open filter 
with an imaging time of 5 s. Data were analysed using Living Image software (also 
from Xenogen) and presented as relative light units (RLU) of light emission/s/cm2 
from ventral imaging and photon flux from a region of interest drawn over a mouse 
that was not given an injection of luciferin. 
 
2.11 Quantification of tumour blood vessels 
 
To visualise the architecture of blood vessels, animals were anaesthetised with 
isoflourane and injected with FITC-conjugated Lycopersicon esculentum (tomato 
lectin; 100 µl, 2 mg/ml; Vector Laboratories) via the tail vein 3 min before animals 
were perfused with 4% paraformaldehyde. Following fixation overnight in 4% 
paraformaldehyde, resected primary tumours were cryoprotected in 12%, 15%, and 
18% sucrose for 1 hr each. Tumours were subsequently snap frozen in ornithine 
carbamyl transferase compound (Sankura Finetek) and sectioned at 50 µm intervals. 
Vessels were visualised using confocal microscopy (Zeiss LSM S10 META) and 
microvessel density was quantified with image Pro Plus software (Image Pro Plus, 
Media Cybernetics). Microvessel density was expressed as mean percentage of 
microvessel surface area. 
 
2.12 Serum processing and cytokine analysis 
 
All mice had 100 µl of blood taken via the tail vein prior to and, 2 and 4 wks after 
tumour cell injection. These were aliquoted into eppendorfs and stored on ice for 1-2  
 96 
 
hr prior to centrifugation at 13 200 rpm for 15 min at 4°C. The serum samples were 
then snap frozen on dry ice and stored at -80°C. Human and murine cytokine analyses 
with ECL assays were performed according to manufacturer’s instructions (MSD® 
human IL-6, TNF-α, IL-8 and VEGF multi-plex microplate, N45CA-1; MSD® 
murine IL-6, TNF-α, IFN-γ and VEGF, N45IB-1). 
 
2.13 Protein extraction from frozen tumours 
 
Tumours were homogenised, dounce homogeniser (Janke & Kunkel GmbH), in 1 ml 
PBS/TDS buffer (PBS containing 12.06 mM sodium deoxycholate, 3.59 mM SDS, 
0.5 µg/ml leupeptin, 1 µg/ml pepstatin, 0.2 mM PMSF (all from Sigma)). Samples 
were incubated on ice for 10 min. Debris was pelleted by centrifugation at 13 000 rpm  
for 10 min. The supernatant was transferred to a fresh tube, 20 µl was removed for 
protein determination, and the remaining sample stored at -20° C. 
 
2.14 Analysis of RNA expression 
2.14.1 Isolation of RNA 
RNA from tumour deposits collected from mice at post mortem was prepared using 
the Tri-Reagent method as follows. For 100 mg tumour tissue 1ml Tri-Reagent (TR) 
was added and the sample homogenised (Janke & Kunkel GmbH). This was 
transferred to a fresh Ribonuclease-free 2 ml tube and 100 µl of 1-bromo-3-
chloropropane per 1 ml TR was added. The contents were vortexed for 15 sec and left 
for 15 min at room temperature (RT) and the tube was centrifuged at 14 000 rpm for 
15 min at 4°C. The upper aqueous layer was removed and placed into a fresh 
Ribonuclease-free 2 ml tube. 500 µl of isopropanol per 1ml TR used was added and 
left to stand for 10 min at RT; and the tube was centrifuged at 14 000 rpm for 10 min 
at 4°C. The supernatant was removed and the pellet was resuspended in 1 ml of 75% 
(v/v) ethanol (Merck/BDH made with DEPC-treated water). The contents were 
vortexed briefly and centrifuged at 14 000 rpm for 5 min at 4°C.  The ethanol was  
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removed and the pellet was air-dried. Finally, the pellet was resuspended in an 
appropriate volume of DEPC treated water, normally to a concentration of 1 µg/µl. 
2.14.2 RNA quantification 
RNA was quantified using the UV mini 1240 spectrophotometer (Shimadzu Europa) 
set at 260 nm and 280 nm. RNA was quantified using the following formula: 
 
RNA concentration (µg/µl) = A260 x 40 µg/ml x Dilution factor 
 
Where A260 is the absorbance at 260 nm; the dilution factor is the final volume of 
water and RNA (1 ml) divided by the volume of RNA (µl); 40 µg/ml is the 
concentration of RNA that gives an A260 reading of 1. 
2.14.3 DNase treatment of RNA 
Total RNA was DNase-treated to remove contaminating genomic DNA, using RNase  
free DNase I (Amersham Pharmacia). The following reagents were added to a 
ribonuclease-free 1.5 ml microfuge tube in the following order: 
 
• RNasin® ribonuclease inhibitor (Promega)  2 µl 
• Transcription optimised 5x buffer (Promega) 5 µl 
• RNA (in DEPC water)    44 µl (1-20 µg) 
• DNaseI (Amersham Pharmacia)   1.5 µl 
 
The contents were incubated at 37°C for 1 hr. 
 
The contents were then phenol:chloroform extracted as follows: 50 µl of DEPC-
treated water was added to the tube, followed by 100 µl of citrate-buffered phenol: 
chloroform (5:1 ratio Sigma). The contents were vortexed for 15 sec, then centrifuged 
at 13 000rpm fro 5 min at 4°C. The upper aqueous phase was transferred to a fresh 
tube and 100 µl of chloroform: isoamyl alcohol (24:1 ratio Merck/BDH) was added, 
followed by vortexing for 15 sec and centrifugation at 13 000 rpm for 5 min at 4°C.  
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The upper aqueous phase was transferred to a fresh tube. 1 µl glycogen (Roche), 1/5 
volume (i.e. 20 µl) of 5 M ammonium acetate (Sigma) and 2.5 volumes (i.e. 250 µl) 
of absolute alcohol (Merck/BDH) were added. The tube was placed on dry ice for 30 
min, and then centrifuged at 13 000 rpm for 15 min at 4°C. The supernatant was 
removed and the pellet was washed by vortexing with 0.5 ml 755 (v/v) ethanol 
(Merck/BDH made with DEPC-treated water). The tube was centrifuged at 13 000 
rpm for 5 min at 4°C. The supernatant was removed and the pellet was air-dried. 
Finally, the pellet was resuspended in an appropriate volume of DEPC-treated water 
(normally at a concentration of 1 µg/µl), and heated at 55°C for 15 min to ensure 
RNA was in solution. 
 
2.14.4 Reverse Transcription (RT) of RNA 
cDNA was synthesised from 2 µg of DNase treated RNA using the M-MLV reverse 
transcriptase (Promega). The following reagents were added to a ribonuclease-free 1.5 
ml microfuge tube, followed by incubation at 75°C for 5 min: 
 
a) Random hexamers (Promega)  2 µl (1 µg) 
b) DNase-treated RNA    2 µg 
c) DEPC-treated water to a final volume:  14 µl 
 
The tube was cooled on ice for 5 min and the following reagents were added to the 
microfuge tube, followed by incubation at room temperature for 10 min and then 
40°C for 50 min. 
 
d) dNTPs 1:1:1:1 (PerkinElmer)   5 µl 
e) M-MLV RT 5x reaction buffer (Promega) 5 µl 
f) M-MLV RT enzyme (Promega)  1 µl 
 
The cDNA was made up to 100 µl in nucleotide-free water to give a final 
concentration of 20 ng/µl of total RNA. 
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2.14.5 TaqMan quantitative real time PCR 
a) Principle of the method 
The TaqMan method makes use of the 5’-3’ endonuclease activity of Taq polymerase 
to cleave a specific fluorogenic probe hybridised to the specific cDNA of interest. The 
probe is designed to have the primary fluorophor (usually FAM or VIC) at the 5’ end 
of the probe and a quencher dye (TAMRA) at the 3’ end. Because the proximity 
between the dyes are close fluorescence resonance energy transfer (FRET) will occur 
where, upon activation, the fluorescent signal will be at the wavelength of the 
quencher dye. Cleavage of the probe during the extension cycle of the assay results in 
increased fluorescence that can be measured in the sealed 96-well plate. Another dye,  
ROX, is also present in the reaction mixture that acts as a reference dye during the 40-
50 cycle reaction. 
 
b) cDNA preparation 
cDNA was prepared using the method described in 2.14.4; cDNA was at a 
concentration of the equivalent to 20 ng/µl of total RNA.  
 
c) Multiplex real-time PCR 
Multiplex real-time RT-PCR analyses were performed with the ABI PRISM 7700 
Sequence Detection System instrument and software (PE Applied Biosystems). RT-
PCR was reformed using pre-made human CCL2, CCL5, CXCR4, CXCL12, IFNγ, 
IL-1β, IL-6, IL-8, Jagged1, Notch3, PDGFA/C, TNF-α and VEGF and 18s rRNA 
(VIC) specific primers and probes. 
 
2.15 Histology and Immunohistochemistry (IHC) 
2.15.1 Histology 
Tumour sections of diagnostic biopsies from evaluable patients in the CO328X05 
study were processed at the Royal London Hospital Histopathology Unit according to 
standard procedures. Histology was evaluated in haematoxylin and eosin stained 
sections obtained from paraffin embedded material. 
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At the post-mortem examination in the xenograft experiments, tumours were removed 
and placed in either liquid nitrogen or paraffin. These were processed at the Pathology 
Department at the Institute of Cancer Research, Charterhouse Square, according to 
standard procedures. 
 
2.15.2 Immunohistochemistry 
Immunohistochemistry was performed on paraffin embedded sections of diagnostic 
biopsies obtained from patients in the CO328X05 study, tumour sections in the 
human ovarian cancer xenograft models and tissue arrays of malignant and normal 
ovarian tissue (Insight Biotech, BC11012 and OV806).  Frozen tumour cryostat 
sections were used for Ki67 and F4/80 immunohistochemistry in tumours from the 
TOV21G xenograft model. The antibodies and dilutions used are summarised in table 
2.3. The streptavidin-peroxidase method for immunostaining was performed on all 
tissue sections using the ABC kit (Vector) with the following steps: 
 
1)  Tissue sections from diagnostic biopsies and xenograft tumours were 
deparaffinised in xylene then rehydrated in graded ethanol as follows; 
xylene   2 x 5 min 
100% ethanol  2 x 2 min  
95% ethanol  2 x 2 min 
70% ethanol  2 x 2 min 
50% ethanol  1 x 2 min 
ddH20   2 x 2 min 
  
As the tissue array sections were coated with thicker layers of paraffin, the 
slides were immersed in xylene overnight at RT prior to rehydration in 
ethanol. 
 
2) Antigens were retrieved by immersing tissue sections in citrate buffer 
consisting of 2.5 ml Vector Antigen Unmasking solution (Vector) in 250 ml 
ddH20 and microwaving at 700W in a chamber for 10 min; followed by 
incubation at RT for 15 min. 
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3) Sections were then washed in three changes of PBS  (3 min each). 
 
4) Hydrophobic Pen (Vector) was used to draw around the sections allowing 
smaller volumes of antibody to be used. 
 
5) Sections were then incubated in 1x blocking buffer (rabbit or goat serum 
depending on species of antibody; Invitrogen) for 45 min and drained. 
 
6) The primary antibody was applied and incubated at 4°C overnight at optimal 
dilution in 0.5x blocking buffer with PBS. 
 
7) The primary antibody was aspirated the next day and washed in three changes 
of PBS (3 min each). 
 
8)  Incubation with biotinylated secondary antibody at 1:200 dilution in 0.5x 
blocking buffer in PBS (Vector) at RT for 45 min. 
 
9) Sections were washed in two changes of PBS (3 min each). 
 
10) Avidin-Biotinylated enzyme Complex (ABC, Vectastain Standard Kit, Vector, 
PK-4000) was prepared and left on ice for at least 30 min. 
 
11) Endogenous peroxide activity was blocked using 5 ml of 30% H2O2 in 250 ml 
methanol at RT for 20 min. 
 
12) Washed in three changes of PBS (3 min each). 
 
13) Incubation with ABC in a covered humidified chamber at RT for 30 min. 
Sections were washed in three changes of PBS (3 min each). 
 
14) Peroxidase substrate was prepared by vortexing one diaminobenzidine (DAB) 
tablet with one tris/peroxide tablet in 15 ml dH2O (Sigma Aldrich, D4418).  
 
 102 
 
The DAB solution was applied through a 0.45 µm filter and sections were 
incubated for 3-20 min. 
 
15) Washed briefly in water and counterstained in haematoxylin for 1 min, then 
immersed in differentiating solution (750 µl ammonium hydroxide in 250 ml 
dH2O). 
 
16) Slides were dehydrated as follows; 
100% Isobutanol 20 dips 
100% Isobutanol  2 x 2 min 
Xylene   2 x 2 min 
 
17)  Sections were cleared and mounted whilst moist with DPX (Fisher); 
coverslips were placed and slides left to air dry. 
 
 
2.16 Statistical analysis 
 
Statistical methods including the Mann Whitney U test, unpaired t test, log-rank tests 
and linear regression analysis were calculated with GraphPad Prism software (version 
5.0).  In all figures, points and bars represent mean ± standard deviation (s.d.), unless 
otherwise stated. 
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Primary antibody Species Dilution Secondary antibody species 
 
IL-6  
(Santa Cruz, sc-7920) 
 
Human 1:50 
 
Rabbit 
(Vector, BA-1000) 
 
gp80 
(Santa Cruz, sc-661) 
 
Human 1:50 Rabbit 
 
gp130 
(Abcam, ab59389) 
 
Human 1:50 Rabbit 
 
SOCS3 
(Abcam, ab16030) 
 
Human 1:100 Rabbit 
 
pSTAT3 
(Cell Signaling, #9135) 
 
Human 1:10-1:50 Rabbit 
 
CD68 
(Dako, IR609) 
 
 
Human No dilution 
 
Mouse 
(Vector, BA-2000) 
 
Ki67 
(Dako, M7240) 
 
Human 1:100 Mouse 
 
Jagged1 
      (R&D Systems, 
           AF1277) 
 
 
Human 1:100 
 
Goat 
(Fisher, 31732) 
 
IL-6 
(R&D Systems,  
AF-406-NA) 
 
Murine 1:50 
 
Goat 
 
 
F4/80 
(AbD Serotec, Oxford, 
UK; MCA497R) 
 
 
Murine 1:200 Rat (Vector, BA-4001) 
 
Table 2.3 Summary of antibodies for IHC analysis. 
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Full company names and locations 
Abcam, Cambridge, UK  
AbD Serotec, Oxford, UK 
Amersham Pharmacia Biotech, Little Chalfont, UK 
Autogen Bioclear, Calne, Wiltshire, UK  
BD Falcon &BD Pharmingen, Oxford, UK 
Beckman Coulter, High Wycombe, UK 
Cell Signaling, Danvers, MA 
Centocor Ortho-Biotech Oncology R&D, Malvern, PA 
CP Pharmaceuticals, Wrexham, UK 
Dako, Glostrup, Denmark  
Dynex Technologies, Worthing, UK 
Fisher Scientific, Loughborough, UK  
GraphPad Prism, San Diego, CA 
Insight Biotech, Wembley, UK 
Invitrogen, Paisley, UK. 
Janke & Kunkel GmbH, Staufen, Germany 
Media Cybernetics Inc, Silver Spring, MD  
Merck/BDH, Lutterworth, UK 
Meso Scale Discovery, Gaithersburg, MD 
PE Applied Biosystems, Foster City, CA 
PerkinElmer, Waltham, MA 
Promega, Southampton, UK 
RandD Systems, Abingdon, UK 
Roche, Welwyn Garden City, UK 
Sankura Finetek, Torrance, CA 
Santa Cruz Biotechnology, Santa Cruz, CA 
Shimadzu Europa, GmBH, Duisburg, Germany 
Sigma Aldrich, Gillingham, UK 
Vector Laboratories, Peterborough, UK 
Xenogen, Alameda, CA 
Zeiss, Welwyn Garden City, UK 
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3 A Phase II Study of Intravenous CNTO328 in Patients 
with Recurrent Epithelial Ovarian Cancer: Toxicity, 
Inflammatory Biomarkers and Response 
 
3.1  Aims 
 
The introduction to this thesis outlined evidence suggesting that IL-6 may be a target 
in patients with ovarian cancer. In order to investigate this I devised and conducted a  
a phase II clinical trial (CO328X05) using a monoclonal anti-IL-6 antibody, 
CNTO328, in patients with recurrent platinum resistant ovarian cancer. This chapter 
will describe the response to treatment, toxicity, pharmacokinetic and survival data 
from the evaluable patients and investigation of plasma biomarkers. 
 
3.2   CNTO328 
3.2.1 Structure and mechanism of action  
CNTO328 is a chimeric (murine-human) immunoglobulin G (IgG1κ), with an 
approximate molecular weight 147750 daltons. CNTO328 binds to the D-loop of 
human IL-6 with high affinity from 10-11 to 10-12 M (Zaki, Nemeth et al. 2004). 
CNTO328 potently neutralises the biological activity of IL-6 with an IC50 of 
approximately 50pM (CNTO328 Investigator’s Brochure; edition no. 5, May 2007). 
Furthermore, it inhibits the binding of IL-6 to both trans-membrane (gp80) and the 
soluble (sgp80) IL-6 receptors (figure 3.1). CNTO328 had a favourable toxicity 
profile in previous clinical trials in patients with prostate cancer, renal cell carcinoma 
and haematological disorders including multiple myeloma (Kurzrock, Voorhees et al. 
2006; Hudes, Nanus et al. 2007; Schipperus, Cornfeld et al. 2009). The commonly 
reported side-effects included fatigue, nausea, coughing, back pain, vomiting, 
dizziness, headache, and coryzal symptoms. Allergic reactions, glucose intolerance, 
hypertriglyceridaemia and haematological toxicities such as neutropenia and  
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thrombocytopenia have been less frequently observed (CNTO328 Investigator’s 
Brochure; edition no. 5, May 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 CNTO328 mechanism of action.   
CNTO328 can bind to IL-6 and IL-6- sgp80 receptor complexes to inhibit both classic 
signalling and trans-signalling. 
 
3.3 Study summary 
3.3.1 Study objectives 
The primary objective of the clinical trial was to determine the efficacy of intravenous 
CNTO328 in women with recurrent platinum-resistant epithelial ovarian cancer. 
 
The secondary objectives were as follows: 
a) To determine changes in quality of life (QoL) in patients with recurrent 
epithelial ovarian cancer following treatment with CNTO328. 
b) To determine the neutralisation of IL-6 in tumour, blood and ascitic specimens 
following treatment with CNTO328. 
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c) To determine the alterations in inflammatory markers in blood, ascitic fluid 
and tumour tissue (where possible) following intravenous delivery of CNTO328 in 
recurrent epithelial ovarian cancer and determine whether any of these biomarkers are 
predictive of response. 
 
3.3.2 Eligibility criteria 
 
Inclusion criteria 
a) Women with recurrent histologically confirmed epithelial ovarian 
carcinoma, Fallopian tube carcinoma, or primary peritoneal carcinoma of 
serous, endometrioid or clear cell sub-types. 
b) Previous treatment with no more than three platinum-containing 
chemotherapy regimes. 
c) Patients were also eligible if they had relapsed within six months of 
completing first-line platinum-containing chemotherapy or experienced 
documented progression whilst receiving first-line platinum-containing 
chemotherapy. 
d) Life expectancy of at least 3 months. 
e) Age ≥ 18 years. 
f) WHO performance status of 0, 1 or 2. 
g) Patients must have had the following clinical laboratory values: 
• Granulocyte count > 1.0 x 109/l 
• Platelet count > 100 x 109/l 
• Hb > 9.0 g/dl 
• Serum creatinine < 1.5 x Upper Limit of Normal (ULN) 
• Bilirubin < 30 µmol/l 
• Albumin > 30 g/dl 
• Prothrombin and activated partial thromboplastin times < 1.5 x 
ULN 
• Alk Phos < 5 x ULN 
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Exclusion criteria 
a) Tumours of malignant mixed mesodermal (MMMT) or mucinous types. 
b) Unresolved bowel obstruction. 
c) Prior administration of or hypersensitivity to humanised and/or chimeric 
monoclonal antibodies or other such proteins. 
d) Chemotherapy within the preceding 3 weeks. 
e) Radiotherapy within the preceding 3 weeks. 
f) Treatment with any investigational agent within the preceding 4 weeks or 
within 5 half-lives of the investigational agent, whichever was longer. 
g) Known leptomeningeal involvement or intracranial disease. 
h) Pregnant or lactating females. 
i) Inability or unwillingness to give informed consent. 
j) Ongoing active infection or a documented history of HIV infection, 
Hepatitis B or C. 
k) Concurrent congestive heart failure or prior history of New York Heart 
Association (NYHA) class III/IV cardiac disease. 
l) Concurrent autoimmune disorder, e.g. systemic lupus or any 
demyelinating disease. 
m) Use of immunosuppressive therapy or corticosteroids taken within the 4 
weeks prior to study entry and during the treatment period. 
 
3.3.3 Study methodology 
Eligible patients received CNTO328 as a 2-hour intravenous injection.  In patients 
who had evidence of ascites, an abdominal drain was inserted and fluid removed for 
analysis before and after the infusion of CNTO328. One cycle of treatment involved 
an infusion of CNTO328 dosed at 5.4mg/kg every 2 weeks.  This dosing schedule was 
chosen as it was shown to effectively suppress CRP concentrations below the lower 
limit of quantification (LLOQ) in previous studies. 
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At enrolment the following investigations were performed and repeated at each visit 
during the study unless indicated otherwise: 
 
a) Complete medical history: including a detailed history of exposure to 
tuberculosis, primary diagnosis, and previous treatment for ovarian cancer and 
baseline clinical conditions.  
 
b) Complete physical examination: including performance status, temperature, 
pulse rate, systolic and diastolic blood pressure and weight. 
 
c) Laboratory Tests: Haematology, Biochemistry, and Tumour Marker (CA-125) 
            Urinalysis (dipstick) & pregnancy test if applicable (within 2 weeks). 
 
d) Imaging with [18F]-FDG-PET-CT scanning performed at baseline, weeks 6 
and 24.  
 
e) ECG (to be repeated if clinically indicated). 
 
f) Quality of Life questionnaire (EORTC QLQ-C30 and OV-28). 
 
g) Blood sampling to assess cytokine concentrations and CNTO328 levels (prior 
to, 1 hour and 24 hours after each CNTO328 infusion within the initial 6 week 
study period).  
 
The first 12 evaluable patients were staged with [18F]-FDG-PET CT scans after the 
completion of 3 cycles (6 weeks). Due to observations discussed in this chapter, a 
protocol amendment was made so that the remaining evaluable patients were  
re-staged after completion of 5 cycles (10 weeks). If the scans confirmed no evidence 
of disease progression, patients proceeded to receive up to a total of 12 cycles. At this 
point, [18F]-FDG-PET CT scans were repeated. Patients with continuing clinical 
benefit were eligible to receive a further 6 months of CNTO328 therapy where blood 
would be taken prior to and 1 hour after each cycle for cytokine analysis.  
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3.3.4 Study withdrawal criteria 
Patients were to be withdrawn from the study under the following circumstances: 
a) Evidence of disease progression other than the re-accumulation of ascites or 
pleural effusion. 
b) Unacceptable toxicity. 
c) Unforeseen events that in the judgement of the Investigator made further 
treatment inadvisable. 
d) Serious adverse events (SAEs) requiring discontinuation of treatment. 
e) Withdrawal of consent. When a patient was not evaluable additional patients 
were to be recruited to replace them. 
f) Serious violation of the study protocol (including persistent patient attendance 
failure and persistent non-compliance). 
g) Withdrawal by the Investigator for clinical reasons not related to the study 
drug treatment. 
 
If a patient was to be withdrawn from the study or if the patient declined further 
participation, final assessments were to be performed, if possible.  These were to 
include a physical examination, laboratory samples, CA-125, an assessment of AE's, 
recording concomitant medication and drug accountability.  All the results of the 
evaluations and observations, together with a description of the reasons for study 
withdrawal, were to be recorded in the case report forms. A more detailed account of 
the study methodology is contained in the trial protocol (CO328X05 version 5.0) 
attached to this thesis as a CD. 
 
3.3.5 Statistical considerations 
20 patients were to be recruited with an estimated time to accrual of 18-24 months. 
This sample size was determined on the assumption that a response rate of less than 
10% would be of no further interest, whereas a response rate of 30% or more would 
demonstrate clear evidence of activity that would merit further study. Accrual of 20 
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patients will limit to 5% the probability of failing to observe a true response rate of 
10%.  
 
3.4 Clinical trial authorisation, ethics and patient consent 
 
Both the MHRA (CTA number: 21313/0007/001-0003) and Warwickshire Research 
Ethics Committee approved this study (REC reference: 07/Q2803/30) and informed 
consent was obtained from patients attending Medical Oncology clinics at St 
Bartholomew’s Hospital, London.  
 
3.5 Patient profile 
 
A total of 20 patients were recruited to this study. As two patients (study number 18 
and 19) had clinical disease progression after enrolment but prior to the start of 
treatment, 18 patients were deemed evaluable for the primary endpoint. The majority 
of these patients had previously received 2-3 lines of platinum-based chemotherapy 
and had a performance status (PS) of 0 or 1 (figure 3.2). 
 
3.6 Study response summary 
 
The GCIG (Gynaecological Cancer Intergroup) guidelines combining RECIST 
(Response Evaluation Criteria In Solid Tumours) and CA-125 criteria were used to 
assess best overall response to CNTO328 (see CO328X05 protocol v5.0, section 
16.9.3 pp 56-57). In patients who had measurable disease by both criteria, the date of  
response was the date of the earlier of the two events. The following rules applied 
when determining the best overall response. If patients had progressive disease (PD)  
according to RECIST within 28 days of CA-125 response they were classified as PD. 
Overall stable disease (SD) was defined in patients who had SD by RECIST along 
with CA-125 stabilisation. Patients whose best response according to RECIST was 
stable disease (SD) but who had a CA-125 response were classified as partial 
responders (PR). 
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A       B 
 
  
 
 
 
 
   
Figure 3.2 Baseline performance status and platinum-based chemotherapy 
profile.  
A. Baseline Performance Status. PS 0= patient fully active and able to carry out normal 
activity without restriction, PS 1= patient restricted in strenuous activity but able to carry out 
work of a sedentary nature, PS 2= patient ambulatory and able of all self care, but unable to 
carry out any work activities. B. Previous Platinum-based chemotherapy (a line usually 
consists of 3-6 cycles of cisplatin or carboplatin chemotherapy either as a single agent or in 
combination with another cytotoxic agent). 
 
Staging after 6-10 weeks confirmed 1 patient with partial response (PR), 7 patients 
with stable disease (SD) and 10 patients with progressive disease (PD) by combined 
RECIST and CA-125 criteria. The patients who had initial clinical benefit (i.e. SD 
and PR) continued with treatment and had received between 4 to 17 cycles of 
CNTO328 at the point of withdrawal from the study. Of the patients who progressed, 
only patient 02 had to withdraw after completing two cycles due to rapid disease 
progression.  The patient disease characteristics and best overall response status are 
summarised in table 3.1. 
 
3.7 Inflammatory biomarkers 
 
In order to monitor responses induced by CNTO328 throughout the study, the 
inflammatory biomarkers C-Reactive Protein (CRP), β-2 microglobulin and 
erythrocyte sedimentation rate (ESR) were analysed weekly during the initial six-
week study period and with each subsequent cycle. As the data for each inflammatory 
marker were not normally distributed amongst the evaluable patients, the Mann-
Whitney U test was applied for the statistical analysis described in this section.  
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Table 3.1 Patient characteristics and response to CNTO328.  
The disease status for each patient is denoted by the stage and histology documented at the 
time of diagnosis.  The first 12 evaluable patients had [18F]-FDG-PET CT staging after 3 
cycles of CNTO328 and patients within the shaded area were staged after 5 cycles. All 
patients (excluding patient 17 who had poor prognosis early stage disease) were diagnosed 
with advanced stage ovarian cancer. 
Study 
No. 
Age 
(yrs) 
Stage at 
diagnosis 
Histology Best RECIST/CA125 
response 
Duration of  
CNTO328 
treatment  
 
01 
 
68 
 
IIIc 
 
Serous papillary 
carcinoma 
 
 
PD 
 
6 weeks 
02 
 
49 IIIc Adenocarcinoma PD 4 weeks 
03 
 
68 IIIc Adenocarcinoma PD 6 weeks 
04 53 IIIb Serous papillary 
carcinoma 
 
PD 6 weeks 
05 65 IIIc Adenocarcinoma 
 
SD 13 weeks 
06 
 
70 IIIc Serous papillary 
carcinoma 
PD 6 weeks 
07 45 IV Adenocarcinoma 
 
SD 13 weeks 
08 
 
61 IIIc Adenocarcinoma PD 6 weeks 
09 47 IV Serous papillary 
carcinoma 
 
SD 8 weeks 
10 41 IIIc Serous papillary 
carcinoma 
 
SD 13 weeks 
11 49 IIIc Serous papillary 
carcinoma 
 
PD 6 weeks 
12 66 IV Serous papillary 
carcinoma 
 
SD 24 weeks 
13 59 IIIc Serous papillary 
carcinoma 
 
PR 24 weeks 
14 70 IV Serous papillary 
carcinoma 
PD 6 weeks 
15 64 IIIc Serous papillary 
carcinoma 
 
PD 10 weeks 
16 47 IIIc Serous papillary 
carcinoma 
SD 24 weeks 
17 72 IIa Clear cell carcinoma 
 
PD 10 weeks 
20 75 IIIc Adenocarcinoma SD 34 weeks 
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3.7.1 C-Reactive Protein (CRP) 
 
CRP is an acute phase protein that was originally named for its ability to bind the C-
polysaccharide of Pneumococcus. It behaves as an opsonin for bacteria and immune 
complexes and activates the classical complement pathway. CRP is synthesised by 
hepatocytes and is potently stimulated by IL-6. The serum CRP concentrations for the 
evaluable patients at baseline (i.e. just prior to treatment at week 1) in this study are 
illustrated as ‘box and whisker’ plots where the box represents the 25th- 75th quartile 
range, the line and cross represent the median and mean values respectively and the 
whiskers the minimum and maximum values (figure 3.3). 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Baseline CRP concentrations.  
Patients with clinical benefit (SD/PR) had significantly lower baseline mean CRP values 
compared to those with progressive disease (PD) (12.63 mg/L vs. 40.5 mg/L; Mann-Whitney 
U test,  **p=0.0098). 50% of patients with clinical benefit had baseline levels less than the 
lower limit of quantification (LLOQ) which is 5mg/L. All PD patients had elevated CRP levels 
at initiation of CNTO328 (normal range <5-10mg/L). 
 
At this time-point, the mean CRP concentration was significantly lower in patients 
who had clinical benefit patients compared to patients who had progressive disease 
(p=0.0098). The CRP values for all patients during the initial 6–week study period 
and with subsequent treatment up to 6 months for the patients with clinical benefit are 
shown in figure 3.4. Serum CRP, as shown in figure 3.4, was measured at baseline 
(range SD/PR < 5-48, PD 15-104), during each week of the initial 6-week study 
period and with every cycle of treatment thereafter. All patients achieved complete 
CRP suppression by week 2. This was maintained in all patients achieving clinical  
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C 
Figure 3.4 Serum CRP concentrations during 6-week study period and beyond.   
A. Patients with clinical benefit, B. Progressive disease, C. Patients with clinical benefit until 
study withdrawal. Green=SD/PR, Red=PD 
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benefit (figure 3.4 (A)) throughout the remainder of the six weeks. Beyond six weeks 
of therapy (figure 3.4 (C)), the majority of patients showing clinical benefit had 
continued CRP suppression until the point of study withdrawal. Patient 20 had 
occasional CRP fluctuations that never exceeded the lower limit of quantification 
(LLOQ), and patient 13 had a brief increase at week 21 which normalized after the 
resolution of sub-acute bowel obstruction. With respect to the PD patients, CRP 
appeared to decrease a week after each treatment and then increase by the time of the 
next CNTO328 infusion in patients 01 and 03 (figure 3.4 (B)). Patient 02 and 04 had 
increased CRP at the end of the 6-week study period compared with baseline. For the 
remaining six patients who progressed (patients 06, 08, 11, 14, 15 and 17), CRP was 
suppressed from week 2 onwards. 
 
The results observed in the patients with clinical benefit certainly support recent 
publications confirming that levels of CRP during cytotoxic therapy correlate directly 
with response and prognosis in EOC (Sharma, Hook et al. 2008). However, effective 
CRP suppression was also evident in over half of the patients with progressive 
disease. Furthermore, two patients (01 and 06) who had considerable CRP 
suppression after 6 weeks had only minimal disease progression. This was the 
rationale behind extending CNTO328 treatment to five cycles prior to repeat imaging. 
However despite this, two patients (15 and 17) treated with this protocol amendment 
still showed overt disease progression after ten weeks of therapy. 
 
3.7.2 β-2 microglobulin 
 
β-2 microglobulin (B-2M) is a 11.6 kDa polypeptide consisting of 99 amino acids and 
is an integral component of MHC class I molecules (Cunningham, Wang et al. 1973; 
Suggs, Wallace et al. 1981; Gussow, Rein et al. 1987). In healthy subjects, B-2M is 
induced by interferon-α (Espinosa, Martin-Malo et al. 2001) and TNF-α (Menaa, 
Esser et al. 2008). However, in relation to malignancies, Homma et al showed that 
stimulating human hepatoblastoma and hepatoma cell lines in vitro with IL-6 resulted 
in the secretion of B2-M in a time dependent fashion. (Homma, Tsujinaka et al. 
1992).  B2-M also has an emerging role in ovarian cancer. Yang et al compared the  
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growth of SKOV3-neo (i.e. SKOV3 mock) and SKOV3-B2-M (B2-M over-
expressing transfectant) cells in vitro and showed that B2-M increased cell 
proliferation through PI3K/Akt signalling and also increased anchorage independent 
growth of ovarian cancer cells (Yang, Li et al. 2009). The baseline serum B-2M levels 
for the evaluable patients in this study are shown in figure 3.5. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Baseline β-2 microglobulin concentrations.  
Mean baseline B-2M levels were significantly lower in patients achieving clinical benefit 
compared to progressive disease subjects (2.05 vs. 4.038, Mann-Whitney U test **p=0.0027). 
B-2M levels were not available for 2 PD patients at this time-point. 
 
 
Patients who obtained clinical benefit had significantly lower mean baseline 
concentrations of B-2M compared to those patients who progressed (p=0.0027) and 
these levels generally remained stable during the initial 6-week study period and 
beyond (figure 3.6 (A) and (C)). The majority of patients with progressive disease 
also showed B-2M stabilisation by week 6 (figure 3.6 (B)). However, in comparison 
with the SD and PR patients, these values fluctuated more with the first three cycles 
of CNTO328. 
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C 
 
Figure 3.6 Serum β-2 microglobulin during 6-week study period and beyond. 
A. Clinical benefit, B. Progressive disease, C. Patients with clinical benefit until study 
withdrawal. Green=SD/PR, Red=PD. 
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3.7.3 Erythrocyte Sedimentation Rate (ESR) 
 
ESR is a non-specific measure of inflammation that represents the rate at which red 
blood cells in a column separate from blood serum over an hour. ESR is significantly 
influenced by fibrinogen; another acute phase protein which is induced by IL-6 in 
hepatocytes (Gabay 2006).  The ESR values at baseline for all evaluable patients are 
illustrated in figure 3.7. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Baseline ESR values.  
Mean baseline ESR values for clinical benefit patients are lower than progressive disease 
patients (48 mm/hr vs. 59 mm/hr), however this difference is not statistically significant 
(Mann Whitney U test, p=0.607. Baseline analysis was not performed in 3 patients (2 with 
clinical benefit and 1 PD). 
 
 
In contrast with CRP and B2-M, the mean baseline ESR values for patients with 
clinical benefit and PD were not significantly different. However, all patients who had 
clinical benefit showed a decrease in ESR values after 3 cycles of CNTO328 
treatment (figure 3.8 (A)). These levels remained suppressed throughout the treatment 
continuation period (figure 3.8 (C)). In parallel with CRP, the ESR increased slightly 
for patient 13 towards the end of the study, possibly due to intermittent bowel 
obstruction. Suppression of ESR below baseline levels was also evident in all 
progressive disease patients at 6 weeks (figure 3.8 (B)). 
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B 
 
 
 
 
 
 
 
 
 
C 
Figure 3.8 ESR values.  
A. Clinical benefit patients, B. Progressive disease patients, C. Patients with clinical benefit 
until study withdrawal. (No ESR levels were obtained for patient 20 during the initial 6-10 
week study period). Green=SD/PR, Red=PD. 
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3.8 CA-125 
 
As previously mentioned, CA-125 is secreted by the majority of epithelial ovarian 
cancer subtypes (Cannistra 2004). The most useful clinical application of CA-125 is 
in monitoring recurrence and progression throughout treatment. Good prognosis is 
associated with a rapid decrease in CA-125 values following chemotherapy. 
Conversely, CA-125 half-lives greater than 3 weeks during cytotoxic therapy are 
associated with poor prognosis (Hunter, Daly et al. 1990). According to the GCIG 
guidelines (Rustin 2003), CA-125 response is defined as at least a 50% reduction in 
CA-125 levels from a pre-treatment serum sample. The response must be confirmed 
and maintained for at least 28 days. Patients can be evaluated according to CA-125 
levels if they have a pre-treatment sample taken within 2 weeks of starting treatment 
that is ≥ twice the upper limit of normal. CA-125 progression can be monitored by 
analysing the CA-125 doubling time throughout treatment. Rustin et al proposed that 
in patients achieving CA-125 normalisation after chemotherapy, doubling from the 
upper limit of normal (ULN), i.e. >70 IU/ml, can predict progression (Rustin, Marples 
et al. 2001). Furthermore, for patients with persistently elevated CA-125 levels, 
doubling from nadir levels can also confirm progressive disease (Rustin, Marples et 
al. 2001).  
 
Serum CA-125 was measured in all evaluable patients at baseline (i.e. just prior to 
cycle 1) and on the day of each subsequent treatment. The results preceding study 
initiation and throughout CNTO328 treatment are illustrated in figure 3.9. Prior to 
study recruitment, CA-125 values had increased in all patients and radiological 
disease progression was confirmed. During the initial 6-10 week study period, the 
patients who had clinical benefit showed varying alterations in CA-125 levels. Patient 
13 had a definitive CA-125 response according to GCIG criteria (see section 3.9) and 
for patients 05, 09 and 10 who had stable disease, the rate of CA-125 progression with 
previous chemotherapy appears to either plateau or decline (figure 3.10). Both 
patients 07 and 20 had relatively lower baseline CA-125 levels (> double ULN but 
<150 IU/ml) and neither showed evidence of tumour marker response or doubling 
from nadir levels observed during the trial.  
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Figure 3.9  Serum CA-125 values during previous platinum based chemotherapy 
and CNTO328 treatment.  
A. Patients with clinical benefit, B. Progressive disease patients.  
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Figure 3.10 Stable disease CA-125 linear regression curves.  
In the weeks preceding CNTO328 treatment, the linear regression curves confirm a steady 
rate of disease progression. With 6-10 weeks of CNTO328 therapy, there is a distinct change 
in the gradient of these curves whereby CA-125 levels either decline (patient 5) or plateau 
(patients 09 & 10). In these cases, stabilisation of CA-125 occurred as none of these changes 
amounted to a response defined by GCIG criteria. 
 
Patient 12 showed CA-125 fluctuations that may have been related to intermittent 
constipation throughout the study. Although a CA-125 response was not attained in 
this patient, a 38% decrease was evident after three cycles and levels were equivalent 
to baseline values at several points throughout 6 months of treatment. Patient 16, who 
remained clinically well, had a CA-125 increase despite radiological evidence of 
disease stabilization after 10 weeks. However, at this point the CA-125 had not 
doubled from the nadir value at week 1 (<50% increase).  
 
Excluding patient 12, 13 (both of whom at 6 months had continual radiological 
disease stabilization but were withdrawn from the study due to deteriorating PS) and 
20, who continued beyond 6 months and received five further cycles of CNTO328, 
the elevation seen at the point of study withdrawal in the remaining patients who had 
previously gained clinical benefit reflected their eventual disease progression. All 
patients with PD had continual increases in CA-125 after initiation of CNTO328 with 
doubling evident in 3 patients within 6-10 weeks.  
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3.9 Partial response profile 
 
Partial response as confirmed by the combined RECIST and CA-125 criterion was 
obtained in one patient, patient 13, who completed 12 cycles of CNTO328. Her  
CA-125 which had increased prior to the initiation of therapy, decreased significantly 
after the completion of 5 cycles (figure 3.11).  
 
 
 
 
 
 
 
A 
 
 
 
 
 
 
B 
Figure  
 
 
Figure 3.11 Partial response CA-125 profile.  
After 4 cycles of CNTO328 (7 weeks), CA-125 levels have decreased to >50% of the initial 
value at week 1. The duration of this response is approximately 14 weeks, which amounts to a 
partial response by GCIG CA-125 criteria. 
 
With [18F]-FDG-PET imaging, the standardised uptake value (SUV) is used to 
measure the metabolic activity of a lesion; i.e. the intensity of a hot spot. The scale 
range is 0 (no uptake) to 15 (maximal uptake) and the majority of cancers have SUVs  
greater than 2-3. The serial PET-CT images for patient 13 at baseline, week 10 and 
week 24 are shown in figure 3.12.  
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Figure 3.12 Patient 13: [18F]-FDG-PET/CT images.  
A. Baseline, B. Week 10 (5 cycles), C. Week 24 (12 cycles).  These images of bulky pelvic 
disease confirm reduction in metabolic activity that continued throughout 6 months of 
CNTO328 treatment. 
 
During 6 months of CNTO328 treatment, the CA-125 response also correlated with 
SUV reductions in the pelvic lesions shown in these [18F]-FDG-PET images (figure 
3.13). 
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Figure 3.13 CA-125 correlations with pelvic lesion SUV.   
By week 10, a partial response in CA-125 is observed alongside a decline in SUV. Although 
the CA-125 starts to increase by week 21, the SUV response continues for up to 6 months. 
 
Response on PET imaging is defined as a greater than 50% reduction in SUV. In the 
case of patient 13, at weeks 10 and 23, the SUVs had decreased by 11% and 31% 
respectively which by RECIST only amounts to stable disease. However, with respect 
to the combined GCIG criteria, in view of the duration and extent of the CA-125 
decline this patient was classed as a ‘partial responder’. Although the CA-125 had 
more than doubled from the nadir of 31 U/ml at week 11 to 78 IU/ml at the time of 
study withdrawal (week 24), there was no demonstrable evidence of radiological 
disease progression (figure 3.12 (C)) and the SUV for the pelvic lesions had 
continued to decrease.  
 
3.10 Toxicity profile 
 
Toxicities experienced by all evaluable patients with each cycle of CNTO328 were 
documented according to the National Cancer Institute Common Terminology  
Criteria for Adverse Events (NCI CTCAE). The grade 3 and 4 toxicities observed in 
this study are summarised in table 3.2.  
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 Grade 3 Grade 4 
   
Hypersensitivity - - 
Pain 9/18 (50%) 4/18 (22.2%) 
Infection - - 
Wt Gain - - 
Fatigue 6/18 (33.3%) 1/18 (5.5%) 
Taste Alteration - - 
Stomatitis - - 
Nausea 1/18 (5.5%) - 
Vomiting - - 
Constipation 4/18 (22.2%) 2/18 (11.1%) 
Diarrhoea - - 
Anorexia 2/18 (11.1%) - 
Alopecia - - 
Dyspnoea 1/18 (5.5%) 1/18 (5.5%) 
Sensory Neuropathy 1/18 (5.5%) - 
Hand Foot 1/18 (5.5%) - 
Dizziness - - 
   
 
Table 3.2  NCI CTCAE grade 3 and 4 toxicity profile with CNTO328.  
Although the most common side-effects related to grade 3 pain, fatigue and constipation, 
these were reported in ≤ 50% of the evaluable patients. 
 
Consistent with other trials using CNTO328, the drug is well tolerated in this group of 
patients. The most common side effect relating to grade 3 pain was predominantly 
abdominal in origin and although this was probably due to underlying disease, this is 
a symptom that has been previously reported with monoclonal antibodies in general.   
Overall, it is most likely that the majority of the toxicities that have been detailed are 
secondary to disease as opposed to CNTO328. At the completion of the study 
(September 2009), 26 serious adverse events (SAE) were reported since the initiation 
of recruitment and none of these SAEs were attributed to CNTO328. 
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3.11 Haematological profiles 
 
The effects of IL-6 on haematopoietic cells are well documented. Anaemia in chronic 
disease and malignancy has an inflammatory origin whereby iron metabolism is 
tightly regulated by proinflammatory cytokines (Rogers 1996; Ludwiczek, Aigner et 
al. 2003). This is principally mediated through hepcidin, a hormone potently induced 
by IL-6 which limits incorporation of iron into haem moieties by decreasing intestinal 
absorption and promoting preferential iron storage in the liver and reticuloendothelial 
system (Nemeth, Rivera et al. 2004; de Mast, van Dongen-Lases et al. 2009). IL-6 is 
also linked to tumour-associated thrombocytosis through its effects on 
megakaryocytopoiesis and in EOC, high IL-6 levels in ascites can correlate with 
circulating platelet counts (Gastl, Plante et al. 1993).  Furthermore in bone marrow 
homeostasis, IL-6 has established roles in regulating lymphocyte differentiation and 
granulopoiesis (Zhang, Iwama et al. 1998; Pal, Janz et al. 2009). 
 
3.11.1 Haemoglobin 
The haemoglobin (Hb) profiles during the initial 6-week study period and throughout 
6 months of treatment are illustrated in figures 3.14 and 3.15. Throughout the study, 
the Hb remained stable for the majority of patients and there were no significant 
differences between both groups of patients throughout the first 6 weeks of the study. 
Amongst the patients with PD, 3 patients (01, 02 and 14) received blood transfusions 
shortly after the first cycle. However the Hb for patient 02, who had rapidly 
progressive disease, dropped towards 9g/dl only two weeks later. Two patients who 
had clinical benefit required blood transfusions, patient 10 (weeks 4 and 9) and patient 
12 (week 23). Apart from malignancy, none of these patients had any other causes for 
anaemia. 
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Figure 3.14 Haemoglobin profiles: 6-week study period. 
A. Patients with clinical benefit, B. Progressive disease patients, C. Evaluable patient profile 
at baseline, weeks 2 and 6. 
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Figure 3.15 Haemoglobin profiles: 6-month continuation period.  
This graph illustrates the Hb profiles for SD/PR patients throughout their treatment with 
CNTO328. The perforated line denotes where blood transfusion is usually indicated (≤ 9 
g/dl). 
 
 
3.11.2 Platelet count 
The platelet profiles throughout this study are illustrated in figures 3.16 and 3.17. At 
baseline, seven patients had thrombocytosis (platelet count > 400 x 109/l); patients 09, 
10 and 13 who had clinical benefit and patients 01, 02, 04 and 17 with PD.  Their 
platelet counts normalised after the initial cycle of CNTO328 and the levels for the 
majority of the remaining patients were within normal limits after the completion of 3 
cycles. Recurrent thrombocytosis occurred in 2 patients; patient 02 at the point of 
disease progression and patient 13 on numerous occasions with the counts not 
reaching baseline levels. Although mild thrombocytopenia was evident in five 
patients at various points throughout the study these levels were never less than 100 x 
109/l (NCI CTCAE grade 1 thrombocytopenia). Between both patient groups, there 
were no statistically significant differences in mean platelet counts during the initial 
6-week study period.  
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Figure 3.16 Platelet count profiles: 6-week study period.  
A. Patients with clinical benefit, B. Progressive disease patients, C. Evaluable patient profile 
at baseline, weeks 2 and 6. (ULN=upper limit of normal, LLN=lower limit of normal). 
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Figure 3.17 Platelet count profiles: 6-month continuation period. 
Platelet count profiles for SD/PR patients throughout their treatment with CNTO328. 
ULN=upper limit of normal, LLN=lower limit of normal). 
 
 
3.11.3 Neutrophil count 
The effects induced by CNTO328 on neutrophil counts for the evaluable patients 
throughout the study are illustrated in figure 3.18 and 3.19. During the first six weeks 
and beyond, neutrophils remained stable in the clinical responders and both baseline 
and week 6 mean neutrophil levels were significantly lower in the patients with 
clinical benefit compared to the PD group (Mann Whitney U test p= 0.0164 and 
0.0268 respectively). Although stable neutrophil counts were also observed in a 
portion of the PD patients, there appeared to be more fluctuations throughout the three 
courses of CNTO328. In addition, at the point of disease progression at week 6, there 
were clear increases in neutrophil counts compared to baseline in 50% of these 
patients.  During the treatment continuation period beyond 6 weeks, only patients 12 
and 20 had transient periods of neutropenia (<1.0 x 109/l) during which both patients 
remained clinically well and the counts recovered spontaneously prior to the 
subsequent cycle. The neutrophilia at week 21 for patient 13 was possibly secondary 
to her aforementioned episode of sub-acute bowel obstruction at this time.  
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Figure 3.18 Neutrophil count profiles: 6-week study period.  
A. Patients with clinical benefit, B. Progressive disease patients, C. Evaluable patient profile 
at baseline, weeks 2 and 6. 
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Figure 3.19 Neutrophil count profiles: 6-month continuation period. 
Neutrophil counts for SD/PR patients throughout their treatment with CNTO328. 
(LLN=lower limit of normal). 
 
 
 
3.11.4  Lymphocyte count 
 
The lymphocyte profiles for the evaluable patients throughout the study are illustrated 
in figure 3.20 and 3.21. During this study, patients who had baseline lymphopenia had 
sustained counts <1.0 x 109/l throughout the first 3 cycles of CNTO328. Along with 
patient 04 who developed lymphopenia by week 6, none of these patients were 
compromised by concomitant infections. There were no significant differences in 
mean lymphocyte counts between both cohorts during the initial 6 weeks and they 
remain stable throughout the 6-month treatment continuation period in patients with 
clinical benefit.
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Figure 3.20 Lymphocyte count profiles. 
A. Patients with clinical benefit, B. Progressive disease patients, C. Evaluable patient profile 
at baseline, weeks 2 and 6. 
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Figure 3.21 Lymphocyte profiles: 6-month continuation period. 
Neutrophil counts for SD/PR patients throughout their treatment with CNTO328. LLN=lower 
limit of normal). 
 
 
 
3.12 Quality of Life  
 
The quality of life (QoL) for each patient recruited to this study was assessed during 
every week of the 6-week study period using standard EORTC questionnaires (QLQ-
C30 version 3.0 and OV28). The QLQ-C30 questionnaire is composed of both multi-
item and single item measures. These include five functional scales, three symptom 
scales, a global health status (QoL scale) and six single items (table 3.3). The scoring 
system for the ovarian module, QLQ-OV28 is identical to that used for the 
scales/items in the aforementioned QLQ-C30 questionnaire. This is outlined in table 
3.4. 
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 Scale Number of items Item range 
Global health 
status/QoL QL2 2 6 
    
Functional scales    
Physical functioning PF2 5 3 
Role functioning RF2 2 3 
Emotional 
functioning EF 4 3 
Cognitive 
functioning CF 2 3 
Social functioning SF 2 3 
    
Symptom scales    
Fatigue FA 3 3 
Nausea and 
vomiting NV 2 3 
Pain PA 2 3 
Dyspnoea DY 1 3 
Insomnia SL 1 3 
Appetite loss AP 1 3 
Constipation CO 1 3 
Diarrhoea DI 1 3 
Financial difficulties FI 1 3 
 
Table 3.3 Scoring the QLQ-C30 version 3.0. 
The items for each scale are numbers which are circled on the questionnaire according to the 
degree of symptomatology the patients experience at the relevant timepoint. The item range is 
the difference between the possible maximum and minimum response to individual items; 
most items take values from 1-4, giving range= 3.  
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Symptom scale Number of items Item range 
 
Abdominal/GI 
 
6 3 
 
Peripheral neuropathy 
 
2 3 
 
Hormonal 
 
2 3 
 
Body image 
 
2 3 
Attitude to 
disease/treatment 
 
3 3 
 
Chemotherapy side-effects 
 
5 3 
 
Other single items 
 
4 3 
 
Table 3.4. Scoring the QLQ-OV28 questionnaire. 
 
All of the scales and single-item measures range in score from 0 to100. A high scale 
score represents a higher response level. Hence, a high score for a functional scale 
represents a high/healthy level of functioning, a high score for the global health 
status/QoL represents a high QoL, but a high score for a symptom scale/item 
represents a high level of symptomatology. The principle for scoring these scales is 
the same in all cases. Firstly, the average of the items that contribute to the scale is 
calculated. This is the raw score (RS). Subsequently, a linear transformation 
(provided by EORTC) is used to standardise the raw score, so that scores range from 
0 to 100. A higher score represents a higher level of functioning, or a higher level of 
symptoms. The linear transformations used for each scale  are as follows: 
 
Functional scale score =  (1- ((RS-1) ÷ range)) x 100 
Symptom scales/items  =  ((RS-1) ÷ range) x 100 
Global health status/ QoL =  ((RS-1) ÷ range) x 100 
 139 
 
The global QoL scores for the clinical benefit and progressive disease patient cohorts 
are shown in figure 3.22.  
 
 
 
 
 
 
 
 
 
 
 
    
Figure 3.22 EORTC QLQ-C30 global QoL scores.   
During the initial 6-week study period significant differences in QoL scores were only seen 
after the first cycle of CNTO328. 
 
There appear to be some intriguing correlations between QoL and CNTO328 response 
during the initial 6-week study period.  At week 2, the patients who attained clinical 
benefit had a significantly higher mean QoL score compared to progressive disease 
patients (p=0.0102). However the increase in score for these patients from baseline is 
not significant. The improvement seen after the completion of one cycle may 
represent a placebo effect as it was not maintained at week 6, with mean scores 
reaching sub-baseline levels and equal with those seen in the PD patients. This 
observation may also be due to two patients (05 & 09) being hospitalised for medical 
procedures (paracentesis and pleural drainage respectively) and patient 07 who had an 
exacerbation of her pre-existing depressive symptoms.  During the initial 6-week 
study period, there were no significant differences in the scores between patients with 
clinical benefit and PD patients for any components of the functional and symptom 
scales outlined in table 3.3. Interim results from a recent study have questioned the 
validity of multiple questionnaires assessing QoL in patients undergoing treatment for 
EOC (Friedlander, unpublished data, 2009). In 30 women treated for platinum-  
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resistant disease, ANZGOG-0701 study analysed the results from four QoL 
questionnaires (including QLQ-C30 and OV-28) and ranked the ten most noticed 
symptoms in the last week. The top three of these were fatigue, general pain and 
abdominal bloating in order of prevalence (Friedlander, unpublished data, 2009). The 
scores for these symptoms along with global QoL for the four patients who continued 
treatment for up to 6 months are illustrated in figure 3.23. 
 
 
 
 
Figure 3.23 6-month QoL parameters profile.  
These graphs illustrate the scores for global Qol, fatigue, pain and abdominal symptoms 
during 6 months of CNTO328 treatment in four patients.  
 
The six-month profiles for the QoL parameters showed a degree of variability 
between the four patients.  Patient 12 maintained stable QoL, pain and abdominal 
symptom scores throughout the study. Although her fatigue initially improved over 
the first three months, the score at study withdrawal was the same as baseline. Both  
patients 16 and 20 maintained high global QoL scores and low levels of pain, fatigue 
and abdominal symptomatology. Despite encouraging improvements in QoL and pain  
scores after 6 weeks for the partial responder, patient 13, this paradoxically 
deteriorated after six months.  Furthermore no improvements were seen in fatigue  
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levels and her recurrent paracentesis resulted in increased abdominal symptoms.  
Table 3.5 summarises the QoL parameter scores observed over 6 months including 
the percentage change from baseline. 
 
 Patient 12 Patient 13 
  
Base 
 
Wk 6 
 
Wk 12 
 
Wk 24 
 
Base 
 
Wk 6 
 
Wk 12 
 
Wk 24 
Global QoL 50 50 
(-) 
50 
(-) 
50 
(-) 
75 
 
83.33 
(↑11%) 
58.33 
(↓22%) 
41.66 
(↓44%) 
Fatigue 55.55 33.33 
(↓40%) 
33.33 
(↓40%) 
55.55 
(-) 
33.33 33.33 
(-) 
33.33 
(-) 
33.33 
(-) 
Pain 33.33 33.33 
(-) 
33.33 
(-) 
33.33 
(-) 
  50 16.66 
(↓67%) 
66.66 
(↑33%) 
66.66 
(↑33%) 
Abdominal 
symptoms 
27.77 33.33 
(↑20%) 
33.33 
(↑20%) 
33.33 
(↑20%) 
11.11 16.66 
(↑50%) 
61.11 
(↑450%) 
33.33 
(↑200%) 
         
 Patient 16 Patient 20 
  
Base 
 
Wk 6 
 
Wk 12 
 
Wk 24 
 
Base 
 
Wk 6 
 
Wk 12 
 
Wk 24 
Global QoL 100 83.33 
(↓17%) 
83.33 
(↓17%) 
83.33 
(↓17%) 
83.33 66.66 
(↓20%) 
83.33 
(-) 
83.33 
(-) 
Fatigue 33.33 11.11 
(↓67%) 
11.11 
(↓67%) 
11.11 
(↓67%) 
22.22 22.22 
(-) 
22.22 
(-) 
11.11 
(↓50%) 
Pain 16.66 16.66 
(-) 
16.66 
(-) 
16.66 
(-) 
16.66 33.33 
(↑100%) 
16.66 
(-) 
16.66 
(-) 
Abdominal 
symptoms 
5.55 5.55 
(-) 
5.55 
(-) 
5.55 
(-) 
0 27.77 
(n/a) 
11.11 
(n/a) 
5.55 
(n/a) 
 
Table 3.5 6-month QoL parameters summary.  
Functional and symptom scores from QLQ-C30 and OV28 for global QoL, fatigue, pain and 
abdominal symptoms throughout 6 months CNTO328 therapy. Percentage change from 
baseline scores is indicated in parentheses. 
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3.13 CNTO328 serum pharmacokinetics 
 
The serum CNTO328 PK parameters (Cmax and Cmin) during the initial 6-week 
study period are summarized in table 3.6. Following each i.v. infusion of CNTO328 
(5.4 mg/kg delivered via a Baxter Colleague 1 Volumetric infusion pump), a large 
inter-subject variability in serum concentration was observed. CNTO328 was infused 
in 250 ml 5% Dextrose at a set-rate of 2ml/min for each patient. In all circumstances 
the infusion time was monitored and logged with a variability of no more than 5 
minutes for all evaluable patients. Blood for serum processing was always taken from 
the opposite arm of the infusion.  
       
  PK Parameters (μg/mL) 
 Dose 1 Dose 2 Dose 3 
ID Cmin Cmax* Cmin Cmax* Cmin Cmax* 
1 <LLOQ 18.80 17.87 103.77 38.89 145.30 
2 <LLOQ 154.62 13.89 75.37 NS NS 
3 <LLOQ 93.40 27.50 95.78 29.24 103.05 
4 <LLOQ 123.28 15.30 NS 14.18 131.82 
5 <LLOQ 69.84 19.94 66.34 30.76 59.11 
6 <LLOQ 60.37 14.51 79.02 21.49 140.84 
7 <LLOQ 93.87 23.52 120.17 46.80 151.05 
8 <LLOQ 87.06 27.30 110.15 37.86 133.66 
9 <LLOQ 6.22 18.45 74.19 20.20 71.13 
10 <LLOQ 7.35 0.38 12.50 30.93 21.46 
11 <LLOQ 11.30 3.48 131.07 6.66 16.96 
12 <LLOQ 12.12 0.37 8.51 66.78 28.51 
13 <LLOQ 1.16 3.86 119.77 6.89 19.59 
14 <LLOQ 96.82 25.21 132.27 5.80 7.69 
15 <LLOQ 141.01 10.36 165.73 0.42 13.80 
16 <LLOQ 19.13 45.79 170.46 15.92 212.64 
17 <LLOQ 2.08 1.22 1.70 0.85 20.95 
20 <LLOQ 5.19 4.21 15.86 9.36 44.78 
No. of pt 0 18 18 17 17 17 
Min NC 1.16 0.37 1.70 0.42 7.69 
Max NC 154.62 45.79 170.46 66.78 212.64 
Median <LLOQ 39.75 14.90 95.78 20.20 59.11 
Mean <LLOQ 55.76 15.17 87.22 22.53 77.78 
s.d. NC 52.67 12.10 53.07 18.13 63.82 
 
Table 3.6 CNTO328 concentrations for evaluable patients during initial 6-week 
study period. 
 *: obtained 1 hour after end of infusion. ID: patient identification. LLOQ = 0.045 µg/mL in 
serum at a dilution of 1:4. Max: maximum. Min: minimum. NC: Not calculated.  
No. of pt: number of patients. NS: No sample was collected. s.d: standard deviation. 
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Figure 3.24 Mean serum CNTO328 concentrations during the initial 6-week 
study period. 
During the initial 3 cycles, the highest mean Cmax was seen at day 14 and plateaus by day 
28, indicating that CNTO328 concentrations stabilise at the end of the 6-week study period  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25 CNTO328 pharmacokinetic profile during initial 6-week study 
period 
The scatter plots indicate wide variations in Cmin and Cmax values within both groups of 
patients.  By the completion of 3 cycles, the mean Cmax values are equal for both patients 
with clinical benefit and progressive disease. 
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The mean  (± s.d.values) of serum Cmax, which were based on the 18 subjects, were 
55.76 ± 52.67 µg/mL, 87.22 ± 53.07 µg/mL and 77.78± 63.82 µg/mL following the 
first three infusions, respectively (figure 3.24). The mean serum Cmin values 
following cycles 2 and 3 were 15.17 ± 12.10 µg/mL and 22.53 ± 18.13 µg/mL, 
respectively. Both Cmin and Cmax values with each cycle varied widely within each 
patient cohort. As the mean CNTO328 concentrations were not significantly different 
(figure 3.25), no correlations exist between CNTO328 pharmacokinetics and response 
in this study. 
 
3.14 Survival data  
 
In platinum resistant ovarian cancer patients receiving drugs such as liposomal 
doxorubicin or gemcitabine in the second or third-line setting, the median overall 
survival (OS) has recently been quoted at approximately 12 months (Ferrandina, 
Ludovisi et al. 2008).  Out of the 18 evaluable patients in this trial to date 15 have 
died, 2 are alive and clinically well and one patient has been lost to follow up.  The 
Kaplan-Meier survival curve for patients where mortality data was available in this 
study is illustrated in figure 3.26. 
 
 
   
  
 
 
 
 
 
 
 
 
Figure 3.26 Kaplan-Meier survival curve for evaluable patients treated with 
CNTO328. 
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The median OS for patients with relapsed platinum resistant ovarian cancer treated 
with CNTO328 is 48 weeks, which is comparable to other single agents commonly 
employed in the chemotherapeutic management of this disease (Ferrandina, Ludovisi 
et al. 2008).  A proportion of patients with progressive disease survived beyond the 
median survival of 48 weeks (patients 01, 03 & 08). 6 patients with clinical benefit  
survived beyond this point, two of whom are currently alive and well. The difference 
in median OS between patients with clinical benefit and PD reached statistical 
significance (66.43 weeks vs. 32.07 weeks; log-rank test *p=0.024). 
 
3.15 Discussion 
 
The results outlined in this chapter suggest that anti-IL-6 therapy with CNTO328 
shows a degree of efficacy in patients with recurrent platinum resistant ovarian 
cancer. Although, it could be argued that the true response rate only amounts to 5.5% 
(1 PR), disease stabilisation was observed in patients who had demonstrable disease 
progression prior to the initiation of CNTO328. Hence, the overall clinical benefit 
(SD + PR) observed in this study amounts to 44.4%. Although there was no 
significant impact on improving QoL parameters, the drug was well tolerated and had 
no attributable SAEs. CNTO328 shows considerable anti-inflammatory effects with 
suppression of both CRP and B-2M seen up to 6 months. Furthermore, CRP 
concentrations below the LLOQ was seen in all patients with clinical benefit 
throughout the initial 6-week study period. Although, this was also evident in some 
patients with progressive disease, there were some other PD patients who’s CRP was 
not continually suppressed during this period. In conclusion the relationship between 
CRP levels and response to CNTO328 is not clear; however failure to suppress CRP 
below the LLOQ is associated with poor outcome.   
 
With respect to other observations in the study, there appeared to be no correlation 
between response and disease burden, with patient 13 (PR) having a larger tumour 
bulk in comparison with some of the patients who progressed. The serum 
pharmacokinetics revealed a large inter-subject variability in Cmin and particularly 
with Cmax. Based on previous clinical trials with CNTO328, dosing in this study was  
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based on ideal body weight to circumvent any problems with calculating doses in 
patients with ascites. Any large discrepancies between ideal and actual body weight 
could potentially explain the variability in PK parameters evident in this trial and this 
particular phenomenon will be investigated in future studies. Nevertheless, as there 
was no difference in mean serum PK values between SD/PR and PD patients with the 
initial three cycles of CNTO328, this suggests that the reason for the differential 
response in the study was not purely due to dosing issues.  However, if tumour 
biopsies were available at the end of the six-week study period, PK analysis of 
CNTO328 in tumour lysates would have clarified whether response correlated to the 
concentrations of antibody found in these specimens. 
 
Overall, this chapter has shown evidence to support the theory that targeting IL-6 can 
have a clear effect in arresting ovarian cancer progression. In order to assess how this 
efficacy related with changes to other influential cytokines and chemokines in the 
tumour microenvironment, further analyses of plasma and ascitic samples collected in 
this study were performed.  
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4 A Phase II Study of Intravenous CNTO328 in Patients 
with Recurrent Epithelial Ovarian Cancer: Plasma and 
Ascites Cytokine Analysis 
 
4.1 Aims 
 
The aim of the experiments in this chapter is to see whether changes in cytokine 
concentrations in plasma and ascites collected from the evaluable patients related to 
the clinical outcome seen in the CO328X05 trial. The profiles obtained from both the 
patients with clinical benefit and those who had disease progression during the initial 
6-10 week study period will be compared in order to investigate potential biomarkers 
of response and to gain some insight into the mechanism of action of CNTO328. 
 
4.2 Cytokine analysis 
 
Cytokine analysis using electrochemiluminescence detection with MSD assays were 
performed on plasma samples taken from evaluable patients throughout the study. 
This analysis was also performed on ascitic fluid from 3 patients (04, 05 and 13) who 
had paracenteses at various time-points during the course of the trial. The MS2400 
Human single-plex and multi-plex ultra-sensitive kits were used to analyse plasma 
concentrations of IL-1β, IL-6, IL-8, TNF-α, IFN-γ, CCL2, VEGF and soluble IL-6 
receptors (sgp80 and sgp130). R&D Human Quantikine ELISA kits were used to 
measure CXCL12 in the same samples. In parallel with these experiments analysis 
was also performed on plasma samples from three normal healthy female controls 
(age range 24-55 years). These inflammatory mediators were chosen on the basis of 
their established roles in the ovarian cancer microenvironment along with their 
associations with IL-6 (Toutirais, Chartier et al. 2003; Wall, Burke et al. 2003; 
Balkwill 2004; Maccio, Madeddu et al. 2005; Nilsson, Langley et al. 2005; Kulbe, 
Thompson et al. 2007). 
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4.3 IL-6 
 
The primary objective of the cytokine analysis was to assess the effects of the 
CNTO328 on plasma IL-6 levels. The baseline IL-6 profile in all evaluable patients is 
shown in figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Baseline IL-6 concentrations.  
Box and whisker graph illustrating the baseline IL-6 levels in patients with clinical benefit 
(range 0.86 pg/ml -10.7 pg/ml)) and progressive disease (range 2.17 pg/ml -20.8 pg/ml).  
 
Although patients with clinical benefit had lower mean levels of IL-6 at baseline 
compared with patients who had progressed, this difference was not statistically 
significant (4.373 pg/ml vs. 8.216 pg/ml, Mann-Whitney U test p=0.146). Within 24 
hours of initial CNTO328 treatment, IL-6 levels increased and reached concentrations 
that were 2-3 logs higher than baseline in all patients but this phenomenon was not 
associated with any symptomatology. As this observation may have been due to the 
ECL assay detecting the IL-6 binding epitope on CNTO328, I performed an 
experiment where CNTO328 (10-100µg/ml) was added to baseline samples from 4 
patients to see if IL-6 levels increased. In each case, the IL-6 concentrations remained 
the same and therefore the logarithmic changes in IL-6 were not due to detection of 
CNTO328 (data not shown). This finding was substantiated by a further experiment 
that compared IL-6 concentrations in these baseline samples spiked with either 
recombinant human IL-6 (rhIL-6, 500pg/ml) or rhIL-6 + CNTO328 (10-100µg/ml) 
and no differences were identified after incubation for 16 hours (data not shown).   
 149 
 
Despite the findings in the ex-vivo experiment, it is still a possibility that the MSD 
platform detected IL-6 complexed with CNTO328 in these patients from 24 hours 
onwards. This has been recognised in previous studies with antibodies targeting IL-
6R (Nishimoto, Terao et al. 2008) and with the anti-TNF-α antibody, infliximab, 
where TNF-α levels had risen (Harrison, Obermueller et al. 2007; Brown, Charles et 
al. 2008). Attempts were made to estimate non-complexed IL-6 by replacing the 
detection antibody provided in the MSD kit with CNTO328 developed specifically for 
this purpose. The hypothesis behind this experiment was based on the assumption that 
in IL-6-CNTO328 complexes, the epitope on the D loop of IL-6 which binds to 
CNTO328 would be saturated, hence preventing any further complexing with the 
CNTO328 detection antibody. Therefore any IL-6 detected by CNTO328 on the MSD 
platform would be representative of bioactive (i.e. unbound) IL-6 within the plasma 
samples. The results obtained using the standard MSD and alternative CNTO328 
detection antibodies are shown in figure 4.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 IL-6 profiles with MSD and CNTO328 detection antibodies.  
IL-6 levels start to increase after 24 hours of initiating CNTO328 treatment. This trend 
continues in a logarithmic fashion after the completion of 3 cycles. IL-6 levels at both 24 
hours and week 6 were significantly higher in progressive disease patients using both types of 
detection antibody concentrations of 1µg/ml. 
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At baseline, the IL-6 levels detected by both antibodies appear to be the same and 
therefore it appears that the MSD and CNTO328 antibodies detect IL-6 with equal  
affinity. During the course of the initial study period, the concentration of IL-6 
measured in the PD patients remained significantly higher at both 24 hours and 6  
weeks (p=0.03 and 0.04 respectively) compared to patients who had clinical benefit.  
However at these time-points there were no significant differences in the mean IL-6 
levels between these detection antibodies for either SD/PR or PD patients and 
logarithmic increases were still seen with both methods. Therefore it seems that the 
CNTO328 detection antibody was not able to detect non-complexed IL-6.  
 
Another plausible explanation for the high concentrations of IL-6 is that the inhibition 
of downstream signalling by CNTO328 induced compensatory increases in IL-6 in 
the absence of negative feedback mechanisms that are usually regulated through 
pSTAT3 transcription of SOCS3. Alternatively, CNTO328 may have increased IL-6 
concentrations by impeding IL-6 elimination; a hypothesis derived from the 
mechanisms by which tocilizumab (anti-IL-6R antibody) increased plasma IL-6 levels 
in patients with rheumatoid arthritis (Nishimoto, Terao et al. 2008).  In addition, a 
possible explanation as to why the patients in this study remained asymptomatic is 
that IL-6 signalling was being effectively down-regulated by CNTO328. In 
conclusion, it is possible that the MSD platform was detecting a combination of free 
and complexed IL-6.  
 
4.3.1  IL-6, QoL score and biomarker correlations 
 
As there were limitations in assessing the effects of CNTO328 on bioactive IL-6 
levels, other biomarkers have been used as surrogates of IL-6 activity.  In view of the 
associations between IL-6 and a variety of clinical parameters that were outlined in 
the previous chapter, my next aim was to correlate baseline IL-6 concentrations with 
specific inflammatory markers, haematological indices and QoL scores for all 
evaluable patients in this study (figure 4.3).  
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Although statistical significance was observed between SD/PR and PD patients for 
mean baseline CRP levels as opposed to IL-6, a strong positive correlation exists 
between these two indices at this time-point (r2 = 0.7502). For this reason, CRP  
suppression seen with subsequent cycles of CNTO328 may have indicated effective 
down-regulation of IL-6 signalling.   
 
 
 
  
  
   
 
 
 
 
 
 
Figure 4.3 Baseline IL-6 correlation curves.  
Pre-treatment IL-6 levels show correlations with CRP, QoL score, haemoglobin and platelet 
counts. The curved dashed lines represent the 95% confidence interval of the solid regression 
line.  
 
4.4 Soluble IL-6 receptors (sgp80 and sgp130) 
 
The effects of CNTO328 on trans-signalling were investigated by analysing sgp80 
and sgp130 plasma concentrations throughout the study. Concentrations of plasma 
sgp130 in excess of sgp80 were seen in all patients in this trial. However, there were 
no significant differences between SD/PR and PD patients within the initial 6-week 
study period and CNTO328 did not appear to have any early effects on trans-
signalling (figure 4.4 (A)). There were variable effects during the 6-month 
continuation period. After 12 cycles sgp80 concentrations in patients 13, 16 and 20  
moderately increased from baseline but remained stable for patient 12.  Interestingly, 
in all 4 patients, sgp130 concentrations increased sharply by 3 months. Apart from 
patient 12 where levels continued to rise, sgp130 plateaued until the end of treatment  
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in the remaining three subjects (figure 4.4 (B)). Despite this, the mean sgp130 
concentrations for all of these patients were significantly higher at both 3 and 6 
months compared to baseline levels (p<0.05 for both time-points). As CNTO328 
treatment continued, further compensatory increases in IL-6 would be expected. 
Hence, any ‘free’ IL-6 that could potentially exert its biological effects via trans-
signalling could be buffered by the antagonistic actions of sgp130. This suggests that 
the extension of clinical response conferred by CNTO328 in these 4 patients may in 
part be due to the surge in sgp130 activity from 6 weeks onwards. 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Soluble IL-6 receptor profiles. 
(A) The 6-week study period profiles for sgp80 and sgp130 confirmed no significant changes 
after 3 cycles or differences between SD/PR and PD patients. (B) The line graphs illustrating 
the 6-month profiles of 4 patients indicate significant rises in both soluble receptors at 3 and 
6 months with sgp130 which is an antagonist to IL-6 trans-signalling (p=0.029 for both time-
points). 
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4.5 TNF-α  
 
TNF-α is a major mediator of a myriad of processes in the EOC tumour 
microenvironment including tumour proliferation and promotion of metastasis 
(Kulbe, Thompson et al. 2007). Through NF-κB, TNF-α regulates of IL-6 with both 
experimental models and clinical trial evidence confirming that TNF-α inhibition can 
diminish IL-6 levels (Madhusudan, Muthuramalingam et al. 2005; Kulbe, Thompson 
et al. 2007). The effects of IL-6 inhibition with CNTO328 on TNF-α in plasma are 
illustrated in figure 4.5. 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
Figure 4.5 Plasma TNF-α  levels. 
(A) Mean TNF-α concentrations were significantly lower for patients attaining clinical 
benefit throughout the initial 6-week study period (baseline & 24 hrs p<0.05, week 6 p<0.01). 
(B) During 6-months of CNTO328 treatment in 4 patients there were mild fluctuations in 
these levels but they generally remained stable.  
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TNF-α concentrations at baseline, 24 hours and 6 weeks (figure 4.5 (A)) were 
significantly lower in patients who had clinical benefit compared to those with PD 
(Mann Whitney U test, p = 0.0205, 0.015 and 0.002 respectively). However, for both 
groups of patients, mean TNF-α levels remained stable throughout the initial 6-week 
study period. With respect to the 4 patients with long- term response, although levels 
initially decreased during the initial 6 weeks of therapy, TNF-α subsequently rises 
back to baseline concentrations by the completion of 12 cycles of CNTO328 (figure 
4.5 (B)). 
4.6 IL-1β  
 
Along with TNF-α, IL-1β is another cytokine that potently induces IL-6 during 
inflammatory processes.   Plasma IL-1β levels have been shown to be  elevated in 
ovarian cancer (Zeisler, Tempfer et al. 1998) and this significantly correlated with 
high plasma IL-6 concentrations (Maccio, Madeddu et al. 2005). The plasma levels of 
IL-1β in patients treated with CNTO328 are shown in figure 4.6. During the initial 3 
cycles, mean IL-1β concentrations were generally stable (figure 4.6 (A)). The mean 
concentrations for patients with clinical benefit were lower than in  the PD patients, 
although the differences were not significant. After 6 months, IL-1β remained stable, 
with the exception of patient 12 where it declines (figure 4.6 (B)).  
 
4.7 VEGF 
 
In human ovarian cancer xenograft models, IL-6 induces VEGF in a pSTAT3 
dependent manner, and promotes endothelial cell migration and angiogenesis 
(Nilsson, Langley et al. 2005). Figure 4.7 illustrates the plasma VEGF profiles 
throughout this study. At baseline and 24 hours after cycle 1 (figure 4.7 (A)), mean 
plasma VEGF concentrations were significantly lower in the SD/PR patients (p= 
0.0155 for each time-point). At the end of 6 weeks these levels had decreased 
amongst some patients in both groups with the most prominent change seen with the 
partial responder (78.9pg/ml to 27.7pg/ml). Further VEGF ‘responses’ were seen in 3 
of the 4 patients who continued CNTO328 treatment for 6 months (figure 4.7 (B)).  
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Figure 4.6 Plasma IL-1β  profile. 
(A) Mean IL-1β concentrations remained stable for evaluable patients during the initial 6-
week study period. (B) With the exclusion of patient 12 who had small decreases, stable IL-1β 
levels continued for the remaining patients who completed 6 months of CNTO328 treatment.  
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Figure 4.7 Plasma VEGF profile. 
(A) Decreasing VEGF concentrations were seen in both SD/PR and PD patients after the 
completion of 3 CNTO328 cycles. VEGF levels were lower in patients who had clinical 
benefit compared to PD patients at baseline and 24hrs (p<0.05 at both time-points). (B) 
Continuing VEGF suppression is seen up to 6 months, especially for the partial responder 
(patient 13) who has a >80% decrease from baseline after 12 cycles. 
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4.8 IL-8 
 
IL-8 is a chemokine associated with tumour cell proliferation, angiogenesis and 
development of metastasis (Wang, Yang et al. 2005). In conjunction with IL-6 and 
TGF-β, it subverts tumour immunity within the ovarian cancer microenvironment 
(Toutirais, Chartier et al. 2003). The plasma IL-8 concentrations measured during the 
first 6 weeks and up to 6 months of this study are illustrated in figure 4.8. 
 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8  Plasma IL-8 profile.  
(A) During the initial 6-week study period, mean IL-8 concentrations remained relatively 
stable for patients gaining clinical benefit and steadily increased for patients with progressive 
disease. SD/PR patients had significantly lower IL-8 levels compared with PD patients in this 
period (baseline and 24hr p<0.05, week 6 p<0.01). (B) In the partial responder, alongside 
VEGF, IL-8 also decreased consistently with 6 months of CNTO328 treatment. 
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As with TNF-α, mean IL-8 levels were significantly lower in patients who gained 
clinical benefit at baseline, 24 hours and week 6 (figure 4.8 (A), p= 0.0343, 0.0202 
and 0.0016 respectively). Furthermore, these concentrations remained stable in 
patients who had clinical benefit but increased in patients with disease progression at 
the end of the 6-week study period. During the 6-month continuation period (figure 
4.8 (B)), IL-8 reduced dramatically in the partial responder (patient 13) and remained 
stable for patients 12 and 16. The initial increases seen after 6 weeks in patient 20 
returned to baseline levels after 12 cycles. 
 
4.9 CCL2 
 
CCL2 is a chemokine induced by IL-6 that promotes leucocytic infiltration into 
tumour cells (Balkwill 2004). The effects of CNTO328 on plasma CCL2 levels in the 
evaluable patients are illustrated in figure 4.9. During the initial 6 weeks (figure 
4.9(A)), mean CCL2 levels appeared to fluctuate for patients who had clinical benefit. 
At 24 hours, after the first cycle, the mean concentrations for this group decreased 
marginally and increased in patients with disease progression. Furthermore, the 
difference between the two groups at this point is highly significant (p=0.008). At 
week 6, mean levels increased just above baseline for both SD/PR and PD patients, 
however this rise was not significant. During the 6-month treatment continuation 
period (figure 4.9(B)), all four patients had significant reductions in CCL2 compared 
to baseline (p=0.029) and this is particularly striking for the partial responder where 
after 12 cycles there was a 50% decrease.  
 
4.10 CXCL12 
 
CXCL12 is associated with invasion and metastatic processes in ovarian cancer. As 
with IL-6, CXCL12 is regulated by constitutive production of TNF-α in the tumour 
microenvironment (Kulbe, Thompson et al. 2007). CXCL12 plasma profiles with 
CNTO328 treatment are shown in figure 4.10. 
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Figure 4.9  Plasma CCL2 profile. 
(A) During the initial 6-week study period, mean CCL2 concentrations remained higher for 
patients with progressive disease compared with patients gaining clinical benefit. This 
difference was only significant at 24 hours (p<0.01) and subsequent mean CCL2 levels 
increased for both SD/PR and PD patients at week 6. (B) After 6 months, CCL2 levels had 
decreased significantly in all 4 patients treated during this period (p<0.05). As with IL-8 and 
VEGF, this decrease was most prominent in the partial responder. 
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Figure 4.10 Plasma CXCL12 profile. 
(A) Mean CXCL12 concentrations remained stable throughout the initial 6-week study period 
for both SD/PR and PD patients and there were no significant differences in these levels 
between the two groups. (B) After the completion of 12 cycles, only patient 16 showed any 
substantial decreases from baseline values. 
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For both patients with clinical benefit and progressive disease, the mean plasma 
CXCL12 concentrations were approximately equal and remained stable throughout 
the initial 6-week study period (figure 4.10 (A)). Compared to baseline concentrations 
by the end of 6 months, CXCL12 levels had marginally decreased in all patients apart 
from patient 16 who had a 40% reduction (figure 4.10 (B)). 
 
4.11 IFN-γ  
 
IFN-γ is a dimeric cytokine that is mainly produced by T cells and NK cells and is an 
essential component of the innate and adaptive immune system with anti-viral, anti-
parasitic and anti-tumoural activity.  In both in vitro and in vivo ovarian cancer 
models, IFN-γ can inhibit tumour proliferation and induce apoptosis (Burke, East et 
al. 1997; Burke, Smith et al. 1999; Wall, Burke et al. 2003). Furthermore, varying 
degrees of response have been demonstrated with IFN-γ administered to patients with 
advanced ovarian cancer (Pujade-Lauraine, Guastalla et al. 1996; Windbichler, 
Hausmaninger et al. 2000). In view of these properties, my aim was to investigate 
whether response to anti-IL-6 therapy related to induction of IFN-γ.  
 
The plasma profiles shown in figure 4.11 show that IFN-γ concentrations were very 
low throughout the 6-week study period (range 0.38 pg/ml – 24.3 pg/ml). At baseline 
and 24 hours after the first cycle, mean IFN-γ levels were higher in PD patients 
compared to patients with clinical benefit, but the difference was not significant. By 
week 6, SD/PR patients had significant rises in mean IFN-γ concentrations from 
baseline (1.45pg/ml to 4.34 pg/ml, p=0.049). Although elevations were evident after 
24 hours for the PD patients (p=0.393, ns), the levels started to decrease by the time 
disease progression was confirmed after 3 cycles. During the 6-month continuation 
period, IFN-γ levels remained low with no significant changes seen compared to 
baseline concentrations.  
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Figure 4.11 Plasma IFN-γ  profile. 
(A) IFN-γ concentrations increased in both SD/PR and PD patients throughout the initial 6-
week study period. At the completion of 3 cycles this increase was only significant for patients 
with clinical benefit (p=0.049). (B) During 6 months of CNTO328 treatment, IFN-γ levels 
fluctuated and were generally equal to baseline values after 12 cycles. 
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4.12 Ascitic fluid analysis 
 
During the course of the trial, ascitic fluid was collected from 3 subjects who had 
paracentesis at various time-points; patient 04 (n=2), 05 (n=10) and 13 (n=8).  The 
only significant observation from this analysis was for patient 13, who had log-scale 
reductions in IL-1β, TNF-α, IL-8 and CCL2 concentrations after 3 cycles of 
CNTO328 treatment (figure 4.12 (B)). Apart from this, the wide variability in 
cytokine levels in these patients meant that no other conclusions could be drawn on 
the effects of targeting IL-6 in the ascitic fluid.  
 
4.13 Partial response cytokine profile summary 
 
The partial response (according to combined GCIG criteria) observed in patient 13 
appears to have been associated with either decreased or at least stable concentrations 
of inflammatory mediators in the ovarian cancer microenvironment. Moreover, these 
responses occur early and most are sustained until withdrawal from the study. During 
the initial 6-week study period, decreases were seen in both plasma (VEGF and IL-8, 
figure 4.12 (A)) and ascites (figure 4.12 (B)). Interestingly, plasma IFN-γ 
concentration almost doubled at the same time. 
 
Alongside serum CRP suppression below LLOQ throughout most of the 6 months of 
CNTO328 therapy, there were notable reductions in plasma VEGF, IL-8 and CCL2 
levels from baseline after 12 cycles, figure 4.12 (A)). In addition, the response seen in 
this patient may have been assisted by the restriction in IL-6 trans-signalling that was 
indicated by substantial rises in sgp130 concentrations. Table 4.1 summarises the 
results of the plasma analysis conducted for the partial responder. 
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Figure 4.12  Partial responder: plasma and ascites analysis.  
A. In parallel with serum CRP suppression, decreases in VEGF, IL-8 and CCL2 occurred 
after 6 months treatment. The early increases in IFN-γ were not sustained, but the rise in 
sgp130 that can antagonise trans-signalling may contribute to the prolonged clinical 
response. B. During the initial 6-week study period, logarithmic reductions were observed for 
IL-1β, TNF-α, IL-8 and CCL2 in ascites. The protein concentrations at baseline and week 6 
were approximately the same (>130g/l). 
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% Change from baseline 
with treatment  
 
Baseline 
(pg/ml) 
 
Week 6 
(pg/ml) 
 
3 
months 
(pg/ml) 
 
6 
months 
(pg/ml) Week 6 3 months 6 months 
sgp80 4.78 x 103 
11.45 x 
103 
11.00 x 
103 
11.6 x 
103 ↑139% ↑130% ↑142% 
sgp130 186.6 x 103 
321.4 x 
103 
627 x 
103 
572 x 
103 ↑72% ↑236% ↑206% 
IL-1β  0.22 0.19 0.32 0.23 ↓13% ↑46% ↑4% 
TNF-α  4.01 3.55 3.12 4.26 ↓11% ↓22% ↑6.5% 
VEGF 78.9 27.7 18.5 15.35 ↓65% ↓76.5% ↓80.5% 
IL-8 18.55 16.65 9.22 7.95 ↓10% ↓50% ↓57% 
CCL2 494 641 359 233 ↑30% ↓27% ↓53% 
CXCL12 3055 3405 2905 2855 ↑11.5% ↓5% ↓6.5% 
IFN-γ  1.2 2.24 1.2 1.22 ↑87% (-) ↑1.7% 
 
Table 4.1 Partial responder plasma analysis summary. 
CNTO328 induced key changes within the ovarian cancer microenvironment to evoke a 
partial response in patient 13. This is highlighted by the decreasing levels of VEGF, IL-8 and  
CCL2 along with increases in the sgp130 receptor concentrations throughout 6 months of 
treatment. 
 
 
4.14 Conclusions 
 
It appears that targeting IL-6 with CNTO328 had influences on plasma concentrations 
of cytokines and chemokines that have important roles in the ovarian cancer 
microenvironment. The mean values for both SD/PR and PD patients at baseline and 
at the end of the 6-week study period along with the degree of change observed are 
summarised in table 4.2. This table also includes the mean cytokine levels for the 
three healthy female control samples analysed concurrently with plasma samples from 
the evaluable patients in the study. 
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Baseline (pg/ml) Week 6 (pg/ml) % Change from baseline 
with treatment at 6 
weeks 
 Control 
(pg/ml) 
SD/PR PD SD/PR PD SD/PR PD 
 
IL-6 
 
0.55 
 
4.37 
 
8.22 
(ns) 
 
9541 
 
59407 
(*) 
 
↑>105% 
(***) 
 
↑>106% 
(***) 
 
sgp80 
 
9.28 x 103 
 
10.78 x 
103 
 
12.65 
x 103 
(ns) 
 
11.30 x 
103 
 
11.06 
x 103 
(ns) 
 
↑4.82% 
(ns) 
 
↑12.57% 
(ns) 
 
sgp130 
 
241.7 x 103 
 
252.4 
x103 
 
283 
x103 
(ns) 
 
267.6 
x103 
 
268.2 
x103 
(ns) 
 
↑6% 
(ns) 
 
↑5.22% 
(ns) 
  
TNF-α  
 
3.20 
 
4.69 
 
9.98 
(*) 
 
4.47 
 
11.57 
(**) 
 
↓4.65% 
(ns) 
 
↑15.92% 
(ns) 
 
IL -1β  
 
2.51 
 
0.88 
 
1.54 
(ns) 
 
0.78 
 
2.13 
(ns) 
 
↓11.36% 
(ns) 
 
↑38% 
(ns) 
 
VEGF 
 
16.18 
 
52.6 
 
111.5 
(*) 
 
43.37 
 
66.78 
(ns) 
 
↓17.54% 
(ns) 
 
↓43.69% 
(ns) 
 
IL-8 
 
3.97 
 
10.7 
 
25.29 
(*) 
 
14.2 
 
46.92 
(**) 
 
↑32.71% 
(ns) 
 
↑85.52% 
(*) 
 
CCL2 
 
312.1 
 
501.1 
 
675.8 
(ns) 
 
610.5 
 
873.7 
(ns) 
 
↑21.83% 
(ns) 
 
↑29.28% 
(ns) 
 
CXCL12 
 
1855.83 
 
3053 
 
 
3204 
(ns) 
 
 
3212 
 
3324 
(ns) 
 
↑5.2% 
(ns) 
 
↑3.74% 
(ns) 
 
IFN-γ  
 
2.03 
 
2.25 
 
2.76 
(ns) 
 
4.35 
 
3.98 
(ns) 
 
↑93.5% 
(*) 
 
↑43.85% 
(ns) 
 
Table 4.2 Summary of CNTO328 effects on plasma cytokines after 6 weeks.  
Significant differences between patients with clinical benefit and progressive disease were 
observed for pro-angiogenic factors at various time-points in this study. Mean concentrations 
for the majority of inflammatory mediators in this table are lower in the control samples 
compared to the evaluable patients. Mann Whitney U test p-values * p<0.05, **p<0.01, 
***p<0.001.  
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As previously discussed, the elevations in IL-6 concentrations after initiating 
CNTO328 treatment may have represented a combination of compensatory rises in 
‘free’ IL-6 and IL-6-CNTO328 complexes. Irrespective of the origins of this 
observation, significant differences were seen between both sets of patients at both  
24 hours and 6 weeks with higher circulating levels of IL-6 detected in the PD 
patients. However, with respect to trans-signalling during the initial 6-week study 
period, there were no distinct differences between these patients and CNTO328 does 
not appear to have any effects on these levels after 3 cycles.  
 
Baseline trends for specific cytokines may serve as predictors of response to 
CNTO328. At this time-point and 24 hours after the first cycle, significant differences 
between patients with clinical benefit and progressive disease were seen with TNF-α, 
VEGF and IL-8. By week 6, the significance was more pronounced for both TNF-α 
and IL-8. Another point of interest relates to the reduction in VEGF by CNTO328 in 
both SD/PR and PD patients. In PD patients there was in fact a 40% decrease in mean 
concentrations by week 6, however the levels at this point remained higher compared 
to patients who had clinical benefit. Although increased IL-8 concentrations were 
seen for both SD/PR and PD patients at the completion of 3 cycles, this was only 
significant for the PD group where the value almost doubled (*p<0.05). 
 
In both groups of patients, CNTO328 also appeared to induce transient production of 
IFN-γ, a cytokine that promotes anti-tumour immunity. However, this was only 
significant for patients who had clinical benefit where mean levels increased by over 
90% at week 6 and the levels remained very low. With respect to the remaining 
cytokines and chemokines analysed, excluding CCL2 levels after 24 hours, there were 
no significant differences between the patients with clinical benefit and progressive 
disease. 
 
The plasma cytokine profiles in the four patients who completed 6 months of therapy 
highlighted the long-term effects of CNTO328 (table 4.3). Furthermore these effects 
in both plasma and ascites are particularly clear in the partial responder, patient 13, as 
outlined in section 4.13.  The soluble IL-6 receptors that generally remained stable 
throughout the first 6 weeks steadily increased as treatment continued. However the  
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rate of increase was more pronounced with sgp130, indicating that long-term response 
may be associated with down-regulation of trans-signalling. In addition, the mean 
sgp130 concentration for all 4 patients increased significantly at 3 and 6 months 
(Mann-Whitney U-test, *p = 0.029 for both time-points). 
 
 
 
Baseline 
(pg/ml) 
 
Week 6 
(pg/ml) 
 
3 months 
(pg/ml) 
 
6 months 
(pg/ml) 
sgp80 11.53 x 103 12.43 x 10
3 
(ns) 
14.66 x 103 
(ns) 
16.42 x 103 
(ns) 
sgp130 260.4 x 103 261.8 x 10
3 
(ns) 
609.3 x 103 
(*) 
664.2 x 103 
(*) 
IL-1β  0.65 0.57 (ns) 
0.54 
(ns) 
0.49 
(ns) 
TNF-α  4.91 4.37 (ns) 
4.72 
(ns) 
5.19 
(ns) 
VEGF 44.33 44.86 (ns) 
34.09 
(ns) 
22.86 
(ns) 
IL-8 9.5 10.81 (ns) 
7.41 
(ns) 
7.01 
(ns) 
CCL2 450.9 469.8 (ns) 
362.1 
(ns) 
293.3 
(*) 
CXCL12 2955 3058 (ns) 
3083 
(ns) 
2422 
(ns) 
IFN-γ  1.33 2.12 (ns) 
1.84 
(ns) 
1.69 
(ns) 
 
Table 4.3 Summary of 6-month plasma cytokine profile. 
This table summarises the mean cytokine concentrations for the 4 patients who completed 6-
months of CNTO328. The significance difference compared to baseline concentrations are 
indicated in parentheses. Mann Whitney U test p-value *p<0.05. 
 
There was also evidence of continual reduction in VEGF and IL-8 over 6 months and 
the degree of inhibition correlated with partial response where both cytokines 
decreased from baseline by 80.5% and 57% respectively at the time of study 
withdrawal; the most seen out of all 4 patients who initially obtained clinical benefit. 
Significant reductions in the mean CCL2 levels of these patients were also seen at 6  
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months (Mann-Whitney U test *p= 0.029). Again this diminution was more effective 
in the partial responder, where CCL2 concentrations, which had initially increased at  
week 6 by 30%, then decreased by 60% at the completion of 12 cycles. For IFN-γ, 
significant increases were seen after 6 weeks in the SD/PR patients but overall 
concentrations were low. During this period, no significant changes were seen with 
IL-1β, TNF-α and CXCL12 and these 6-month concentrations were almost equal to 
baseline levels.  
 
The changes to the aforementioned cytokines certainly provide a hint on the processes 
within the ovarian cancer microenvironment that are being targeted by CNTO328. 
The modulation of IL-6 trans-signalling by sgp130 appears to be enhanced by this 
therapy. Furthermore, the pro-angiogenic cytokines, VEGF and IL-8 are effectively 
inhibited by CNTO328 and this effect is most pronounced in the partial responder. In 
addition CCL2, a major mediator of macrophage infiltration in ovarian cancer cells, is 
significantly reduced after 6 months of anti-IL-6 therapy. These observations have 
provided a basis for the in vivo and in vitro experiments outlined in this thesis to 
elucidate a mechanism of action for IL-6 antagonists such as CNTO328 in ovarian 
cancer. 
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5 The Effects of Anti-IL-6 Treatment in Human Ovarian 
Cancer Cells in vitro 
 
5.1 Aims 
 
The results from the clinical trial showed that clinical benefit was evident with 
CNTO328 treatment in advanced ovarian cancer. Although the plasma analysis of 
inflammatory markers and cytokines showed certain correlations with response, the 
mechanisms behind these responses remained unclear. Consequently the next 
objective of my thesis was to answer the following questions: 
 
1. Can CNTO328 effectively inhibit IL-6 release from human ovarian cancer cell 
lines? 
2. Does CNTO328 have other effects on ovarian cancer cells in vitro? 
 
From previous research, we know that a number of ovarian cancer cell lines produce 
IL-6, but there are conflicting in vitro data relating to its role as a growth factor 
(Watson, Sensintaffar et al. 1990; Watson, Berek et al. 1993). Therefore I conducted 
experiments that aimed to first characterise IL-6 production and IL-6 receptor 
expression in four ovarian cancer cell lines and second, study the actions of 
CNTO328 on their growth and constitutive release of cytokines. 
 
5.2 Ovarian cancer cell lines: Supernatant cytokine analysis 
 
IGROV-1, TOV21G, TOV112D and SKOV-3 ovarian cancer cell lines were cultured 
on plastic plates containing RPMI medium supplemented with 10% FBS. After three 
days of culture, the cells were counted using a Vi-cell cell counter and the 
supernatants were collected for analysis of IL-6 and other related inflammatory  
cytokines using ECL assays. Some of the cytokines released by these cell lines are 
illustrated in figure 5.1. This analysis showed that two cell lines constitutively  
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produced IL-6, with TOV21G releasing two log higher concentrations than IGROV-1. 
Neither TOV112D or SKOV-3 produced any detectable levels of IL-6. These trends 
recapitulate the previous findings from Kulbe et al where IL-6 levels in supernatants 
from the same four cell lines were analysed using ELISA (Kulbe, Thompson et al. 
2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Ovarian cancer cell line supernatant cytokine and chemokine profile. 
In comparison with the non-IL-6 producing cell lines, both IGROV and TOV21G produce 
higher concentrations of IL-1β, TNF-α, IL-8, CCL2 and VEGF. All bars represent the mean 
+ s.d. and illustrate the typical results seen with ECL cytokine analysis in three repeated 
experiments. 
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Another aim of the supernatant analysis was to see whether these patterns of IL-6 
expression correlated with other cytokines and chemokines known to have principal 
functions in the ovarian cancer microenvironment. The results indicated that cell lines 
with constitutive IL-6 production also secreted significant concentrations of TNF-α, 
IL-1β, IL-8, CCL2 and VEGF (figure 5.1). As with IL-6, these were all found to be 
considerably higher in TOV21G compared to IGROV-1, apart from VEGF. By 
contrast, these cytokines were either undetectable or present in relatively lower 
concentrations in the non IL-6 producing cell lines, TOV112D and SKOV-3. This 
suggests that IL-6 production might be linked to other cytokines and chemokines. 
 
5.3 IL-6 receptor analysis in ovarian cancer cell lines 
 
The next experiments investigated the expression of IL-6 receptors (gp80 and gp130) 
that would enable downstream signalling and induction of autocrine actions on 
tumour cells. Both trans-membrane and soluble forms of the receptors were assessed 
using FACS and ECL analysis respectively (figure 5.2 and 5.3). The results from the 
FACS analysis illustrated in the histogram plots show that the trans-membrane gp80 
receptor was clearly expressed on both IL-6 producing cell lines and at very low 
levels on SKOV-3 cells (figure 5.2). The signal transducing gp130 trans-membrane 
receptor showed higher expression on the TOV21G cells compared to both IGROV-1 
and SKOV-3 cells where only minimal levels were detectable. The ECL analysis 
(figure 5.3) showed that IGROV-1 cells released sgp80 in concentrations greater than 
100pg/ml/106 cells, but only small levels of sgp80 were evident in the TOV21G 
supernatant (<10pg/ml/106). For the sgp130 receptor, which functions as an antagonist 
to IL-6 trans-signalling, these concentrations appeared to be marginally higher in 
TOV21G compared to IGROV-1. Interestingly IGROV-1, TOV112D and SKOV-3 all 
showed detectable levels of sgp130, which contrasts with the weak trans-membrane 
gp130 expression seen in the FACS analysis. In summary, IL-6 could potentially 
induce autocrine effects through either classic signalling or trans-signalling in 
IGROV-1 and TOV21G cell lines. Furthermore, SKOV-3 cells may also respond to 
IL-6 as they appear to express both gp80 and gp130 receptors albeit at low levels. 
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Figure 5.2 FACS analysis of trans-membrane IL-6 receptors in ovarian cancer 
cell lines.  
Both IL-6 producing cell lines expressed the ligand binding receptor gp80, but more 
prominent gp130 expression was seen on TOV21G cells compared to IGROV-1. In the non 
IL-6 producing cell lines, only SKOV-3 cells showed weak expression for both receptors 
(n=2).  
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Figure 5.3  Soluble IL-6 receptor analysis in ovarian cancer cell lines.   
Both sgp80 and sgp130 were secreted by all four cell lines. All bars represent the mean + s.d. 
and illustrate the typical results seen with ECL analysis of these IL-6 soluble receptors in 
three repeated experiments.  
 
5.4 CNTO328 treatment of ovarian cancer cell lines in optimal 
conditions 
 
Having established the expression of IL-6 and IL-6 receptors in ovarian cancer cell 
lines, experiments were conducted to investigate the effects of IL-6 inhibition on 
autocrine cell growth in vitro. All four cell lines were cultured on plastic wells 
supplemented with RPMI + 10% FCS for 24 hours prior to treatment with CNTO328. 
The antibody concentrations (10, 25, 50 and 100µg/ml) were based on the serum 
levels observed in patients treated with CNTO328 in the CO328X05 study and 
previous clinical trials (CNTO328 Investigator’s Brochure; edition no. 5, May 2007). 
Cells were counted in triplicate wells for each antibody concentration at set time-
points over a subsequent period of 10 days and supernatants were collected for 
cytokine analysis. The growth curves from these experiments are illustrated in figure 
5.4 and 5.5. These show that irrespective of constitutive IL-6 production, CNTO328 
did not inhibit growth of ovarian cancer cells cultured on plastic. Hence, in these 
particular conditions IL-6 does not behave as an autocrine growth factor. Similarly, 
IL-6 inhibition had no effects on cell growth when these experiments were repeated in 
suboptimal conditions (RPMI + 1% FBS) (data not shown). To observe whether IL-6 
inhibition had any effects on the inflammatory milieu in vitro, I measured the release 
of inflammatory mediators in the supernatants from IGROV-1 and TOV21G cells 
cultured in optimal conditions after 4 days (figure 5.6). 
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IGROV-1                                             TOV21G 
10µg/ml 
CNTO328 
 
 
 
 
 
 
 
 
25µg/ml 
CNTO328 
 
 
 
 
 
 
 
 
50µg/ml 
CNTO328 
 
 
 
 
 
 
 
100µg/ml 
CNTO328 
                                      
 
                                
 
 
 
Figure 5.4 IGROV-1 and TOV21G growth curves with CNTO328 treatment. 
CNTO328 did not appear to inhibit cell growth in either of the IL-6 producing cell lines. On 
days 4 and 7, CNTO328 and IgG control antibodies were added to refreshed medium. All 
points represent the mean ± s.d. and illustrate the typical results seen with the Vi-cell cell 
counter in three repeated experiments. 
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Figure 5.5 TOV112D and SKOV-3 growth curves with CNTO328 treatment. 
CNTO328 had no effect on the growth of the non-IL-6 producing ovarian cancer cell lines. 
On days 4 and 7, CNTO328 and IgG control antibodies were added to refreshed medium.  
All points represent the mean ± s.d. and illustrate the typical results seen with the Vi-cell cell 
counter in three repeated experiments. 
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Figure 5.6 Profile of inflammatory mediators in IGROV-1 and TOV21G 
supernatants treated with CNTO328 after 3 days in optimal conditions. 
The in vitro inhibition of IL-6 release in both IGROV-1 and TOV21G cell lines also led to 
reduced release of other inflammatory cytokines and chemokines known to have key roles 
within the ovarian cancer microenvironment. All points represent the mean ± s.d. and 
illustrate the typical results seen with ECL cytokine analysis in two repeated experiments. 
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Despite the negative results relating to the influence of CNTO328 on IGROV-1 and 
TOV21G cell growth in vitro, the supernatant analysis showed that the antibody 
effectively inhibited IL-6 release, with significant decreases seen with concentrations 
of 10 -100µg/ml (table 5.1).  
 
 IGROV-1 
 10µg/ml 25µg/ml 50µg/ml 100µg/ml 
 IgG 
(pg/106 
cells) 
CNTO328 
(pg/106 
cells) 
IgG 
(pg/106 
cells) 
CNTO328 
(pg/106 
cells) 
IgG 
(pg/106 
cells) 
CNTO328 
(pg/106 
cells) 
IgG 
(pg/106 
cells) 
CNTO328 
(pg/106 
cells) 
IL-6 6717 
 
888 
(*) 
8000 1001 
(**) 
7000 962 
(***) 
10946 597 
(**) 
IL-1β  0.72 
 
0.45 
(ns) 
 
0.81 0.29 
(ns) 
0.8 0.45 
(ns) 
0.65 0.54 
(ns) 
TNF-α  103 61 
(*) 
98 71 
(ns) 
105 119 
(ns) 
187 67 
(**) 
IL-8 4879 2308 
(**) 
6085 3211 
(*) 
5404 4800 
(ns) 
8000 2489 
(**) 
CCL2 182 
(*) 
215 223 209 
(ns) 
303 225 
(ns) 
397 74 
(***) 
     
 TOV21G 
 10µg/ml 25µg/ml 50µg/ml 100µg/ml 
 IgG 
(pg/106 
cells) 
CNTO328 
(pg/106 
cells) 
IgG 
(pg/106 
cells) 
CNTO328 
(pg/106 
cells) 
IgG 
(pg/106 
cells) 
CNTO328 
(pg/106 
cells) 
IgG 
(pg/106 
cells) 
CNTO328 
(pg/106 
cells) 
IL-6 174701 
 
51569 
(***) 
170543 37567 
(***) 
172438 31519 
(***) 
186989 28958 
(***) 
IL-1β  214 118 
(*) 
206 62 
(*) 
213 56 
(**) 
177 58 
(*) 
TNF-α  3258 2803 
(ns) 
2848 1630 
(**) 
3234 1635 
(***) 
3011 1510 
(**) 
IL-8 24113 
(**) 
29388 
 
22456 
 
21169 
(*) 
23698 21009 
(*) 
25879 20302 
(**) 
CCL2 31939 
(ns) 
36722 
 
30293 
(ns) 
30500 
 
27400 
(ns) 
28350 
 
30255 25561 
(ns) 
 
Table 5.1 Summary of supernatant cytokine profiles after CNTO328 treatment. 
CNTO328 significantly inhibited the release of pro-inflammatory cytokines in both IGROV-1 
and TOV21G cells in vitro (unpaired t test *p<0.05, **p<0.01, ***p<0.001). 
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This also led to the reduction in constitutive production of other cytokines with 
significant inhibition of TNF-α, IL-8 and CCL2 in IGROV-1; IL-1β and TNF-α in 
TOV21G (table 5.1). However, there were certain anomalies encountered with 
CNTO328 treatment at 10µg/ml where CCL-2 and IL-8 concentrations (in IGROV-1 
and TOV21G respectively) were significantly lower with the IgG control antibody. 
Although the reasons for this are not clear, higher concentrations of CNTO328 
effectively inhibited the release of these cytokines. Of note, CNTO328 did not affect 
soluble IL-6 receptor or VEGF release in these two cell lines (data not shown). 
Supernatants from the TOV112D and SKOV-3 cells were also analysed for cytokine 
release, but the levels were either undetectable or below the detection limit of the 
ECL assay (data not shown) and CNTO328 treatment did not change this. 
 
5.5 Discussion 
 
The experiments outlined in this chapter were conducted for the purpose of gaining 
insights into the mechanism of action of CNTO328 in ovarian cancer.  Out of the four 
cell lines investigated, IGROV-1 and TOV21G released detectable levels of IL-6. 
This production was also related to the release of other cytokines including IL-1β, 
TNF-α, VEGF, IL-8 and CCL2; which is in concordance with previously published 
research from our laboratory (Szlosarek, Grimshaw et al. 2006; Kulbe, Thompson et 
al. 2007). 
 
Despite the abundance of IL-6 in these cell lines, the association with the IL-6 
receptors is not clear. With regard to the trans-membrane receptors, FACS analysis 
confirmed that gp80 was expressed in both IL-6 producing cell lines, but gp130 was 
more prominent on TOV21G cells compared to IGROV-1 where the expression level 
was weak. However, the effect of CNTO328 on autocrine IL-6 release in the IGROV-
1 supernatants suggests active signalling through the gp130 receptor. As the FACS 
data may not be truly representative of gp130 expression in IGROV-1, this could be 
investigated further with real time RT-PCR analysis of gp130 mRNA in protein 
lysates from this cell line. Furthermore, the level of downstream IL-6 signalling and 
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the effects induced by CNTO328 could also be verified by western blot analysis of 
pSTAT3 in these lysates.  
 
All four cell lines released both soluble gp80 and gp130 receptors. These are formed 
by either the action of protein kinase C on trans-membrane IL-6 receptors or by 
alternate mRNA splicing (Mullberg, Schooltink et al. 1993; Horiuchi, Koyanagi et al. 
1994; Montero-Julian, Brailly et al. 1997; Jones, Horiuchi et al. 2001). In TOV21G 
cells the expression of trans-membrane gp80 is in stark contrast to the minimal levels 
of sgp80 seen in the supernatant. The higher level of sgp80 in the other cell lines 
implies that TOV21G may be less susceptible to shedding of the gp80 receptor. 
However, as all cells secrete approximately the same level of sgp130, the mechanism 
behind the formation of both of these soluble receptors may differ. The influence of 
protein kinase C on the formation of soluble receptors in these cell lines could be 
assessed by western blot analysis in future work. 
 
Having established that ovarian cancer cell lines release IL-6, my next aim was to 
investigate the effects of IL-6 inhibition on cell growth. All experiments were 
conducted with cells cultured in both optimal and suboptimal conditions on plastic 
surfaces and no effects on growth were seen. Accounting for the fact that CNTO328 
arrested disease progression in 8 out of 18 patients in the clinical trial, alternative 
methods would have to be adopted for any subsequent in vitro research into the 
effects of this antibody on cell growth. Clonogenic assays with these cell lines could 
be used to assess the cytotoxic potential of CNTO328. Furthermore, the effects of 
targeting IL-6 on cell colony formation could be analysed by repeating these 
experiments with culture on soft agar. 
 
Despite the negative results seen with the growth curves, CNTO328 treatment of both 
IL-6 producing cell lines did have ramifications on the autocrine network by 
decreasing IL-6, IL-1β, TNF-α, IL-8 and CCL2; all of which are associated with 
ovarian cancer progression in a clinical setting. These effects mirror the observations 
seen with targeting TNF-α in ovarian cancer cell lines by shRNA (Kulbe, Thompson 
et al. 2007).  Additionally, in the clinical trial substantial decreases in IL-8 and CCL2 
were seen in the partial responder after 6 months of anti-IL-6 therapy.  
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However, in contrast to the cytokine analysis in the CO328X05 study, IL-6 inhibition 
in vitro had no influence on VEGF and soluble IL-6 receptor release. All of these 
were also detectable in TOV112D and SKOV-3, which implies that their release 
maybe more dependent on other pathways; hence any effects exerted by CNTO328 
could potentially be compensated. 
 
In summary, these in vitro experiments have shown that CNTO328 is effective in 
inhibiting the release of IL-6 and other cytokines by ovarian cancer cells in vitro.  
From the plasma cytokine analysis in the clinical trial the effect of CNTO328 on IL-6 
derived from tumour cells was difficult to interpret. However the in vitro studies 
inferred that biological activity might have been related to IL-6 inhibition in tumour 
cells. To further investigate this theory and to gain more insight into the mechanisms 
of action, my aim was to conduct a series of experiments focusing on anti-IL-6 
treatment of ovarian cancer in mouse models. As I had difficulty in obtaining a 
murine anti-IL-6 antibody, it was not possible to perform these studies using 
syngeneic models. Hence, in view of the positive results seen with the CO328X05 
study, the next chapter describes the effects of CNTO328 in ovarian cancer by using 
human xenografts in nude mice. 
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6 The Effects of Targeting IL-6 in Ovarian Cancer 
Xenograft Mouse Models 
6.1 Aims 
 
The previous chapter showed that targeting IL-6 in vitro effectively inhibited 
inflammatory cytokine and chemokine release in the supernatants of IL-6 producing 
ovarian cancer cell lines cultured on plastic.  However, further studies were required 
in order to clarify which specific processes could account for the responses observed 
with CNTO328 in the clinical trial. Therefore the aim of the experiments described in 
this chapter was to study the effects of this anti-human IL-6 antibody on the growth 
and biology of ovarian cancer cell lines when grown as intraperitoneal xenografts in 
nude mice. These studies were conducted in collaboration with Dr Hagen Kulbe 
(Postdoctorate research assistant) and Richard Thompson (Laboratory technician). 
 
6.2 Analysis of biological processes in human ovarian cancer 
xenografts  
 
As CNTO328 did not inhibit the growth of ovarian cancer cells on plastic surfaces, 
my first objective was to demonstrate the effects of anti-IL-6 treatment on the growth 
of IGROV-1, TOV21G and TOV112D cells that were injected i.p into nude mice. 
These cells had previously been infected in vitro with lentivirus containing a 
luciferase reporter construct in order to assess tumour burden in vivo with 
bioluminescence imaging. Cohorts of mice were subsequently injected i.p twice 
weekly with either PBS, IgG control antibody or CNTO328 (400µg per mouse) and 
tumour growth was monitored at 1 hour, 1 week, 2 and 4 weeks after cell injection. 
The antibody concentration was based on the dose used in previous in vivo studies 
where CNTO328 effectively inhibited the growth of human cancer xenografts in nude 
mice (Mauray, Fuzzati-Armentero et al. 2000; Smith and Keller 2001; Wallner, Dai et 
al. 2006). My next objective was to investigate the mechanisms by which CNTO328 
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impeded disease progression in these models.  If IL-6 behaved as an autocrine growth 
factor in vivo, its effects on cell proliferation could possibly be reversed by 
CNTO328. Therefore I aimed to evaluate this by performing immunohistochemistry 
(IHC) staining for the proliferation marker, Ki67, on paraffin embedded sections of 
tumour deposits collected at post mortem after 4 weeks of treatment.  
 
As these experiments were performed in immunocompromised mouse models, I 
planned to analyse the influence of anti-IL-6 treatment on the innate immune system, 
which has an emerging role in tumour progression. Macrophages have been 
implicated in the progression of ovarian cancer whereby IL-6 causes phenotypic 
switching to M2 cells (Duluc, Delneste et al. 2007) that facilitate angiogenesis and 
metastatic development (Mantovani, Sozzani et al. 2002). Hence, if these processes 
could be driven by macrophages, it is feasible that they could be inhibited by 
CNTO328. In order to address this hypothesis, IHC analysis for the mouse specific 
macrophage marker, F4/80, was performed at the completion of treatment to assess 
any differences between the cohorts of mice in macrophage infiltration on tumour 
sections. In addition to the relationship between macrophages and angiogenesis in 
tumour progression, an in vivo study with human ovarian cancer xenografts has 
shown IL-6 to be a potent pro-angiogenic cytokine (Nilsson, Langley et al. 2005). 
Consequently the objective of these experiments was to analyse the effects of 
CNTO328 on angiogenesis by using confocal microscopy to visualise vascular areas 
in tumour deposits. 
  
In view of the previously described results relating to the effects of CNTO328 on the 
cytokine network in the clinical trial and in vitro experiments, my final aim in these 
experiments was to verify two points: 
1. Can the effect of CNTO328 on IL-6 in mouse serum mimic the observations 
seen in plasma from patients in the CO328X05 study? 
2. Can CNTO328 inhibit IL-6 and other cytokines in tumours after 4 weeks of 
treatment? 
To answer these questions, blood (100µl) was taken from all mice prior to cell 
injection and on the completion of 2 and 4 weeks of treatment, and mRNA extracts  
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from tumour lysates were analysed for specific cytokines using real time PCR with 
human primers and probes.  
6.3 Bioluminescence imaging 
 
The bioluminescence images obtained in the IGROV-1 and TOV21G xenografts 
along with graphs illustrating the quantification of luciferase activity in relative light 
units (RLU) after 4 weeks of treatment are shown in figures 6.1-6.2. 
6.3.1 IGROV-1 
A    
      PBS      IgG Control      CNTO328 
 
 
B 
 
 
 
 
 
 
 
 
 
Figure 6.1 Luciferase activity in IGROV-1 xenografts treated with CNTO328. 
A. Bioluminescence imaging in vivo of IGROV-1 4 weeks after i.p injection. Bioluminescence 
is presented as a pseudocolour scale: red: highest photon flux, blue: lowest photon flux. B. 
Quantification of bioluminescence from primary tumours (n=6 each group) in relative light 
units (RLU). Images taken an hour after i.p. injection confirm that baseline luciferase activity 
between the treatment groups was approximately the same. After 24 hours treatment 
commenced and imaging was repeated at 1 week, 2 and 4 weeks. After 4 weeks reduced 
luciferase activity is shown with CNTO328 compared to the IgG control group (unpaired t 
test, ns p=0.06), All bars illustrate mean RLU (x109) ± s.d. This experiment was performed 
twice and the typical results are shown. 
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6.3.2 TOV21G 
A 
          PBS        IgG Control        CNTO328 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Luciferase activity in TOV21G xenografts treated with CNTO328. 
A. Bioluminescence imaging in vivo of TOV21G 4 weeks after i.p injection. B. Quantification 
of bioluminescence from primary tumours (n=5 each group). Although reduced luciferase 
activity was seen after 4 weeks in the CNTO328 treated group, the difference compared to the 
IgG control was not significant (unpaired t test, ns p=0.5). All bars illustrate mean RLU 
(x109) ± s.d. This experiment was performed twice and the typical results are shown. 
 
Despite the variability encountered in luciferase activity using the IVIS device, the 
imaging for both the IGROV-1 and TOV21G xenografts showed decreased tumour 
burden in the CNTO328 treated group in comparison with the PBS and IgG controls. 
Although these differences did not reach statistical significance there was certainly a 
trend, with IGROV-1 in particular, suggesting that anti-IL-6 therapy did exert 
biological activity by impeding tumour progression. The logarithmic differences 
in the IL-6 production by the cell lines in vitro might explain the contrasting efficacy 
seen with CNTO328 in these xenografts. 
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6.4 Immunohistochemical analysis of tumour sections 
 
As the bioluminescent images suggested that CNTO328 inhibited tumour growth (at 
least in the IGROV-1 model), my next aim was to examine the effects of IL-6 
inhibition on malignant and stromal compartments in tumours collected after the 
completion of treatment. This section details the immunohistochemical staining used 
to analyse cell proliferation and macrophage influx seen on paraffin embedded 
sections of tumour deposits. For each antigen, a negative control was used whereby 
the primary antibody was omitted (data not shown). All primary antibodies described 
in this chapter were validated in this manner in previous experiments conducted by Dr 
Hagen Kulbe (Postdoctorate research assistant) with IGROV-1 and TOV21G 
xenograft mouse models. 
6.4.1 Ki67 staining 
 
The nuclear antigen Ki67 is a proliferation marker expressed only in cycling cells 
(Burcombe, Wilson et al. 2006). As strong correlations have been shown between 
Ki67 index and S-phase fraction, IHC assessment can provide an accurate measure of 
the proliferative index of individual tumours (Vielh, Chevillard et al. 1990; Gasparini, 
Boracchi et al. 1994). The images and quantification for Ki67 staining in the IGROV-
1 and TOV21G xenograft models after 4 weeks of treatment are illustrated in figure 
6.3. 
 
In parallel with the effects shown in the bioluminescence images, the proliferative 
indices for the CNTO328 treated groups in both IGROV-1 and TOV21G xenografts 
were lower than both control groups. Furthermore, the quantification confirmed that 
these differences were statistically significant and were more pronounced with 
IGROV-1 compared to TOV21G.  Once more, the efficacy of the anti-IL-6 antibody 
appears to be related to the level of IL-6 release by these cells; with enhanced anti-
proliferative activity being associated with lower concentrations of IL-6 secreted by 
IGROV-1 cells compared to TOV21G. 
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Figure 6.3 Ki67 proliferative index in ovarian cancer xenograft models at 4 
weeks. 
A. Ki67 staining in IGROV-1 and TOV21G xenograft sections (x20 hpf). B. Quantification of 
Ki67 staining represented by box and whisker plots. CNTO328 significantly reduced cell 
proliferation compared to IgG control in both IGROV-1 and TOV21G xenografts (unpaired t 
test p= 0.001 and 0.01 respectively). The proliferative index was calculated by estimating the 
percentage of tumour cells in 10 randomly selected areas in tissue sections showing positive 
staining in each of two repeated experiments. 
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6.4.2 Macrophage (F4/80) staining 
 
The F4/80 antigen is a mouse-specific cell surface glycoprotein characteristically 
expressed on the surface of tissue fixed macrophages including Kupfer cells in the 
liver and red-pulp macrophages in the spleen (Schaller, Macfarlane et al. 2002). F4/80 
expression also increases with the maturation of macrophage precursors in bone 
marrow and blood (Malorny, Michels et al. 1986). The effects of CNTO328 on 
macrophage influx in tumour sections obtained from the xenograft models after 4 
weeks of treatment are shown in figure 6.4. 
 
Macrophage influx appears to be have been modulated by the anti-IL-6 antibody as 
shown by the reduction in F4/80 + cells seen in tissue sections from both IGROV-1 
and TOV21G xenografts. However, the effect on macrophages was only significant in 
IGROV-1, a cell line that produces moderate amounts of IL-6 in vitro. In TOV21G, 
where IL-6 production was substantially higher, the influence of CNTO328 on 
F4/80+ staining was not as apparent, but the same trend in relation to reduced 
macrophage infiltration still applied. 
 
 
6.5 Quantification of tumour blood vessels  
 
In ovarian cancer, IL-6 can promote angiogenesis by facilitating endothelial cell 
migration via pSTAT3 signalling (Nilsson, Langley et al. 2005). This chapter has 
presented data suggesting that targeting IL-6 can affect tumour growth by reducing 
cell proliferation. In order to see if these observations correlated with any potential 
anti-angiogenic effects associated with CNTO328, confocal microscopy was used to 
visualise the architecture of blood vessels after 4 weeks of treatment in the IGROV-1 
and TOV21G sections (figure 6.5). 
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Figure 6.4 F4/80 analysis in ovarian cancer xenograft models after 4 weeks. 
A. F4/80 staining in IGROV-1 and TOV21G xenograft sections (x20 hpf). B. Quantification of 
F4/80 staining represented by box and whisker plots. Significant decreases in macrophage 
influx were seen with CNTO328 compared to IgG control in the IGROV-1 xenograft 
(unpaired t test **p=0.007). The quantification was calculated by counting the number of 
F4/80+ cells from 10 randomly selected areas of tumour sections in each of two repeated 
experiments. 
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Figure 6.5 Tumour vasculature in ovarian cancer xenografts after 4 weeks. 
A. Microvessel density images for IGROV-1 and TOV21G xenografts (x20 hpf). All mice in 
each group (i.e. IGROV-1 n=6 and TOV21G n=5) were injected with tomato lectin 3 min 
prior to fixation. B. Quantification of microvascular density. Compared to IgG control, 
CNTO328 appeared to have a significant effect on tumour vasculature in both IGROV-1 and 
TOV21G (unpaired t test p=0.0263 and 0.005 respectively). The mean vascular area in each 
group was quantified by selecting 10 random areas of tumour sections from each of two 
repeated experiments. 
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For each group, the mean vascular area of four (IGROV-1) and six (TOV21G) 
tumours of matched size from each of two repeated experiments was assessed. The 
confocal images and quantification of microvessel density showed that IL-6 inhibition 
significantly affects angiogenesis in these xenograft models.  For the IGROV-1 and 
TOV21G tumours respectively, CNTO328 treated groups had a mean vascular area of 
4.1% and 4.2% compared with 12.7% and 11.2% in the IgG control treated groups. 
 
6.6 Analysis of an autocrine cytokine network in vivo 
 
As described in the previous chapter, CNTO328 inhibited the release of IL-6 and 
other cytokines from ovarian cancer cell lines in vitro. These results were similar to 
the in vitro effects seen with stable TNF-α knockdown in ovarian cancer cell lines 
published by Kulbe et al (Kulbe, Thompson et al. 2007). This publication also showed 
that TNF-α along with IL-6, CXCR4 and CXCL12 were produced by malignant cells 
and co-regulated in vitro and in vivo (Kulbe, Thompson et al. 2007), hence creating a 
‘TNF-α network’. Subsequently, further research has shown that via pSTAT3 this 
network can regulate Notch-3 signalling and its ligand Jagged1 (Kulbe et al, 
manuscript submitted 2010, figure 6.6); both of which have been linked to ovarian 
cancer cell growth (Park, Li et al. 2006; Choi, Park et al. 2008). 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 A model for the proposed TNF-α  network in ovarian cancer. 
Adapted from Kulbe et al. Regulation and mechanisms of action of a network of inflammatory 
cytokines in human ovarian cancer (manuscript submitted 2010). 
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This model would predict that targeting IL-6 would inhibit other members of this 
network and indeed this has been shown in vitro (Kulbe et al, manuscript submitted 
2010). In view of this model, my objective was to investigate the effects of CNTO328 
on the expression of cytokines and chemokines in this network in vivo.  For this 
purpose, I conducted real time quantitative RT PCR with human primers and probes 
on mRNA extracts from the IGROV-1 tumour lysates (figure 6.7).  
 
 
 
 
Figure 6.7 Effects of CNTO328 on the human autocrine cytokine network in the 
IGROV-1 xenograft model. 
After 4 weeks of CNTO328 treatment there were marked decreases in both human IL-6 and 
Jagged1 mRNA expression. Lysates from 3 tumour samples in each group were used for this 
analysis. The units on the y-axis represent the fold change in mRNA expression for each 
probe compared with the lowest value obtained in each treatment group. The bars represent 
mean fold change + s.d. and illustrate the average values obtained from two repeated 
experiments. 
 
These data showed that CNTO328 induced substantial decreases in both IL-6 and 
Jagged1 mRNA expression in tumour cells from the IGROV-1 xenograft model after 
4 weeks. Reductions were also seen with TNF-α, Notch3, CXCL12, CCL2 and CCL5 
expression, although this effect was minimal.  The other notable finding was the 
increase in IL-1β expression. As this cytokine is upstream from IL-6 this rise could 
represent a compensatory response to IL-6 inhibition.  In light of the these results, 
exploratory IHC analysis was performed for both human IL-6 and Jagged1 on the 
IGROV-1 paraffin embedded sections and down-regulated expression was also seen 
for both ligands (figure 6.8).   
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Figure 6.8 Human IL-6 and Jagged1 IHC analysis on IGROV-1 tumour sections 
(x20 hpf). 
IHC analysis also showed decreased expression for IL-6 and Jagged1 with anti-IL-6 
treatment. This preliminary analysis was conducted in order to recapitulate the observations 
seen with the real time RT PCR and was not formally quantified. 
 
6.7 Serum IL-6 analysis 
 
The plasma analysis in the clinical trial described in chapter 4 revealed significant 
rises in IL-6 concentrations throughout the initial 6-week study period. This was 
possibly due to the detection of IL-6-CNTO328 complexes in addition to un-
complexed IL-6. By measuring human IL-6 (hIL-6) in serum collected after 2 and 4 
weeks of CNTO328 in the nude mice, I was aiming to see if the same phenomena 
were apparent in the in vivo models. Furthermore, in view of the paracrine effects on 
macrophage influx and angiogenesis previously described and the homology between 
human and murine IL-6 (mIL-6) (Kishimoto 1989), I also wanted to establish whether 
anti-human IL-6 antibody treatment affected mIL-6 release. The ECL analyses for 
both human and murine serum IL-6 in IGROV-1 and TOV21G xenografts are shown 
in figure 6.9. These bar charts illustrate that human IL-6 (hIL-6) was detected in the 
serum of xenograft bearing mice. As with the in vitro analysis, TOV21G tumour cells  
retain their inherent capacity to secrete substantially higher levels of IL-6 compared to 
IGROV-1 cells in vivo.  In both control groups, hIL-6 concentrations had increased by  
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the end of four weeks, which was to be expected with the increased tumour growth. 
However in the IGROV-1 xenograft there were logarithmic increases seen with the 
CNTO328 treated group from week 2 to week 4 (unpaired t test **p=0.001), which 
mirrored the observations seen with plasma IL-6 levels in patients treated with 
CNTO328 in the clinical trial. At the end of treatment the difference between the anti-
IL-6 antibody and the two control groups was also significant (**p=0.001 for both 
PBS and IgG).  
   
    IGROV-1                                                        TOV21G 
 
 
 
 
 
 
 
 
Figure 6.9 Serum human and murine IL-6 profiles in IGROV-1 and TOV21G 
xenografts. 
After week 2 in IGROV-1, hIL-6 significantly increased with CNTO328 treatment (unpaired t 
test **p<0.01). At this point, the high hIL-6 concentration seen with TOV21G reached the 
upper detection limit of the MSD platform (10,000pg/ml), hence any further increases could 
not be accurately detected at week 4. In IGROV-1, mIL-6 levels decreased from 42pg/ml (wk 
2) to 21pg/ml (wk 4), but this was not significant. However in TOV21G these concentrations 
increased from 145pg/ml (wk 2) to 360pg/ml (wk 4) which was significant (**p<0.01). All 
bars represent the mean + s.d. and illustrate the typical results seen with ECL analysis of 
serum hIL-6 and mIL-6 for both xenograft models in two repeated experiments.  
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For TOV21G, by week 4 it appears that serum hIL-6 remained stable but was still 
substantially higher than the controls. This was probably artefactual as the 
concentrations at week 2 and beyond (i.e. >10 000 pg/ml) would have exceeded the 
upper detection limit of the MSD® assay. Taking into consideration the results 
showing decreased IL-6 mRNA expression in tumour cells with CNTO328, it now 
appears that the serum hIL-6 levels seen in the mice treated with CNTO328 are likely 
to represent IL-6-antibody complexes being detected in the MSD® assay rather than 
compensatory increases in IL-6 produced by tumour cells. 
 
Interestingly, there were contrasting effects with anti-human IL-6 treatment on serum 
mIL-6 levels in the two xenograft models. For IGROV-1, whilst mIL-6 levels 
continued to rise in the control groups, mIL-6 decreased with CNTO328 from 42 
pg/ml at week 2 to 21 pg/ml at week 4 (ns, p=0.09). The differences in these serum 
concentrations in mice treated with CNTO328 compared to those in both PBS and 
IgG groups were not significant at week 4 (p=0.07 for both). However, in the serum 
from TOV21G xenografts, mIL-6 concentrations had increased in all three treatment 
groups after four weeks and had more than doubled in the mice treated with 
CNTO328.   
 
6.8 TOV112D xenograft model 
 
The in vivo effects of CNTO328 on a non-IL-6 producing ovarian cancer cell line 
were also studied by using a TOV112D xenograft model (5 mice per group). At the 
completion of treatment, distinct differences were noted in comparison to the 
experiments with IGROV-1 and TOV21G models. Tumour sections from the PBS 
control groups in all 3 xenografts were analysed for Ki67 staining in order to assess 
cell proliferation after 4 weeks (figure 6.10). The quantification indicated that the 
proliferative index for TOV112D cells was significantly less than both IL-6 producing 
cells (p<0.001). In addition these sections also appeared to have more necrotic areas 
and the luciferase activity at week 4 was not representative of tumour burden in this 
model (images not shown). 
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Figure 6.10 Ki67 proliferative index in human ovarian cancer xenograft PBS 
control groups at 4 weeks. 
A. Ki67 staining in IGROV-1, TOV21G and TOV112D xenograft sections (x20 hpf).  
B. Quantification of Ki67 staining. Compared to both IGROV-1 and TOV21G, tumour cell 
proliferation was significantly less in TOV112D cells.  
 
 
 
 
 
 
 
 
 
Figure 6.11 Serum human IL-6 profile in PBS treated xenograft models at 4 
weeks. 
Serum IL-6 levels were undetectable in the TOV112D xenografts (5 mice). 
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As with the in vitro ECL analysis, hIL-6 remained undetectable in the serum taken 
from the TOV112D xenograft at the end of treatment (figure 6.11) Furthermore there  
were no differences in the tumour weights measured in all 3 treatment groups at this 
point (figure 6.12). 
 
 
 
 
 
 
 
 
 
Figure 6.12 TOV112D tumour weights after 4 weeks treatment. 
There were no significant differences between the weights of tumours in each treatment group 
(5 mice per group). 
 
6.9 Discussion 
 
The primary aim of the in vivo experiments described in this chapter was to add to our 
understanding of the biological effects of anti-human IL-6 antibody therapy in ovarian 
cancer by using human xenograft mouse models with the same cell lines used in the in 
vitro experiments. 
 
Firstly, the bioluminescent images gave some indication that CNTO328 does have 
activity in xenografts that express IL-6. Compared to the IgG and PBS control groups, 
decreased luciferase activity was seen with this antibody. However as these 
differences were not statistically significant, this did not amount to an objective 
response. Nevertheless, there was certainly a trend found in both IGROV-1 and 
TOV21G suggesting that a degree of efficacy in terms of tumour growth arrest can be 
attributed to CNTO328. This hint is substantiated by the IHC analysis for the Ki67, 
where the quantification showed significant decreases in cell proliferation with  
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anti-IL-6 treatment in both of these cell lines. Although the Ki67 staining provides 
some evidence relating to the effects on cell growth, further investigations into the  
effects on cell death could be performed with future IHC analysis for apoptotic 
markers such as cPARP or caspase-3.  
 
Second, these experiments also provided some insight into the possible paracrine 
actions of human IL-6 in these models. I analysed F4/80 staining in the tumour 
sections as interaction between macrophages and tumour cells has been implicated in 
the progression of ovarian cancer (Hagemann, Wilson et al. 2005). The quantification 
of the IHC staining shows significantly reduced macrophage influx in the IGROV-1 
xenograft sections treated with CNTO328 (**p<0.01). This trend was also seen with 
TOV21G but was not significant. The abrogation of tumour vessel development seen 
with the confocal images serves as further evidence that human IL-6 is exerting 
paracrine effects. The tumour vascular areas in both IGROV-1 and TOV21G sections 
were also significantly reduced with anti-IL-6 therapy. The quantification of 
luciferase activity and F4/80+ cell numbers suggest that the efficacy of CNTO328 is 
dependent on the level of IL-6 production in these models, whereby excess production 
IL-6 production by TOV21G cells diminishes the efficacy of the antibody. 
 
Thirdly, due to the paucity of tumour samples obtained during the clinical trial, I was 
unable to gain an impression on the effects of CNTO328 on IL-6 expression in 
biopsies from evaluable patients. Although the in vitro experiments provided some 
clues that CNTO328 inhibited the release of IL-6 in ovarian cancer cell lines, this was 
not associated with any effects on cell growth.  Furthermore, although clinical benefit 
was seen in the clinical trial, the plasma IL-6 levels increased with treatment. The real 
time quantitative RT PCR analysis revealed some intriguing results. In tumour lysates 
from the IGROV-1 xenograft, substantial reductions were seen with IL-6 after 4 
weeks of CNTO328 treatment. The other purpose of this analysis was to observe the 
consequences that targeting IL-6 had on the autocrine cytokine network in vivo. In 
addition to IL-6, Jagged1 expression decreased, which is an observation that was seen 
for both ligands on subsequent IHC analysis. This was a particularly interesting 
finding with respect to the unpublished data from Kulbe et al where IL-6 has been  
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shown to regulate Jagged1 expression through pSTAT3 signalling (Kulbe et al, 
manuscript submitted 2010). Furthermore, as both IL-6 and Jagged1 have known  
pro-angiogenic activity in malignant processes, this may be an explanation for the 
results seen with the confocal microscopy in the IGROV-1 xenograft. The minimal 
effects seen with other mediators such as Notch3, CXCL12 and CCL2 may be due to 
the overriding effect of TNF-α that is upstream of IL-6. 
 
The results from the serum analysis for both human and murine IL-6 also proved to be 
quite interesting. My aim was to see if the results relating to the increased hIL-6 seen 
in plasma samples from the clinical trial would be recapitulated in the xenograft 
models. This proved to be the case with significant increases in IL-6 seen with 
CNTO328 treatment compared to the control groups. With the real time data showing 
that this antibody decreased IL-6 expression in the tumour cells, it now seems more 
apparent that these exceedingly high IL-6 levels were due to the detection of IL-6-
antibody complexes in the ECL assay. The reduction of serum mIL-6 levels in the 
IGROV-1 xenograft also implies another mechanism by which CNTO328 can impede 
paracrine processes. The inhibition in this case was only seen with IGROV-1, as the 
levels actually increased in the TOV21G model. The higher concentration of mIL-6 at  
week 2 in the latter xenograft (almost one log difference) could provide an 
explanation for this. 
 
In summary, it appears that the biological activity of CNTO328 is reflected in its 
ability to impede cell proliferation, inhibit angiogenesis, and interrupt both autocrine 
and paracrine IL-6 networks in the ovarian cancer microenvironment. Furthermore, 
the in vivo xenograft models implied that the efficacy of anti-IL-6 therapy correlated 
with the level of IL-6 production.  Taking all these observations into consideration, 
the next objective was to perform IHC analysis for IL-6 and downstream signalling on 
the diagnostic biopsies from the clinical trial patients in order to verify whether 
particular malignant and/or stromal IL-6 signalling expression patterns could predict 
response to CNTO328 therapy. 
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7 Immunohistochemical Analysis of IL-6 and IL-6 
Signalling Pathways in Ovarian Cancer 
 
7.1 Aims 
 
The results from the in vivo experiments in chapter 6 suggested that the response to 
CNTO328 corresponded to the level of IL-6 released in the xenograft models. In 
addition, anti-IL-6 therapy had influences on both autocrine and paracrine networks 
implicated in ovarian cancer progression. With regard to the clinical trial, as there 
were no tumour biopsies taken at the time of recruitment and after the 6-10 week 
study period, I was unable to assess the effects of CNTO328 on IL-6 expression or 
IL-6 stimulated pathways in these specimens. Therefore, as a prelude to studying 
diagnostic biopsies from evaluable patients in the CO328X05 trial, my aim was to 
assess IL-6 pathways in ovarian cancer by performing IHC on tissue arrays. Having 
established IL-6 pathway expression in these arrays, my next aim was to repeat the 
IHC analysis on the diagnostic biopsies from the trial patients in order to see if 
particular patterns of expression in malignant and stromal compartments could serve 
as predictors of response to CNTO328.  
 
The staining on all tissue sections documented in this chapter was scored in a blinded 
manner by a histopathologist and an experienced cell biologist and all scores agreed. 
For each antigen, a negative control was used whereby the primary antibody was 
substituted with species-specific immunoglobulin (images not shown). I had 
previously validated all primary antibodies described in this chapter in this manner 
with previous experiments using cytospin slides derived from the IL-6 producing 
human ovarian cancer cell lines; IGROV-1 and TOV21G. 
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7.2 Analysis of IL-6 signalling in ovarian cancer tissue arrays 
  
Prior to analysing the patient biopsies, I assessed the expression of IL-6, IL-6 
receptors (gp80 and gp130) and activation of pSTAT3 signalling by conducting IHC  
staining on ovarian cancer arrays and compared this to IHC staining for the same IL-6 
pathway components found on normal ovarian tissue core biopsies. Despite using a  
variety of pSTAT3 antibodies at different concentrations (1:10-1:50), poor results 
were obtained with these methods (images not shown). Hence other genes transcribed 
by IL-6 via the IL-6-gp130-pSTAT3 axis had to be analysed as a surrogate of 
pSTAT3 activity. The SOCS3 gene is induced by pSTAT3 and serves as a feedback 
inhibitor of IL-6 signalling through pSTAT3 by binding to the JAK2 tyrosine kinase 
domain (Masuhara, Sakamoto et al. 1997; Croker, Krebs et al. 2003; Lang, Pauleau et 
al. 2003). Therefore, for the purposes of this chapter, SOCS3 staining was used to 
signify active pSTAT3 signalling in the tissue cores. Typical IHC staining patterns for 
IL-6, gp80, gp130 and SOCS3 in both ovarian cancer and normal ovarian tissues are 
illustrated in figure 7.1.  
 
All of the ovarian cancer images represent serous histology, as it was the predominant 
subtype on the array (i.e. 40 out of 69 cores). The scores for the tumour and stromal 
compartments are documented in tables 7.1 and 7.2 respectively. With respect to 
serous subtypes, the majority of these tissue cores had 25% (+) to 50% (++) cellular 
staining for both the ligand and receptors in malignant cell areas, but there was no 
correlation with tumour grade. Furthermore, all of these positive samples showed 
extensive staining for SOCS3; suggesting constitutive activation of pSTAT3 
signalling. Expression of IL-6 pathway components was also apparent in the stromal 
compartments, but was present in a lower percentage of cells compared to the 
malignant sections (table 7.2). In particular cores where IL-6 staining was either weak 
or strong, the same intensity applied to other components of the IL-6 signalling 
pathways in the same specimens. Moreover, stromal IL-6 staining was only present 
when malignant cells also expressed IL-6. 
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Figure 7.1 IHC analysis for IL-6 signalling pathway components in ovarian 
cancer and normal ovarian tissue arrays (x20 hpf).  
These images show clear expression of IL-6, IL-6 receptors and SOCS3 in the malignant 
compartments of the serous papillary tissue cores in comparison to the negative or weak 
staining on the epithelial cells in normal ovarian tissue.  
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Table 7.1 Summary of IHC scoring in malignant/epithelial cells on human 
ovarian tissue arrays. 
All tissue arrays were viewed and quantified by a histopathologist and cell biologist. The 
scores were graded according to the degree of cellular staining. +++ ≥75% cells, ++≥50% 
cells and +≥25% cells. These results show that IL-6 and components of IL-6 signalling 
pathways are expressed in all subtypes of ovarian cancer. 
 
 
 
 
 
IL-6 gp80 gp130 SOCS3 
Stroma 
+++ ++ + +++ ++ + +++ ++ + +++ ++ + 
Normal 1/60 49/60 6/60 - - 60/60 11/60 41/60 8/60 - - 59/60 
Serous  - - 12/40 - 2/40 15/40 - 11/40 26/40 1/40 6/40 27/40 
Mucinous - - - - - 1/2 - - 2/2 - - - 
Endometrioid - - - - - - - - 1/1 - - 1/1 
Clear cell - - - - - - - - 2/2 - - 2/2 
Squamous 
cell - - - - - 1/1 - - 1/1 - - 1/1 
Metastatic - - 1/5 - - 1/5 - - 5/5 - 2/5 3/5 
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Table 7.2 IHC scoring of stromal areas on human ovarian tissue arrays. 
IL-6 signalling pathway components are also expressed in the stromal compartments of both 
normal ovarian tissue and ovarian tumours.  
 
In the normal ovarian tissue cores the staining in the epithelial cells was generally 
negative and in cases where staining was present the intensity was weak. The 
exception to this was with gp130 where 10 out of 60 cores show >50% of epithelial  
 
IL-6 gp80 gp130 SOCS3 Malignant or 
Epithelial  
cells 
+++ ++ + +++ ++ + +++ ++ + +++ ++ + 
Normal (-) 
 
2/60 
 
1/60 (-) (-) 11/60 5/60 5/60 1/60 (-) (-) 8/60 
Serous  (-) 10/40 20/40 (-) 7/40 20/40 15/40 23/40 2/40 10/40 24/40 6/40 
Mucinous (-) (-) 1/2 (-) 1/2 1/2 1/2 (-) 1/2 (-) (-) 2/2 
Endometrioid (-) 1/1 (-) (-) 1/1 (-) (-) 1/1 (-) 1/1 (-) (-) 
Clear cell (-) 1/2 (-) (-) (-) (-) (-) 2/2 (-) (-) 2/2 (-) 
Squamous 
cell (-) (-) 1/1 (-) 1/1 (-) (-) 1/1 (-) (-) 1/1 (-) 
Metastatic (-) (-) 4/5 (-) 1/5 1/5 3/5 2/5 (-) 3/5 2/5 (-) 
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cells with staining of moderate intensity. This observation was to be expected as this 
receptor is ubiquitously expressed in non-malignant cells. However, compared to  
the tumour samples, expression of IL-6 signalling pathway components in the stroma 
was more prominent in normal ovarian tissues.  All other non-serous subtypes of 
ovarian cancer showed variable staining in both compartments (tables 7.1 and 7.2).  
 
7.3 Diagnostic biopsy IHC analysis from CO328X05 patients 
 
The IHC analysis previously described showed that components of IL-6 signalling 
were expressed in both malignant and stromal compartments in ovarian cancer tissues. 
This implied the possibility of both autocrine and paracrine IL-6 signalling loops in 
these specimens. My next aim was to repeat this analysis on paraffin embedded 
sections of diagnostic biopsies from evaluable patients in the CO328X05 study to see 
if particular expression patterns could predict response to anti-IL-6 treatment. I was 
able to obtain diagnostic biopsies from 14 patients, 6 who had clinical benefit and 8 
who had progressive disease after the initial 6-10 week study period. These were 
predominantly serous sub-types (nine cases) with the remaining being defined as 
poorly differentiated carcinomas. There was no relationship between tumour grade 
and clinical outcome in the trial. The images for the malignant and stromal 
compartments from three patient biopsies (PR, SD and PD) are illustrated in figures 
7.2 and 7.3 respectively and the staining quantification is represented by box and 
whisker plots shown in figure 7.4. The mean scores showed that the IL-6 signature 
expression on malignant cells in tissue sections from patients who had clinical benefit 
and progressive disease were approximately the same (table 7.3). Although the 
differences in the stromal compartment scores were not significantly different, there 
was a trend suggesting a higher IL-6 signature expression in SD/PR patients 
compared to those who progressed. 
 
 
 
 
 
 206 
 
 
 
             PR           SD                    PD 
 
 
IL-6 
  
 
 
   
 
gp80 
 
 
 
 
gp130 
 
 
 
 
SOCS3 
 
 
 
 
Figure 7.2 CO328X05 diagnostic biopsies: Malignant compartment IL-6, IL-6 
receptor and SOCS3 IHC analysis (x20 hpf). 
These images show the staining for components of IL-6 signalling pathways in the diagnostic 
biopsies from patient 13 (PR), 12 (SD) and 02 (PD).  
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Figure 7.3 CO328X05 diagnostic biopsies: Stromal compartment IL-6, IL-6 
receptors and SOCS3 IHC analysis (x20 hpf). 
These images show that stromal expression for components of the IL-6 signalling pathway is 
higher in the patients who had clinical benefit (PR and SD) compared to the patient who had 
progressive disease. 
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Figure 7.4 Quantification of IL-6, IL-6 receptors and SOCS3 staining in 
diagnostic biopsies. 
For quantification, the scores were converted to arbitrary numbers i.e. +++=3, ++=2 and 
+=1. There were no significant differences between SD/PR and PD patients in the mean 
compartmental scores. 
 
 
Tumour Stroma  
SD/PR PD SD/PR PD 
IL-6 2.83 2.5 
 
2.33 1.75 
 
gp80 2.5 2.56 
 
2.25 1.69 
 
gp130 2.4 2.0 
 
1.4 0.75 
 
SOCS3 2.25 2.38 
 
1.33 0.81 
 
 
Table 7.3 Summary of mean IL-6 signature IHC scores. 
The mean IHC scores suggest that the stromal IL-6 signature expression is higher for patients 
who had clinical benefit compared to those who progressed. 
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In view of the effects observed with CNTO328 on macrophage influx in the xenograft 
models, my next objective was to see if the extent of macrophage infiltration at 
diagnosis correlated with the clinical outcome seen in the trial. For this purpose, I 
performed IHC analysis for the macrophage antigen CD68 (figure 7.5). The staining 
quantification showed a highly significant difference in CD68 expression (unpaired t 
test **p=0.002) with fewer focal macrophage aggregates per high power field (hpf)  
found in the diagnostic biopsies of patients who had clinical benefit with CNTO328 
compared to those who had PD. This was particularly evident in the partial responder 
(patient 13, figure 7.5 (A)). 
 
A  
                   PR                              SD                     PD 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure 7.5 IHC analysis of CD68 cells on diagnostic biopsies. 
A. CD68 cell infiltrate images (x20hpf) for patient 13 (PR), 12 (SD) and 02 (PD). B. CD68 
staining quantification; scores: 3=numerous aggregates, 2=widely spaced aggregates (up to 
50 cells), 1= very focal aggregate. 
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7.4 Discussion 
 
This chapter has outlined the results from the IHC analysis of IL-6 and specific 
components of IL-6 signalling pathways in ovarian cancer tissue arrays and diagnostic 
biopsies from 14 evaluable patients in the CO328X05 trial. The primary objective of 
the tissue array analysis was to gain some insight into the patterns of IL-6 expression 
in the various ovarian cancer subtypes and compare this with normal ovarian tissue. In 
the case of the ovarian cancer tissue arrays, the images and quantification showed that  
the malignant compartments in approximately 75% and 65% of the tissue cores 
showed some degree of IL-6 and gp80 staining respectively.  All of the tissues 
expressed both gp130 and SOCS3 indicating that downstream IL-6 signalling was 
active in these biopsies. IL-6, IL-6 receptors and SOCS3 were also expressed to a 
lesser extent in the stromal compartments of these cores. Furthermore, cores that had 
no malignant cell staining always corresponded with negative staining in the stromal 
sections. With respect to the epithelial cells in normal ovarian tissues, very few of 
these expressed IL-6 but up to 18% of these cores showed some evidence of staining 
for IL-6R and SOCS3. However, it appears that these normal tissues were more 
reliant on stromal IL-6 signalling as the expression of components of these pathways 
was more prominent in this compartment. The main conclusion from this analysis was 
that IL-6 and IL-6 signalling is up-regulated in ovarian cancer and can serve as a 
potential therapeutic target. However, one drawback to these experiments related to 
the small number of non-serous ovarian cancer sub-types present on the arrays. This 
made it difficult to make any correlations between IL-6 expression and sub-types 
associated with either poor prognosis (e.g. clear cell) or those with relatively better 
prognosis (e.g. endometrioid). 
 
Having established the expression of IL-6 and IL-6 signalling in ovarian cancer 
biopsies, my next aim was to repeat this analysis in diagnostic biopsies from 
evaluable patients in the CO328X05 trial. Most had the same serous histology and 
there appeared to be no relationship between tumour grade and response to 
CNTO328. The quantification of the malignant compartment showed a high 
expression for IL-6 and IL-6 signalling that was equivalent for both SD/PR and PD 
patients. In comparison the stromal expression was lower for all patients, particularly  
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for gp130 and SOCS3. However, there was a trend suggesting that the expression of 
stromal IL-6 and IL-6 signalling was higher for patients with clinical benefit; but the 
difference in mean IHC scores was not significant. Although only a small number of 
tissue sections were analysed, these findings imply that CNTO328 may induce a 
response by disrupting stromal interactions with malignant cells. Similar to the results 
seen with the xenograft experiments where there was a relationship between IL-6 
concentrations and biological activity, the extent of response may also correlate with  
the level of IL-6 signalling in the stroma. Clinical benefit was evident in patients who 
had moderate expression of stromal IL -6 signalling. Interestingly, some of the PD  
patients had either negative or minimal staining for both stromal gp130 and SOCS3; 
meaning that CNTO328 would have been ineffective in these patients as the IL-6 
signalling in this compartment was non-functional. 
 
The analysis of macrophage influx in the diagnostic biopsies also provided some 
useful information. The CD68 quantification showed that patients who went on to 
have clinical benefit had significantly less macrophage infiltration at diagnosis 
compared to those who progressed (unpaired t test **p<0.01).  Recent research using 
CD68 IHC analysis has correlated increased macrophage density in ovarian tumour 
sections to poor prognosis (Wan, Liu et al. 2009). Moreover, from the results 
presented in this chapter it appears that increased macrophage influx can predict poor 
clinical outcome with CNTO328 therapy.  
 
The absence of tissue specimens taken after the 6-10 week study period precludes any 
further investigation into the effects of CNTO328 on stromal IL-6 signalling and 
macrophage influx in these patients. Despite this, the IHC analysis has provided some 
hints relating to particular histological features that could help predict response to 
anti-IL-6 treatment in future studies. 
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8 Discussion and future plans 
 
The inflammatory cytokine IL-6 has been implicated in a number of processes that 
contribute to the progression and poor prognosis of ovarian cancer. Despite this 
evidence, there has been a lack of translational research that has studied the effects of 
targeting IL-6 on the ovarian cancer microenvironment. This thesis has presented the 
results from the first phase II clinical trial of anti-IL-6 therapy with the monoclonal 
antibody CNTO328 in patients with advanced ovarian cancer. This was conducted in 
parallel with a number of laboratory experiments in order to answer three pivotal 
questions: 
 
1. Does targeting IL-6 show biological activity in ovarian cancer? 
2. If so, are there any biomarkers that correlate with response?  
3. What are the mechanisms of action that result in the responses observed? 
 
This chapter aims to discuss the extent to which this research has answered these 
questions and outline future studies that will be conducted as a result of this thesis. 
 
The primary objective of the clinical trial was to assess the efficacy of CNTO328 
therapy in patients with relapsed platinum resistant advanced ovarian cancer. Prior to 
recruitment most patients had received multiple lines of chemotherapy and all had 
progressive disease. Using RECIST and CA-125 response criteria, 8 out of 18 
evaluable patients attained clinical benefit after an initial 6-10 week study period. 
This included one patient with partial response and seven with stable disease, four of 
whom continued treatment for up to six months. The overall survival in this study was 
47 weeks and two patients (16 and 20) who had clinical benefit remain alive and well 
(14 months and 7 months respectively) after study withdrawal. Moreover, the 
difference in median OS between SD/PR and PD patients was statistically significant 
(66.43 weeks vs. 32.07 weeks; log-rank test *p=0.0237). Although the small number 
of patients limited the power of this study, there was evidence to show that CNTO328 
exhibits biological activity in advanced ovarian cancer.  Despite only one patient  
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achieving partial response, the significance of inducing disease stabilisation in this 
patient population should not be understated. All of these patients had poor prognosis 
disease and would not be expected to have spontaneous CA-125 stabilisation after 
radiological confirmation of disease progression. Moreover, the clinical benefit rate of 
44.4% is also encouraging considering that this was a drug used as a single agent in 
patients where partial or complete responses are seldom found after multiple relapses 
with platinum-containing regimes. 
 
The in vivo experiments with ovarian cancer xenografts were conducted to provide 
further insight into the efficacy of targeting IL-6 in ovarian cancer. The 
bioluminescence imaging after 4 weeks of treatment with CNTO328 in both IGROV-
1 and TOV21G xenograft models showed evidence of efficacy in terms of reduced 
luciferase activity compared to the PBS and IgG control groups with a more 
prominent effect seen with IGROV-1. In addition, this treatment showed no evidence 
of biological activity in xenografts with non-IL-6 producing cells, as shown by the 
absence of reduced tumour weight with CNTO328 in the TOV112D model.  These 
results imply that the level of IL-6 expression could be related to the degree of 
response to CNTO328. The high IL-6 concentrations associated with TOV21G could 
saturate the binding capacity of the antibody resulting in less effective inhibition of 
downstream signalling. In comparison, IGROV-1 produced considerably less IL-6 
both in tissue culture and as measured by circulating human IL-6 in tumour bearing 
mouse serum and would seem to be more amenable to the inhibitory effects of 
CNTO328 to induce a biological response. As TOV112D cell growth is independent 
of IL-6, the absence of response was to be expected.  
 
Did these observations translate to those seen in the clinical trial? The mean baseline 
IL-6 levels were lower in patients with clinical benefit compared to those who had 
progressive disease. However this difference was not statistically significant (Mann 
Whitney U- test, p=0.146) and the patient with partial response had a baseline IL-6 
concentration that was higher than all but two of the patients with progressive disease.  
Furthermore, there were patients who had clinical benefit with IL-6 levels that were 
barely detectable. Therefore it would seem that baseline plasma IL-6 levels could not 
accurately predict response to CNTO328 in these patients. Throughout the initial 6-  
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week study period, the plasma IL-6 levels paradoxically increased by up to 2-3 logs 
higher than baseline concentrations. However, the experiments described in chapters 5 
and 6 suggest that this antibody does effectively inhibit IL-6 derived from malignant 
cells in experimental models. Furthermore, the results from the IL-6 serum analysis in 
both the IGROV-1 and TOV21G xenografts proved to be quite important. In this case, 
the human IL-6 levels increased significantly with CNTO328 treatment, an 
observation that was also seen in the clinical trial.  As the IL-6 mRNA expression in 
the IGROV-1 tumour lysates decreased substantially, it can be deduced that the 
plasma and serum IL-6 levels in the CO328X05 trial and in vivo models respectively 
represent IL-6-CNTO328 complexes as opposed to unbound IL-6.   
 
Despite attempts to estimate ‘free’ IL-6 in the plasma, these samples provided no 
definitive answers as to whether the responses seen in the trial related to the extent of 
IL-6 inhibition with CNTO328. Therefore, other baseline characteristics were 
assessed to verify any correlations with response. Clinical outcome was not related to 
the degree of tumour burden measured by CT scan dimensions at the time of study 
enrolment. However, there were a number of interesting patterns seen with certain 
inflammatory biomarkers and cytokines relating to the therapeutic activity of 
CNTO328. CRP, β2-microglobulin, TNF-α, IL-8 and VEGF were all significantly 
lower in the patients who had clinical benefit compared to those who progressed. 
Although baseline CRP levels positively correlated with IL-6 (r2 value of 0.75), 
significant differences at this time-point between SD/PR and PD patients were seen 
only in CRP and not IL-6.  This may have been be due to the influence of other 
cytokines such as IL-1 and TNF-α that are also known to affect CRP expression in 
conjunction with IL-6. However, as CRP transcription is pSTAT3 dependent, its 
suppression may indicate effective inhibition of IL-6 signalling by CNTO328. During 
the initial 6-week study period continual CRP suppression below the LLOQ was seen 
in all SD/PR patients and most patients with PD. In four of the patients who 
progressed, CRP levels fluctuated with treatment suggesting incomplete inhibition of 
IL-6 signalling. Although the baseline concentrations in these patients were above the 
LLOQ (range 24-104), CRP remained suppressed for other PD subjects who had 
higher baseline levels. So although patients with lower baseline CRP levels were 
more likely to gain clinical benefit, high concentrations did not always predict failure  
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of continual CRP suppression. Moreover, it seems that continual CRP suppression is 
not a reliable predictor of response to CNTO328.  
 
To establish whether CNTO328 induced responses through other pathways, cytokines 
related to IL-6 within the ovarian cancer microenvironment were analysed in the 
plasma samples. Throughout the 6-week study period, there were no significant 
changes from baseline in cytokine concentrations for both SD/PR and PD patients. 
However, certain cytokines were significantly higher at particular time-points in 
patients who had progressed, namely TNF-α, IL-8, VEGF and CCL2 at 24 hours, and 
TNF-α and IL-8 at week 6. The cytokine profiles for the 4 patients, in particular the 
partial responder, who continued treatment for 6 months gave some insight into the 
long-term effects of CNTO328 in ovarian cancer. The mean concentrations for IL-1β, 
TNF-α, IL-8, VEGF, CXCL12 and sgp80 remained generally stable. However, 
substantial decreases were seen in VEGF for two patients and IL-8 for one patient. 
Furthermore, after the completion of 12 treatments, CCL2 had decreased significantly 
(p<0.029) for all 4 patients and despite remaining stable during the 6 week study 
period, sgp130 levels increased significantly (p<0.029). It is interesting to note that 
the decline seen in VEGF, IL-8 and CCL2 were most prominent in the partial 
responder. Although the plasma analysis could not delineate the source of these 
cytokines (i.e. malignant or normal cells), it did give some idea of potential 
biomarkers for long-term response.  
 
In order to gain further ideas into the mechanism of action of CNTO328, these results 
should be viewed in context with the observations seen in the in vivo experiments. 
The confocal images showed significantly diminished vascular areas in size-matched 
tumours from IGROV-1 and TOV21G xenografts treated with CNTO328. Alongside 
this, both IHC and qRT-PCR analysis confirmed decreased expression of Jagged1; 
which is known to facilitate angiogenesis in advanced ovarian cancer. With respect to 
the partial responder in the clinical trial, anti-angiogenic effects could be inferred 
from the strong decline seen with both IL-8 and VEGF in the plasma after 6 months.  
Other anti-angiogenic effects may have manifested through the inhibition of 
macrophage infiltration, which is shown in the F4/80 staining in tumour sections from 
IGROV-1 and TOV21G xenografts treated with the human anti-IL-6 antibody.  Again  
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parallels can be drawn with the clinical trial, whereby the 4 patients who continued 
treatment for 6 months had a significant decrease in CCL2; a chemokine that 
promotes macrophage infiltration in tumour cells. Furthermore, it is feasible that the 
inhibition of these processes by CNTO328 could explain the decreased cell 
proliferation seen with the Ki67 quantification in these mice. From these experiments, 
it appears that targeting IL-6 has prominent effects on stromal interactions with 
malignant cells. This is also supported by murine IL-6 analysis in the IGROV-1 
xenografts treated with CNTO328, whereby mIL-6 decreased by 50% at week 4 
compared to week 2.  
 
The IHC analysis of the ovarian cancer tissue arrays and diagnostic biopsies from 
evaluable patients in the CO328X05 trial gave more insight into the potential 
mechanism of action of anti-IL-6 therapy in ovarian cancer.  The majority of cores on 
the ovarian cancer arrays showed that IL-6 and other components of IL-6 signalling 
pathways were expressed in both the malignant and stromal compartments. Although 
the staining scores were generally lower for the stromal sections, IL-6 was never 
detected in the stroma in the absence of malignant cell staining. The diagnostic biopsy 
IHC quantification for the malignant compartment revealed high scores for IL-6, IL-6 
receptors and SOCS3 both for patients who had clinical benefit and those with 
progressive disease, although no significant difference was seen between them. 
Stromal staining scores were higher in SD/PR patients compared with PD patients, 
but again with the small number of sections available the difference was not 
significant. However, there were cases where both gp130 and SOCS3 staining was 
negative in patients who progressed, an observation that did not occur in any of the 
patients who had clinical benefit. These findings infer that higher stromal expression 
of IL-6 and components of IL-6 signalling correlates with favourable clinical response 
to CNTO328 in patients with ovarian cancer.  Hence targeting IL-6 signalling in the 
stroma as opposed to the malignant compartment could be pivotal to inducing a 
biological response. In light of the F4/80 observations in the in vivo models, CD68 
IHC analysis was performed on the diagnostic biopsies. Significantly fewer 
macrophages were evident in the patients who went on to gain clinical benefit than in 
the patients who had progressive disease. Although the effects of CNTO328 on 
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macrophages at the completion of treatment could not be analysed, the results do 
suggest that the degree of macrophage infiltration at the time of diagnosis influences  
the response seen in this study. In general terms, there is recent evidence that 
highlights the correlation between increased macrophage density in ovarian cancer 
biopsies and poor prognosis (Wan, Liu et al. 2009).  In addition, as macrophages can 
influence angiogenesis, the differences in CD68 staining quantification between 
patients with clinical benefit and those with progressive disease may reflect the degree 
of angiogenic activity in their respective tumour sections at diagnosis. 
 
Both the clinical trial and the experimental models outlined in this thesis have shown 
that IL-6 is a potential therapeutic target in ovarian cancer. As a single agent, 
CNTO328 may induce biological responses by impeding stromal interplay with 
malignant cells by inhibiting angiogenesis and macrophage infiltration. Furthermore, 
it appears that in order to evoke this response stromal IL-6 signalling must be 
‘switched-on’. However more detailed experiments need to be executed to 
substantiate these findings and there are still unresolved issues that will need to be 
addressed in future studies. 
 
 
Future plans 
 
The primary objective of my future work will be focused on designing clinical trials 
with CNTO328 in advanced ovarian cancer in different settings. The results in the 
CO328X05 study suggest that there is a case for CNTO328 to be employed as an 
adjunct to established chemotherapy regimes in this disease. Although this antibody 
exhibits biological activity as a single agent, it will be important to investigate 
whether this efficacy is enhanced alongside platinum-taxane containing regimes or 
with other targeted therapies.  My first aim will be to investigate whether CNTO328 
confers any survival advantages as a maintenance therapy in patients with relapsed 
ovarian cancer who have completed chemotherapy. This would be designed as a two-
arm randomised study comparing CNTO328 with observation after platinum-based 
treatment. Despite the importance of the CO328X05 study, there were limitations that  
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prevented further useful analysis relating to the mechanisms of action of CNTO328. 
Hence, one of the inclusion criteria will be that all patients would have to consent to a  
tumour biopsy at enrolment and at the time of study withdrawal. Furthermore, the trial 
will be multi-centred and recruit larger numbers of patients in order to increase the 
power of the study. Another potential trial designed in this manner would be to 
investigate whether response rates to platinum-taxane based treatment could be 
enhanced in combination with CNTO328. In view of the links between IL-6 and 
taxane-resistance in ovarian cancer, it would be very interesting to see if CNTO328 
could abrogate the development of chemoresistance and increase time to disease 
progression. 
 
As a proof of principal, further in vitro and in vivo experimental models would have 
to be conducted prior to the instigation of these trials. Due to the lack of efficacy with 
CNTO328 treatment on human ovarian cancer cell growth on plastic, the primary aim 
of the future in vitro studies will be to repeat this analysis with clonogenic assays. 
This will also be performed with the same cell lines cultured on soft agar. 
Furthermore, in order to observe the effects of CNTO328 on IL-6 signalling, cell 
lysates will be prepared for western blot analysis of pSTAT3 and pro-survival genes 
including bcl-xl and cyclin D1. The results relating to anti-IL-6 therapy in the 
xenograft models suggested that the degree of biological response in terms of 
luciferase activity correlated with the extent of IL-6 release by ovarian cancer cells.  
Hence, it would be useful to see if increasing the dose of CNTO328 could enhance the 
response in TOV21G xenografts that secrete substantial concentrations of IL-6.  
Although the in vivo experiments provided hints on the mechanisms of action of 
CNTO328, further studies would have to be repeated in mouse models with 
established tumours in order to reflect the conditions of the clinical trial where all 
patients had advanced disease. In addition, as a prelude to the aforementioned future 
trials, I plan to investigate whether CNTO328 treatment in these models can confer 
any survival advantage either as combination or sequential therapy with carboplatin.  
These experiments could also be conducted in syngeneic models with an anti-murine-
IL-6 antibody in order to gain some insight into the effects on both the innate and 
adaptive immunity. With respect to this research, it was not possible to obtain  
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sufficient quantities of an anti-mouse IL-6 antibody; however I have now identified a 
source suitable for future experiments.  
 
As the Ki67 quantification in the xenograft tumour sections showed that CNTO328 
affected cell proliferation, it will be essential to investigate the effects of this 
treatment on apoptosis in future studies. This will be achieved by IHC analysis of 
apoptotic markers such as cleaved PARP and caspase-3 in tumour sections from both 
the in vivo models and patients treated with CNTO328 in future trials. In addition, 
novel methods can also be used to estimate effects of anti- IL-6 therapy on apoptosis 
in blood samples.  Cummings et al have reported a M30 sandwich ELISA assay that 
is able to estimate a circulating form of cytokeratin 18 that is only detected after 
caspase cleavage of this protein (Cummings, Hodgkinson et al. 2008). At the time of 
writing, I am in the process of collaborating with this group who have kindly agreed 
to perform this assay on plasma samples from the CO328X05 study. 
 
Perhaps the main drawback of the CO328X05 plasma analysis was the inability to 
estimate the effect of CNTO328 on IL-6.  As previously mentioned, the phenomena 
of detecting antibody complexes in similar studies is well recognised. Recently, 
Nishimoto et al attempted to estimate ‘free IL-6’ in rheumatoid arthritis patients 
treated with the anti-IL-6R antibody tocilizumab (Nishimoto, Terao et al. 2008). As 
the ELISA they used measured both complexed and ‘free’ IL-6, an additional 
antibody that recognised a different IL-6 epitope was incubated with the serum 
samples and the free ‘IL-6’ was measured after magnetic separation. This is a 
technique that could also be employed using stored samples from the CO328X05 
study. Furthermore, in future trials, total RNA could be extracted from fresh blood 
pellets and used for qRT-PCR analysis of IL-6 mRNA expression. 
 
Obtaining tissue specimens in future trials will be paramount to confirming a 
hypothesis on the mechanisms of action of anti-IL-6 therapy in patients with ovarian 
cancer. Tumour lysates prepared from biopsies collected before and after CNTO328 
treatment will be essential for western blot analysis of IL-6 signalling pathways, qRT- 
PCR of IL-6 and IL-6 receptors. The pharmacokinetic analysis of CNTO328 in these  
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samples will also be important in order to verify any correlations between response 
and the concentration of antibody observed in the tumours.  
 
Finally, the IHC analysis from the CO328X05 study suggested that stromal IL-6 
signalling could have been linked to response to anti-IL-6 treatment. In these 
experiments only SOCS3 was used as a surrogate of pSTAT3 activity. In future 
studies, pSTAT3 antibodies will have to be optimised in order to give a more specific 
impression on the effects of CNTO328 on IL-6 signalling. In the interim, results from 
the IHC staining of diagnostic biopsies in the CO328X05 study will be validated with 
the same analysis performed on tumour sections from patients in the Australian 
Ovarian Cancer Study (AOCS) with known high and low enriched IL-6 signalling 
pathways. The premise of these experiments is that higher stromal IHC expression of 
IL-6, IL-6R and SOCS3 in the high compared to low enriched pathway specimens 
would suggest that stromal IL-6 signalling is indeed up-regulated in the patients who 
attained clinical benefit. These studies are currently being performed in collaboration 
with David Bowtell and colleagues (Peter MacCallum Cancer Centre, Australia).   
 
In the midst of developing targeted therapies for ovarian cancer, there have been a 
number of agents that have been investigated with most still waiting to be established 
as standard therapies alongside current chemotherapy algorithms. Although it is 
unlikely CNTO328 will be adopted as a monotherapy in patients with advanced 
ovarian cancer, I believe that further investigations into the use of IL-6 antagonists at 
earlier stages of disease in combination with gold-standard treatment or with other 
novel therapies is justified. 
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